



PCT/GB 2003 / U U S 8 0 2

10/526722

MAR 2005

GB 03 / 03862

INVESTOR IN PEOPLE

**PRIORITY
DOCUMENT**SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

REC'D 10 OCT 2003

WIPO

PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.


In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

BEST AVAILABLE COPYSigned *AmB. Jones*

Dated 26 September 2003



**The
Patent
Office**

09SEP 05746535-4 000019
P01/ 0.00-0220770.2

The Patent Office

Cardiff Road
Newport
Gwent NP9 1RH

Request for grant of a patent

See the notes on the back of this form. You can also obtain an explanatory leaflet from the Patent Office to help you fill in this form)

1. Your reference	P031708GB		
2. Patent application number (The Patent Office will fill in this part)	06 SEP 2002	0220770.2	
3. Full name, address and postcode of the or of each applicant (<i>underline all surnames</i>)	ARES TRADING S.A. CHATEAU DE VAUMARCUS CH-2028 VAUMARCUS SWITZERLAND		
Patents ADP number (<i>if you know it</i>)	06275622001		
If the applicant is a corporate body, give the country/state of its incorporation	SWITZERLAND		
4. Title of the invention	PROTEINS		
5. Name of your agent (<i>if you have one</i>)	Carpmaels & Ransford		
"Address for service" in the United Kingdom to which all correspondence should be sent (<i>including the postcode</i>)	43 Bloomsbury Square London WC1A 2RA		
Patents ADP number (<i>if you know it</i>)	83001 ✓		
6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (<i>if you know it</i>) the or each application number	Country	Priority application number (<i>if you know it</i>)	Date of filing (<i>day / month / year</i>)
7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application	Number of earlier application		Date of filing (<i>day / month / year</i>)
8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (<i>Answer 'Yes' if:</i>)	Yes		
a) any applicant named in part 3 is not an inventor, or			
b) there is an inventor who is not named as an applicant, or			
c) any named applicant is a corporate body			
See note (d))			

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description 83

Claim(s) 13

Abstract

Drawing(s) 9 + 9

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patents Form 9/77)

Request for substantive examination (Patents Form 10/77)

Any other documents (please specify)

11. I/We request the grant of a patent on the basis of this application.

Signature

Date

Carpmaels & Ransford
Carpmaels & Ransford

6th September 2002

12. Name and daytime telephone number of person to contact in the United Kingdom

Hugh Goodfellow

020-7242 8692

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

Proteins

This invention relates to novel proteins, termed INSP081, INSP082 and INSP091, herein identified as members of the Germinal Center Kinase (GCK) subfamily of the STE20 family of protein kinases, preferably as NCK-interacting kinases (NIKs) and more preferably as NIK-like embryo specific kinases (NESKs), and to the use of these proteins and nucleic acid sequences from the encoding genes in the diagnosis, prevention and treatment of disease.

All publications, patents and patent applications cited herein are incorporated in full by reference.

10 Background

The process of drug discovery is presently undergoing a fundamental revolution as the era of functional genomics comes of age. The term "functional genomics" applies to an approach utilising bioinformatics tools to ascribe function to protein sequences of interest. Such tools are becoming increasingly necessary as the speed of generation of sequence data is rapidly outpacing the ability of research laboratories to assign functions to these protein sequences.

As bioinformatics tools increase in potency and in accuracy, these tools are rapidly replacing the conventional techniques of biochemical characterisation. Indeed, the advanced bioinformatics tools used in identifying the present invention are now capable of outputting results in which a high degree of confidence can be placed.

Various institutions and commercial organisations are examining sequence data as they become available and significant discoveries are being made on an on-going basis. However, there remains a continuing need to identify and characterise further genes and the polypeptides that they encode, as targets for research and for drug discovery.

25 Introduction

PROTEIN KINASES

Protein kinases catalyse the transfer of a phosphate from ATP to an amino acid residue of protein targets. They are involved in all aspects of signal transduction in eukaryotic cells, from primary transmembrane signalling to control of transcription and the cell cycle.

Protein kinases are classified as Tyrosine kinases and/or Serine/Threonine kinases by the target protein residue that receives the phosphoryl group: either tyrosine or serine or threonine (Hanks, S.K. And Hunter, T. (1995) FASEB 9:576-596).

5 Tyrosine kinases can be grouped into two categories. The first category is tyrosine kinases that have a transmembrane segment, which are usually receptors for extracellular ligands (receptor tyrosine kinases), e.g. Insulin receptor that is involved in various forms of insulin resistance as well as some forms of diabetes mellitus.

Proteins of the second category are nonreceptor tyrosine kinases, which are only intracellular; one example is the proto-oncogene tyrosine-protein kinase ABL. Alterations
10 of the ABL1 gene by chromosomal rearrangement or viral transduction lead to chronic myeloid leukaemia.

Serine/Threonine kinases phosphorylate a number of protein substrates resulting in the activation or inactivation of the protein. Examples of this include enzymes, transcription factors, cytoskeletal proteins, receptors and ion channels. These proteins play a key role in
15 all cellular processes, such as apoptosis, cell cycle and transcription (for review see Kolch W., Biochem J. 2000 Oct 15;351(Pt 2):289-305, Davie JR, Spencer VA., Prog Nucleic Acid Res Mol Biol. 2000;65:299-340, Ham J, *et al*, Biochem Pharmacol. 2000;60(8):1015-21, Reed JC, Bischoff JR., Cell. 2000;102(5):545-8, Saxena M, Mustelin T., Semin Immunol. 2000;12(4):387-96). Serine/Threonine-protein kinase CHK1 for example, is a
20 nuclear protein involved in cell cycle arrest when DNA damage has occurred or when unligated DNA is present, by binding to and phosphorylating CDC25 proteins (Sanchez Y. *et al.*, (1997) Science 277:1497-1501).

Kinases, both serine/threonine and tyrosine have been directly implicated in a variety of diseases, encompassing all therapeutic areas such as oncology (Mimori K, *et al*, Ann Surg
25 Oncol. 2000;7(9):692-5, Erickson LA, *et al*, Mod Pathol. 2000;13(9):1014-9, Hennige AM, *et al.*, Mol Cell Endocrinol. 2000;167(1-2):69-76, Harrington EO, *et al.*, Am J Physiol Lung Cell Mol Physiol. 2000;279(4):L733-42, Amin HM, *et al.*, Br J Haematol. 2000;110(3):552-62, Tang X, *et al.*, J Natl Cancer Inst. 2000;92(18):1511-1516, Dreys J, *et al.*, Cancer Res. 2000;60(17):4819-24), metabolism (Coghlan M.P., *et al*, Chem Biol.
30 2000;7(10):793-803, Coghlan MP, *et al.*, Chem Biol. 2000 7(10):793-803, Waeber G, *et al.*, Nat Genet. 2000;24(3):291-5), central nervous system (CNS) (Tan J., *et al.*, J Neurosci. 2000 20(20):7587-94, Leclerc S, *et al.*, J Biol Chem. 2000 275: 30144-30152),

cardiovascular (Mounsey JP, *et al.*, Hum Mol Genet. 2000;9(15):2313-20, Sanz-Gonzalez SM, *et al.*, Front Biosci. 2000;5:D619-28, Petkova SB, *et al.*, Front Biosci. 2000;5:D452-60), inflammation (Lee S.J., *et al.*, J Immunol. 2000;165(8):4658-4666, Fiebich B.L., *et al.*, J Neurochem. 2000;75(5):2020-2028, Barchowsky A, *et al.*, Cytokine 2000;12(10):1469-1479, Cuzzocrea S, *et al.*, Lab Invest. 2000;80(9):1439-53), and infection (Warny M, *et al.*, J Clin Invest. 2000;105(8):1147-56, Read TD, *et al.*, Nucleic Acids Res. 2000;28(6):1397-406).

STE-20 kinase family

The STE20 kinase family of protein kinases is involved in the regulation of the c-Jun N-terminal kinase pathway. STE20 was initially discovered as *S. cerevisiae* MAP4K. A number of mammalian subfamilies have since been discovered. One of these is the Germinal Center Kinase subfamily of STE20 kinases.

Germinal Center Kinase subfamily

The GCK subfamily of STE20 kinases is itself divided up into 2 subfamilies with respect to JNK activation (Kyriakis. J.M. (1999) Signaling by the germinal center kinase family of protein kinases. J. Biol. Chem, 274, 5259-5262).

Group 1 GCKs include GCK, GCK related kinase (GCKR), hematopoietic progenitor kinase 1 (HPK1), GCK-like kinase (GLK), HPK/GCK-like kinase and NCK-interacting kinase (NIK).

The group 1 GCK family members mentioned above have been shown to activate the JNK pathway (Diener, K. *et al.* (1997) Activation of the c-Jun N-terminal kinase pathway by a novel protein kinase related to human germinal center kinase. Proc. Natl. Acad. Sci. USA., 94, 9687-9692; Hu, M.C. *et al.* (1996) Human HPK1, a novel hematopoietic progenitor kinase that activates the JNK/SAPK kinase cascade. Genes Dev. 10, 2251-2264; Pombo, C.M. *et al.* (1995) Activation of the SAPK pathway by the human STE-20 homologue germinal centre kinase. Nature, 377, 750-754; Su *et al.* (1997) NIK is a new STE20-related kinase that binds NCK and MEKK1 and activates the SAPK/JNK cascade via a conserved regulatory domain. EMBO J. 16, 1279-1290).

All members of the group 1 GCK family are known to activate selectively the JNK pathway but not the ERK1 or p38-MAPK pathways when expressed in cultured cells

(Pombo, C.M. *et al.* (1995) Activation of the SAPK pathway by the human STE20 homologue germinal centre kinase. *Nature*, 377, 750-754).

~~Members of the group 1 GCK family have an N-terminal kinase domain which resembles~~
 the catalytic domain found in STE20, a variable intermediate region containing at least two
 5 proline-rich Src homology 3 (SH3) domains and a C-terminal regulatory region. The C-terminal domain further comprises a domain distantly related to part of the murine citron protein (citron homology (CNH) domain). This C-terminal domain may function to couple these kinases to downstream MAP3Ks (Su *et al.* (1997) NIK is a new STE20-related kinase that binds NCK and MEKK1 and activates the SAPK/JNK cascade via a conserved
 10 regulatory domain. *EMBO J.* 16, 1279-1290).

NIK has been shown to interact with NCK, a Src homology 2-Src homology 3 (SH2-SH3) domain containing protein (Su *et al.* (1997) NIK is a new STE20-related kinase that binds NCK and MEKK1 and activates the SAPK/JNK cascade via a conserved regulatory domain. *EMBO J.* 16, 1279-1290). It is proposed to link protein tyrosine kinase signals to
 15 JNK activation and may play a role in cytoskeletal regulation (Xue *et al.* Mesodermal patterning defects in mice lacking the STE20 NCK interacting kinase (NIK), *Development* (2000), 128, 1559-1572).

NIK has been found to be essential for development in mammalian cells. *Nik*^{-/-} mouse embryos have been shown to die postgastrulation. Patterning experiments in mice have
 20 suggested that NIK plays a critical and specific role in regulating the migration of cells that arise from the region of the primitive streak just posterior to the node (Xue *et al.* (2000) Mesodermal patterning defects in mice lacking the STE20 NCK interacting kinase (NIK), *Development*, 128, 1559-1572). These experiments also led to the suggestion that NIK may regulate the mesodermal migration that contributes to the elongation of the body axis.
 25 Xue *et al.* have further speculated that a NCK/NIK complex may be required for segmentation of presomitic mesoderm into somites.

NESK (NIK-like embryo specific kinase) is a further member of the GCK family subgroup (Nakano *et al.* NESK, a member of the Germinal center kinase family that activates the c-Jun N-terminal kinase pathway and is expressed during the late stages of embryogenesis.
 30 *JBC*, (2000) 275, 27, 20533-20539). NESK is expressed exclusively during the late stages of embryogenesis. NESK has been shown to activate the JNK pathway when overexpressed in HEK293 (Nakano *et al.* *JBC*, (2000) 275, 27, 20533-20539). Although

maximal activation of the JNK pathway requires the C-terminal domain of GCK, the kinase domain alone of NESK was able to activate the JNK pathway (Nakano *et al.* JBC, (2000) 275, 27, 20533-20539). Nakano *et al.* have suggested that NESK may play a role in coupling TNF receptor-associated factor 2 (TRAF2), as well as TNF- α , to JNK activation (Nakano *et al.* (2000) NESK, a member of the germinal center kinase family that activates the c-Jun N-terminal kinase pathway and is expressed during the late stages of embryogenesis. JBC, 275(27), 20533-20539). It has been proposed that NESK functions as an intracellular signalling molecule in developmental processes occurring late in the embryogenetic process (Nakano, K. *et al.* (2000) NESK, a member of the germinal center kinase family that activates the c-Jun N-terminal kinase pathway and is expressed during the late stages of embryogenesis. JBC, 275 (27), 20533-20539).

As NIK kinases play such a key role in cellular signalling processes, it is not surprising that dysregulation of these kinases impinges on a variety of disorders. In particular, dysregulation of NESK kinases is likely to result in a disorder of the late stage of embryogenetic development. Identification of NIK and NESK kinases is therefore of extreme importance in increasing understanding of the underlying pathways that lead to the disorders mentioned above and in developing more effective gene or drug therapies to treat these disorders.

THE INVENTION

The invention is based on the discovery that the human INSP081, INSP082 and INSP091 polypeptides are members of the Germinal Center Kinase (GCK) subfamily of the STE20 family of protein kinases, preferably NIK-like kinases and more preferably NIK-like embryo specific kinases (NESK).

In one embodiment of the first aspect of the invention, there is provided a polypeptide which:

- (i) comprises the amino acid sequence as recited in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40 and/or SEQ ID NO:42;

- (ii) is a fragment thereof which is a member of the Germinal Center Kinase (GCK) subfamily of the STE20 family of protein kinases, preferably a NIK-like kinase and more preferably a NIK-like embryo specific kinase (NESK), or has an antigenic determinant in common with the polypeptides of (i); or

- 5 (iii) is a functional equivalent of (i) or (ii).

Preferably, the polypeptide according to this first embodiment of the first aspect of the invention:

- (i) comprises the amino acid sequence as recited in SEQ ID NO:42;
- (ii) is a fragment thereof which is a member of the Germinal Center Kinase (GCK) subfamily of the STE20 family of protein kinases, preferably a NIK-like kinase and more preferably a NIK-like embryo specific kinase (NESK), or has an antigenic determinant in common with the polypeptides of (i); or
- 10 (iii) is a functional equivalent of (i) or (ii).

According to a second embodiment of this first aspect of the invention, there is provided a polypeptide which:

- (i) consists of the amino acid sequence as recited in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40 and/or SEQ ID NO:42;
- 20 (ii) is a fragment thereof which is a member of the Germinal Center Kinase (GCK) subfamily of the STE20 family of protein kinases, preferably a NIK-like kinase and more preferably a NIK-like embryo specific kinase (NESK), or having an antigenic determinant in common with the polypeptides of (i); or
- 25 (iii) is a functional equivalent of (i) or (ii).

The polypeptide having the sequence recited in SEQ ID NO:2 is referred to hereafter as "INSP081 exon 1 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:4 is referred to hereafter as "INSP081 exon 2 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:6 is referred to hereafter as "INSP081 exon 3 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:8 is referred to

hereafter as "INSP081 exon 4 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:10 is referred to hereafter as "INSP081 exon 5 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:12 is referred to hereafter as "INSP081 exon 6 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:14 is referred to hereafter as "INSP081 exon 7 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:16 is referred to hereafter as "INSP081 exon 8 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:18 is referred to hereafter as "INSP081 exon 9 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:20 is referred to hereafter as "INSP081 exon 10 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:22 is referred to hereafter as "INSP081 exon 11 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:24 is referred to hereafter as "INSP081 exon 12 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:26 is referred to hereafter as "INSP081 exon 13 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:28 is referred to hereafter as "INSP081 exon 14 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:30 is referred to hereafter as "INSP081 exon 15 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:32 is referred to hereafter as "INSP081 exon 16 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:34 is referred to hereafter as "INSP081 exon 17 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:36 is referred to hereafter as "INSP081 exon 18 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:38 is referred to hereafter as "INSP081 exon 19 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:40 is referred to hereafter as "INSP081 exon 20 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:42 is referred to hereafter as the "INSP081 polypeptide".

The term "INSP081 polypeptides" as used herein includes polypeptides comprising the INSP081 exon 1 polypeptide, the INSP081 exon 2 polypeptide, the INSP081 exon 3 polypeptide, the INSP081 exon 4 polypeptide, the INSP081 exon 5 polypeptide, the INSP081 exon 6 polypeptide, the INSP081 exon 7 polypeptide, the INSP081 exon 8 polypeptide, the INSP081 exon 9 polypeptide, the INSP081 exon 10 polypeptide, the INSP081 exon 11 polypeptide, the INSP081 exon 12 polypeptide, the INSP081 exon 13 polypeptide, the INSP081 exon 14 polypeptide, the INSP081 exon 15 polypeptide, the INSP081 exon 16 polypeptide, the INSP081 exon 17 polypeptide, the INSP081 exon 18

polypeptide, the INSP081 exon 19 polypeptide, the INSP081 exon 20 polypeptide and the INSP081 polypeptide.

~~In a third embodiment of the first aspect of the invention, there is provided a polypeptide~~
which:

- 5 (i) comprises the amino acid sequence as recited in SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:64, SEQ ID NO:66, SEQ ID NO:68, SEQ ID NO:70, SEQ ID NO:72, SEQ ID NO:74, SEQ ID NO:76, SEQ ID NO:78, SEQ ID NO:80, SEQ ID NO:82, SEQ ID NO:84, SEQ ID NO:86,
10 SEQ ID NO:88, SEQ ID NO:90, SEQ ID NO:92, SEQ ID NO:94, SEQ ID NO:96, SEQ ID NO:98 and/or SEQ ID NO:100;
- (ii) is a fragment thereof which is a member of the Germinal Center Kinase (GCK) subfamily of the STE20 family of protein kinases, preferably a NIK-like kinase and more preferably a NIK-like embryo specific kinase (NESK), or has an antigenic
15 determinant in common with the polypeptides of (i); or
- (iii) is a functional equivalent of (i) or (ii).

Preferably, the polypeptide according to this third embodiment of the first aspect of the invention:

- (i) comprises the amino acid sequence as recited in SEQ ID NO:100;
- 20 (ii) is a fragment thereof which is a member of the Germinal Center Kinase (GCK) subfamily of the STE20 family of protein kinases, preferably a NIK-like kinase and more preferably a NIK-like embryo specific kinase (NESK), or has an antigenic determinant in common with the polypeptides of (i); or
- (iii) is a functional equivalent of (i) or (ii).

25 According to a fourth embodiment of this first aspect of the invention, there is provided a polypeptide which:

- (i) consists of the amino acid sequence as recited in SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:64, SEQ ID NO:66,
30 SEQ ID NO:68, SEQ ID NO:70, SEQ ID NO:72, SEQ ID NO:74, SEQ ID NO:76,

SEQ ID NO:78, SEQ ID NO:80, SEQ ID NO:82, SEQ ID NO:84, SEQ ID NO:86,
SEQ ID NO:88, SEQ ID NO:90, SEQ ID NO:92, SEQ ID NO:94, SEQ ID NO:96,
SEQ ID NO:98 and/or SEQ ID NO:100;

- (ii) is a fragment thereof which is a member of the Germinal Center Kinase (GCK)
subfamily of the STE20 family of protein kinases, preferably a NIK-like kinase and
more preferably a NIK-like embryo specific kinase (NESK), or has an antigenic
determinant in common with the polypeptides of (i); or
- (iii) is a functional equivalent of (i) or (ii).

The polypeptide having the sequence recited in SEQ ID NO:44 is referred to hereafter as
"INSP082 exon 1 polypeptide". The polypeptide having the sequence recited in SEQ ID
NO:46 is referred to hereafter as "INSP082 exon 2 polypeptide". The polypeptide having
the sequence recited in SEQ ID NO:48 is referred to hereafter as "INSP082 exon 3
polypeptide". The polypeptide having the sequence recited in SEQ ID NO:50 is referred to
hereafter as "INSP082 exon 4 polypeptide". The polypeptide having the sequence recited
in SEQ ID NO:52 is referred to hereafter as "INSP082 exon 5 polypeptide". The
polypeptide having the sequence recited in SEQ ID NO:54 is referred to hereafter as
"INSP082 exon 6 polypeptide". The polypeptide having the sequence recited in SEQ ID
NO:56 is referred to hereafter as "INSP082 exon 7 polypeptide". The polypeptide having
the sequence recited in SEQ ID NO:58 is referred to hereafter as "INSP082 exon 8
polypeptide". The polypeptide having the sequence recited in SEQ ID NO:60 is referred to
hereafter as "INSP082 exon 9 polypeptide". The polypeptide having the sequence recited
in SEQ ID NO:62 is referred to hereafter as "INSP082 exon 10 polypeptide". The
polypeptide having the sequence recited in SEQ ID NO:64 is referred to hereafter as
"INSP082 exon 11 polypeptide". The polypeptide having the sequence recited in SEQ ID
NO:66 is referred to hereafter as "INSP082 exon 12 polypeptide". The polypeptide having
the sequence recited in SEQ ID NO:68 is referred to hereafter as "INSP082 exon 13
polypeptide". The polypeptide having the sequence recited in SEQ ID NO:70 is referred to
hereafter as "INSP082 exon 14 polypeptide". The polypeptide having the sequence recited
in SEQ ID NO:72 is referred to hereafter as "INSP082 exon 15 polypeptide". The
polypeptide having the sequence recited in SEQ ID NO:74 is referred to hereafter as
"INSP082 exon 16 polypeptide". The polypeptide having the sequence recited in SEQ ID
NO:76 is referred to hereafter as "INSP082 exon 17 polypeptide". The polypeptide having

the sequence recited in SEQ ID NO:78 is referred to hereafter as "INSP082 exon 18 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:80 is referred to hereafter as "INSP082 exon 19 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:82 is referred to hereafter as "INSP082 exon 20 polypeptide". The

5 polypeptide having the sequence recited in SEQ ID NO:84 is referred to hereafter as "INSP082 exon 21 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:86 is referred to hereafter as "INSP082 exon 22 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:88 is referred to hereafter as "INSP082 exon 23 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:90 is referred to

10 hereafter as "INSP082 exon 24 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:92 is referred to hereafter as "INSP082 exon 25 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:94 is referred to hereafter as "INSP082 exon 26 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:96 is referred to hereafter as "INSP082 exon 27 polypeptide". The polypeptide having

15 the sequence recited in SEQ ID NO:98 is referred to hereafter as "INSP082 exon 28 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:100 is referred to hereafter as the "INSP082 polypeptide".

The term "INSP082 polypeptides" as used herein includes polypeptides comprising the INSP082 exon 1 polypeptide, the INSP082 exon 2 polypeptide, the INSP082 exon 3

20 polypeptide, the INSP082 exon 4 polypeptide, the INSP082 exon 5 polypeptide, the INSP082 exon 6 polypeptide, the INSP082 exon 7 polypeptide, the INSP082 exon 8 polypeptide, the INSP082 exon 9 polypeptide, the INSP082 exon 10 polypeptide, the INSP082 exon 11 polypeptide, the INSP082 exon 12 polypeptide, the INSP082 exon 13 polypeptide, the INSP082 exon 14 polypeptide, the INSP082 exon 15 polypeptide, the

25 INSP082 exon 16 polypeptide, the INSP082 exon 17 polypeptide, the INSP082 exon 18 polypeptide, the INSP082 exon 19 polypeptide, the INSP082 exon 20 polypeptide, the INSP082 exon 21 polypeptide, the INSP082 exon 22 polypeptide, the INSP082 exon 23 polypeptide, the INSP082 exon 24 polypeptide, the INSP082 exon 25 polypeptide, the INSP082 exon 26 polypeptide, the INSP082 exon 27 polypeptide, the INSP082 exon 28

30 polypeptide and the INSP082 polypeptide.

In a fifth embodiment of the first aspect of the invention, there is provided a polypeptide which:

- (i) comprises the amino acid sequence as recited in SEQ ID NO:102, SEQ ID NO:104, SEQ ID NO:106, SEQ ID NO:108, SEQ ID NO:110, SEQ ID NO:112, SEQ ID NO:114, SEQ ID NO:116, SEQ ID NO:118, SEQ ID NO:120, SEQ ID NO:122, SEQ ID NO:124, SEQ ID NO:126, SEQ ID NO:128, SEQ ID NO:130, SEQ ID NO:132, SEQ ID NO:134, SEQ ID NO:136, SEQ ID NO:138, SEQ ID NO:140, SEQ ID NO:142, SEQ ID NO:144, SEQ ID NO:146, SEQ ID NO:148, SEQ ID NO:150, SEQ ID NO:152, SEQ ID NO:154, SEQ ID NO:156 and/or SEQ ID NO:158;
- 10 (ii) is a fragment thereof which is a member of the Germinal Center Kinase (GCK) subfamily of the STE20 family of protein kinases, preferably a NIK-like kinase and more preferably a NIK-like embryo specific kinase (NESK), or has an antigenic determinant in common with the polypeptides of (i); or
- (iii) is a functional equivalent of (i) or (ii).

15 Preferably, the polypeptide according to this fifth embodiment of the first aspect of the invention:

- (i) comprises the amino acid sequence as recited in SEQ ID NO:158;
- (ii) is a fragment thereof which is a member of the Germinal Center Kinase (GCK) subfamily of the STE20 family of protein kinases, preferably a NIK-like kinase and more preferably a NIK-like embryo specific kinase (NESK), or has an antigenic determinant in common with the polypeptides of (i); or
- 20 (iii) is a functional equivalent of (i) or (ii).

According to a sixth embodiment of this first aspect of the invention, there is provided a polypeptide which:

- 25 (i) consists of the amino acid sequence as recited in SEQ ID NO:102, SEQ ID NO:104, SEQ ID NO:106, SEQ ID NO:108, SEQ ID NO:110, SEQ ID NO:112, SEQ ID NO:114, SEQ ID NO:116, SEQ ID NO:118, SEQ ID NO:120, SEQ ID NO:122, SEQ ID NO:124, SEQ ID NO:126, SEQ ID NO:128, SEQ ID NO:130, SEQ ID NO:132, SEQ ID NO:134, SEQ ID NO:136, SEQ ID NO:138, SEQ ID NO:140, SEQ ID NO:142, SEQ ID NO:144, SEQ ID NO:146, SEQ ID NO:148, SEQ ID NO:150, SEQ ID NO:152, SEQ ID NO:154, SEQ ID NO:156 and/or SEQ ID NO:158;
- 30

- (ii) is a fragment thereof which is a member of the Germinal Center Kinase (GCK) subfamily of the STE20 family of protein kinases, preferably a NIK-like kinase and more preferably a NIK-like embryo specific kinase (NESK), or has an antigenic determinant in common with the polypeptides of (i); or

- 5 (iii) is a functional equivalent of (i) or (ii).

The polypeptide having the sequence recited in SEQ ID NO:102 is referred to hereafter as "INSP091 exon 1 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:104 is referred to hereafter as "INSP091 exon 2 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:106 is referred to hereafter as "INSP091 exon 3 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:108 is referred to hereafter as "INSP091 exon 4 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:110 is referred to hereafter as "INSP091 exon 5 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:112 is referred to hereafter as "INSP091 exon 6 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:114 is referred to hereafter as "INSP091 exon 7 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:116 is referred to hereafter as "INSP091 exon 8 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:118 is referred to hereafter as "INSP091 exon 9 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:120 is referred to hereafter as "INSP091 exon 10 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:122 is referred to hereafter as "INSP091 exon 11 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:124 is referred to hereafter as "INSP091 exon 12 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:126 is referred to hereafter as "INSP091 exon 13 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:128 is referred to hereafter as "INSP091 exon 14 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:130 is referred to hereafter as "INSP091 exon 15 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:132 is referred to hereafter as "INSP091 exon 16 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:134 is referred to hereafter as "INSP091 exon 17 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:136 is referred to hereafter as "INSP091 exon 18 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:138 is referred to hereafter as "INSP091 exon 19 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:140 is referred to hereafter as "INSP091 exon

20 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:142 is referred to hereafter as "INSP091 exon 21 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:144 is referred to hereafter as "INSP091 exon 22 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:146 is referred to hereafter as "INSP091 exon 23 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:148 is referred to hereafter as "INSP091 exon 24 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:150 is referred to hereafter as "INSP091 exon 25 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:152 is referred to hereafter as "INSP091 exon 26 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:154 is referred to hereafter as "INSP091 exon 27 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:156 is referred to hereafter as "INSP091 exon 28 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:158 is referred to hereafter as the "INSP091 polypeptide".

The term "INSP091 polypeptides" as used herein includes polypeptides comprising the INSP091 exon 1 polypeptide, the INSP091 exon 2 polypeptide, the INSP091 exon 3 polypeptide, the INSP091 exon 4 polypeptide, the INSP091 exon 5 polypeptide, the INSP091 exon 6 polypeptide, the INSP091 exon 7 polypeptide, the INSP091 exon 8 polypeptide, the INSP091 exon 9 polypeptide, the INSP091 exon 10 polypeptide, the INSP091 exon 11 polypeptide, the INSP091 exon 12 polypeptide, the INSP091 exon 13 polypeptide, the INSP091 exon 14 polypeptide, the INSP091 exon 15 polypeptide, the INSP091 exon 16 polypeptide, the INSP091 exon 17 polypeptide, the INSP091 exon 18 polypeptide, the INSP091 exon 19 polypeptide, the INSP091 exon 20 polypeptide, the INSP091 exon 21 polypeptide, the INSP091 exon 22 polypeptide, the INSP091 exon 23 polypeptide, the INSP091 exon 24 polypeptide, the INSP091 exon 25 polypeptide, the INSP091 exon 26 polypeptide, the INSP091 exon 27 polypeptide, the INSP091 exon 28 polypeptide and the INSP091 polypeptide.

The INSP081 polypeptide is a splice variant of the INSP082 and INSP091 polypeptides. Whilst INSP081 contains a STOP codon over the exon 20/exon 21 splice junction, INSP082 does not. Thus, INSP081 contains 20 exons and is 1132 amino acids long whereas INSP082 contains 28 exons is 1500 amino acids long. The presence of the STOP codon in intron 20 truncates INSP081 such that it does not contain the putative C-terminal regulatory domain. INSP082 on the other hand is predicted to contain this C-terminal regulatory (CNH) domain. INSP091 is also predicted to contain the putative C-terminal

regulatory domain, and is identical to the INSP081 and INSP082 polypeptides from its N-terminus until exon 15. After exon 15 the INSP091 polypeptide is not identical to the INSP081 and INSP082 polypeptides, although it has a similar number of exons and has a

number of exons in common with the INSP081 and INSP082 polypeptides. The INSP091
5 polypeptide contains 28 exons and is 1589 amino acids long.

INSP081, INSP082 and INSP091 all map to the X chromosome at ChrX:101702493-101913965. INSP081, INSP082 and INSP091 each map to the same genomic locus as the human sequence ZC4 DNA disclosed in WO 99/53036. ZC4 DNA has been annotated as a STE20-related kinase. It has a similar number of exons to INSP081, INSP082 and
10 INSP091 polypeptides and has a number of exons in common with the predicted proteins. However, the total complement of exons used by INSP081, INSP082 and INSP091 is different from the total complement of exons used by ZC4 DNA. The sequence of ZC4 DNA is specifically excluded from the scope of this invention.

In a second aspect, the invention provides a purified nucleic acid molecule which encodes
15 a polypeptide of the first aspect of the invention.

In a first embodiment of the second aspect of the invention, the purified nucleic acid molecule comprises the nucleic acid sequence as recited in SEQ ID NO:1 (encoding the INSP081 exon 1 polypeptide), SEQ ID NO:3 (encoding the INSP081 exon 2 polypeptide), SEQ ID NO:5 (encoding the INSP081 exon 3 polypeptide), SEQ ID NO:7 (encoding the
20 INSP081 exon 4 polypeptide), SEQ ID NO:9 (encoding the INSP081 exon 5 polypeptide), SEQ ID NO:11 (encoding the INSP081 exon 6 polypeptide), SEQ ID NO:13 (encoding the INSP081 exon 7 polypeptide), SEQ ID NO:15 (encoding the INSP081 exon 8 polypeptide), SEQ ID NO:17 (encoding the INSP081 exon 9 polypeptide), SEQ ID NO:19 (encoding the INSP081 exon 10 polypeptide), SEQ ID NO:21 (encoding the INSP081
25 exon 11 polypeptide), SEQ ID NO:23 (encoding the INSP081 exon 12 polypeptide), SEQ ID NO:25 (encoding the INSP081 exon 13 polypeptide), SEQ ID NO:27 (encoding the INSP081 exon 14 polypeptide), SEQ ID NO:29 (encoding the INSP081 exon 15 polypeptide), SEQ ID NO:31 (encoding the INSP081 exon 16 polypeptide), SEQ ID NO:33 (encoding the INSP081 exon 17 polypeptide), SEQ ID NO:35 (encoding the
30 INSP081 exon 18 polypeptide), SEQ ID NO:37 (encoding the INSP081 exon 19 polypeptide), SEQ ID NO:39 (encoding the INSP081 exon 20 polypeptide) and/or SEQ ID NO:41 (encoding the INSP081 polypeptide) or is a redundant equivalent or fragment of

any one of these sequences.

The invention further provides that the purified nucleic acid molecule consists of the nucleic acid sequence as recited in SEQ ID NO:1 (encoding the INSP081 exon 1 polypeptide), SEQ ID NO:3 (encoding the INSP081 exon 2 polypeptide), SEQ ID NO:5 (encoding the INSP081 exon 3 polypeptide), SEQ ID NO:7 (encoding the INSP081 exon 4 polypeptide), SEQ ID NO:9 (encoding the INSP081 exon 5 polypeptide), SEQ ID NO:11 (encoding the INSP081 exon 6 polypeptide), SEQ ID NO:13 (encoding the INSP081 exon 7 polypeptide), SEQ ID NO:15 (encoding the INSP081 exon 8 polypeptide), SEQ ID NO:17 (encoding the INSP081 exon 9 polypeptide), SEQ ID NO:19 (encoding the INSP081 exon 10 polypeptide), SEQ ID NO:21 (encoding the INSP081 exon 11 polypeptide), SEQ ID NO:23 (encoding the INSP081 exon 12 polypeptide), SEQ ID NO:25 (encoding the INSP081 exon 13 polypeptide), SEQ ID NO:27 (encoding the INSP081 exon 14 polypeptide), SEQ ID NO:29 (encoding the INSP081 exon 15 polypeptide), SEQ ID NO:31 (encoding the INSP081 exon 16 polypeptide), SEQ ID NO:33 (encoding the INSP081 exon 17 polypeptide), SEQ ID NO:35 (encoding the INSP081 exon 18 polypeptide), SEQ ID NO:37 (encoding the INSP081 exon 19 polypeptide), SEQ ID NO:39 (encoding the INSP081 exon 20 polypeptide) and/or SEQ ID NO:41 (encoding the INSP081 polypeptide) or is a redundant equivalent or fragment of any one of these sequences.

In a second embodiment of the second aspect of the invention, the purified nucleic acid molecule comprises the nucleic acid sequence as recited in SEQ ID NO:43 (encoding the INSP082 exon 1 polypeptide), SEQ ID NO:45 (encoding the INSP082 exon 2 polypeptide), SEQ ID NO:47 (encoding the INSP082 exon 3 polypeptide), SEQ ID NO:49 (encoding the INSP082 exon 4 polypeptide), SEQ ID NO:51 (encoding the INSP082 exon 5 polypeptide), SEQ ID NO:53 (encoding the INSP082 exon 6 polypeptide), SEQ ID NO:55 (encoding the INSP082 exon 7 polypeptide), SEQ ID NO:57 (encoding the INSP082 exon 8 polypeptide), SEQ ID NO:59 (encoding the INSP082 exon 9 polypeptide), SEQ ID NO:61 (encoding the INSP082 exon 10 polypeptide), SEQ ID NO:63 (encoding the INSP082 exon 11 polypeptide), SEQ ID NO:65 (encoding the INSP082 exon 12 polypeptide), SEQ ID NO:67 (encoding the INSP082 exon 13 polypeptide), SEQ ID NO:69 (encoding the INSP082 exon 14 polypeptide), SEQ ID NO:71 (encoding the INSP082 exon 15 polypeptide), SEQ ID NO:73 (encoding the INSP082 exon 16 polypeptide), SEQ ID NO:75 (encoding the INSP082 exon 17

polypeptide), SEQ ID NO:77 (encoding the INSP082 exon 18 polypeptide), SEQ ID NO:79 (encoding the INSP082 exon 19 polypeptide), SEQ ID NO:81 (encoding the INSP082 exon 20 polypeptide), SEQ ID NO:83 (encoding the INSP082 exon 21 polypeptide), SEQ ID NO:85 (encoding the INSP082 exon 22 polypeptide), SEQ ID NO:87 (encoding the INSP082 exon 23 polypeptide), SEQ ID NO:89 (encoding the INSP082 exon 24 polypeptide), SEQ ID NO:91 (encoding the INSP082 exon 25 polypeptide), SEQ ID NO:93 (encoding the INSP082 exon 26 polypeptide), SEQ ID NO:95 (encoding the INSP082 exon 27 polypeptide), SEQ ID NO:97 (encoding the INSP082 exon 28 polypeptide) and/or SEQ ID NO:99 (encoding the INSP082 polypeptide) or is a redundant equivalent or fragment of any one of these sequences.

The invention further provides that the purified nucleic acid molecule consists of the nucleic acid sequence as recited in SEQ ID NO:43 (encoding the INSP082 exon 1 polypeptide), SEQ ID NO:45 (encoding the INSP082 exon 2 polypeptide), SEQ ID NO:47 (encoding the INSP082 exon 3 polypeptide), SEQ ID NO:49 (encoding the INSP082 exon 4 polypeptide), SEQ ID NO:51 (encoding the INSP082 exon 5 polypeptide), SEQ ID NO:53 (encoding the INSP082 exon 6 polypeptide), SEQ ID NO:55 (encoding the INSP082 exon 7 polypeptide), SEQ ID NO:57 (encoding the INSP082 exon 8 polypeptide), SEQ ID NO:59 (encoding the INSP082 exon 9 polypeptide), SEQ ID NO:61 (encoding the INSP082 exon 10 polypeptide), SEQ ID NO:63 (encoding the INSP082 exon 11 polypeptide), SEQ ID NO:65 (encoding the INSP082 exon 12 polypeptide), SEQ ID NO:67 (encoding the INSP082 exon 13 polypeptide), SEQ ID NO:69 (encoding the INSP082 exon 14 polypeptide), SEQ ID NO:71 (encoding the INSP082 exon 15 polypeptide), SEQ ID NO:73 (encoding the INSP082 exon 16 polypeptide), SEQ ID NO:75 (encoding the INSP082 exon 17 polypeptide), SEQ ID NO:77 (encoding the INSP082 exon 18 polypeptide), SEQ ID NO:79 (encoding the INSP082 exon 19 polypeptide), SEQ ID NO:81 (encoding the INSP082 exon 20 polypeptide), SEQ ID NO:83 (encoding the INSP082 exon 21 polypeptide), SEQ ID NO:85 (encoding the INSP082 exon 22 polypeptide), SEQ ID NO:87 (encoding the INSP082 exon 23 polypeptide), SEQ ID NO:89 (encoding the INSP082 exon 24 polypeptide), SEQ ID NO:91 (encoding the INSP082 exon 25 polypeptide), SEQ ID NO:93 (encoding the INSP082 exon 26 polypeptide), SEQ ID NO:95 (encoding the INSP082 exon 27 polypeptide), SEQ ID NO:97 (encoding the INSP082 exon 28 polypeptide) and/or SEQ ID NO:99 (encoding the INSP082 polypeptide) or is a redundant equivalent or fragment of

any one of these sequences.

In a third embodiment of the second aspect of the invention, the purified nucleic acid molecule comprises the nucleic acid sequence as recited in SEQ ID NO:101 (encoding the INSP091 exon 1 polypeptide), SEQ ID NO:103 (encoding the INSP091 exon 2 polypeptide), SEQ ID NO:105 (encoding the INSP091 exon 3 polypeptide), SEQ ID NO:107 (encoding the INSP091 exon 4 polypeptide), SEQ ID NO:109 (encoding the INSP091 exon 5 polypeptide), SEQ ID NO:111 (encoding the INSP091 exon 6 polypeptide), SEQ ID NO:113 (encoding the INSP091 exon 7 polypeptide), SEQ ID NO:115 (encoding the INSP091 exon 8 polypeptide), SEQ ID NO:117 (encoding the INSP091 exon 9 polypeptide), SEQ ID NO:119 (encoding the INSP091 exon 10 polypeptide), SEQ ID NO:121 (encoding the INSP091 exon 11 polypeptide), SEQ ID NO:123 (encoding the INSP091 exon 12 polypeptide), SEQ ID NO:125 (encoding the INSP091 exon 13 polypeptide), SEQ ID NO:127 (encoding the INSP091 exon 14 polypeptide), SEQ ID NO:129 (encoding the INSP091 exon 15 polypeptide), SEQ ID NO:131 (encoding the INSP091 exon 16 polypeptide), SEQ ID NO:133 (encoding the INSP091 exon 17 polypeptide), SEQ ID NO:135 (encoding the INSP091 exon 18 polypeptide), SEQ ID NO:137 (encoding the INSP091 exon 19 polypeptide), SEQ ID NO:139 (encoding the INSP091 exon 20 polypeptide), SEQ ID NO:141 (encoding the INSP091 exon 21 polypeptide), SEQ ID NO:143 (encoding the INSP091 exon 22 polypeptide), SEQ ID NO:145 (encoding the INSP091 exon 23 polypeptide), SEQ ID NO:147 (encoding the INSP091 exon 24 polypeptide), SEQ ID NO:149 (encoding the INSP091 exon 25 polypeptide), SEQ ID NO:151 (encoding the INSP091 exon 26 polypeptide), SEQ ID NO:153 (encoding the INSP091 exon 27 polypeptide), SEQ ID NO:155 (encoding the INSP091 exon 28 polypeptide) and/or SEQ ID NO:157 (encoding the INSP091 polypeptide) or is a redundant equivalent or fragment of any one of these sequences.

The invention further provides that the purified nucleic acid molecule consists of the nucleic acid sequence as recited in SEQ ID NO:101 (encoding the INSP091 exon 1 polypeptide), SEQ ID NO:103 (encoding the INSP091 exon 2 polypeptide), SEQ ID NO:105 (encoding the INSP091 exon 3 polypeptide), SEQ ID NO:107 (encoding the INSP091 exon 4 polypeptide), SEQ ID NO:109 (encoding the INSP091 exon 5 polypeptide), SEQ ID NO:111 (encoding the INSP091 exon 6 polypeptide), SEQ ID NO:113 (encoding the INSP091 exon 7 polypeptide), SEQ ID NO:115 (encoding the

INSP091 exon 8 polypeptide), SEQ ID NO:117 (encoding the INSP091 exon 9 polypeptide), SEQ ID NO:119 (encoding the INSP091 exon 10 polypeptide), SEQ ID NO:121 (encoding the INSP091 exon 11 polypeptide), SEQ ID NO:123 (encoding the INSP091 exon 12 polypeptide), SEQ ID NO:125 (encoding the INSP091 exon 13 polypeptide), SEQ ID NO:127 (encoding the INSP091 exon 14 polypeptide), SEQ ID NO:129 (encoding the INSP091 exon 15 polypeptide), SEQ ID NO:131 (encoding the INSP091 exon 16 polypeptide), SEQ ID NO:133 (encoding the INSP091 exon 17 polypeptide), SEQ ID NO:135 (encoding the INSP091 exon 18 polypeptide), SEQ ID NO:137 (encoding the INSP091 exon 19 polypeptide), SEQ ID NO:139 (encoding the INSP091 exon 20 polypeptide), SEQ ID NO:141 (encoding the INSP091 exon 21 polypeptide), SEQ ID NO:143 (encoding the INSP091 exon 22 polypeptide), SEQ ID NO:145 (encoding the INSP091 exon 23 polypeptide), SEQ ID NO:147 (encoding the INSP091 exon 24 polypeptide), SEQ ID NO:149 (encoding the INSP091 exon 25 polypeptide), SEQ ID NO:151 (encoding the INSP091 exon 26 polypeptide), SEQ ID NO:153 (encoding the INSP091 exon 27 polypeptide), SEQ ID NO:155 (encoding the INSP091 exon 28 polypeptide) and/or SEQ ID NO:157 (encoding the INSP091 polypeptide) or is a redundant equivalent or fragment of any one of these sequences.

Unigene cluster Hs.369523 is annotated as being weakly similar to STE20 protein kinase. Contained within this cluster are the human ESTs AI792963 (sourced from kidney and ovarian tissue), AI791391, AA865818, AI732997, AA977633 and BM546293 (sourced from ovarian tissue). These human ESTs are specifically excluded from the scope of this aspect of the invention. The BG622476 Human EST sequence is also specifically excluded from the scope of this aspect of the invention.

Murine mRNAs AB035267 and AB020741 are also specifically excluded from the scope of this aspect of the invention.

In a third aspect, the invention provides a purified nucleic acid molecule which hybridizes under high stringency conditions with a nucleic acid molecule of the second aspect of the invention.

In a fourth aspect, the invention provides a vector, such as an expression vector, that contains a nucleic acid molecule of the second or third aspect of the invention.

In a fifth aspect, the invention provides a host cell transformed with a vector of the fourth aspect of the invention.

In a sixth aspect, the invention provides a ligand which binds specifically to members of the Germinal Center Kinase (GCK) subfamily of the STE20 family of protein kinases, preferably to a NIK-like kinase and more preferably to a NIK-like embryo specific kinase (NESK) of the first aspect of the invention.

- 5 In a seventh aspect, the invention provides a compound that is effective to alter the expression of a natural gene which encodes a polypeptide of the first aspect of the invention or to regulate the activity of a polypeptide of the first aspect of the invention.

A compound of the seventh aspect of the invention may either increase (agonise) or decrease (antagonise) the level of expression of the gene or the activity of the polypeptide.

- 10 Importantly, the identification of the function of the INSP081, INSP082 and INSP091 polypeptides allows for the design of screening methods capable of identifying compounds that are effective in the treatment and/or diagnosis of disease. As used herein, the term "disease" also includes disorders. Ligands and compounds according to the sixth and seventh aspects of the invention may be identified using such methods. These methods are
15 included as aspects of the present invention.

- In an eighth aspect, the invention provides a polypeptide of the first aspect of the invention, or a nucleic acid molecule of the second or third aspect of the invention, or a vector of the fourth aspect of the invention, or a host cell of the fifth aspect of the invention, or a ligand of the sixth aspect of the invention, or a compound of the seventh
20 aspect of the invention, for use in therapy or diagnosis of diseases in which members of the Germinal Center Kinase (GCK) subfamily of the STE20 family of protein kinases, preferably NIK-like kinases and more preferably NIK-like embryo specific kinases (NESK) are implicated. Such diseases may include cell proliferative disorders, including neoplasm, melanoma, lung, colorectal, breast, pancreas, head and neck and other solid
25 tumours; myeloproliferative disorders, such as leukemia, non-Hodgkin lymphoma, leukopenia, thrombocytopenia, angiogenesis disorder, Kaposi's sarcoma; autoimmune/inflammatory disorders, including allergy, inflammatory bowel disease, arthritis, psoriasis and respiratory tract inflammation, asthma, and organ transplant rejection; cardiovascular disorders, including hypertension, oedema, angina,
30 atherosclerosis, thrombosis, sepsis, shock, reperfusion injury, and ischemia; neurological disorders including central nervous system disease, Alzheimer's disease, brain injury, amyotrophic lateral sclerosis, and pain; developmental disorders; metabolic disorders

including diabetes mellitus, osteoporosis, and obesity, AIDS and renal disease; infections including viral infection, bacterial infection, fungal infection and parasitic infection and other pathological conditions and in particular developmental disorders of late embryogenesis and neural tube defects such as spina bifida. These molecules may also be
5 used in the manufacture of a medicament for the treatment of such disorders.

In a ninth aspect, the invention provides a method of diagnosing a disease or disorder in a patient, comprising assessing the level of expression of a natural gene encoding a polypeptide of the first aspect of the invention or the activity of a polypeptide of the first aspect of the invention in tissue from said patient and comparing said level of expression
10 or activity to a control level, wherein a level that is different to said control level is indicative of disease or disorder. Such a method will preferably be carried out *in vitro*. Similar methods may be used for monitoring the therapeutic treatment of disease or disorder in a patient, wherein altering the level of expression or activity of a polypeptide or nucleic acid molecule over the period of time towards a control level is indicative of
15 regression of disease or disorder.

A preferred method for detecting polypeptides of the first aspect of the invention comprises the steps of: (a) contacting a ligand, such as an antibody, of the sixth aspect of the invention with a biological sample under conditions suitable for the formation of a ligand-polypeptide complex; and (b) detecting said complex.

20 A number of different such methods according to the ninth aspect of the invention exist, as the skilled reader will be aware, such as methods of nucleic acid hybridization with short probes, point mutation analysis, polymerase chain reaction (PCR) amplification and methods using antibodies to detect aberrant protein levels. Similar methods may be used on a short or long term basis to allow therapeutic treatment of a disease to be monitored in
25 a patient. The invention also provides kits that are useful in these methods for diagnosing disease.

In a tenth aspect, the invention provides for the use of a polypeptide of the first aspect of the invention as a Germinal Center Kinase (GCK), preferably as a NIK-like kinase and more preferably as a NIK-like embryo specific kinase (NESK). Suitable uses of the
30 polypeptides of the invention as Germinal Center Kinases (GCK), preferably as NIK-like kinases and more preferably as NIK-like embryo specific kinases (NESK) include use as a regulator of cellular growth, metabolism or differentiation, use as part of a receptor/ligand

pair and use as a diagnostic marker for a physiological or pathological condition.

In an eleventh aspect, the invention provides a pharmaceutical composition comprising a polypeptide of the first aspect of the invention, or a nucleic acid molecule of the second or third aspect of the invention, or a vector of the fourth aspect of the invention, or a host cell
5 of the fifth aspect of the invention, or a ligand of the sixth aspect of the invention, or a compound of the seventh aspect of the invention, in conjunction with a pharmaceutically-acceptable carrier.

In a twelfth aspect, the present invention provides a polypeptide of the first aspect of the invention, or a nucleic acid molecule of the second or third aspect of the invention, or a
10 vector of the fourth aspect of the invention, or a host cell of the fifth aspect of the invention, or a ligand of the sixth aspect of the invention, or a compound of the seventh aspect of the invention, for use in the manufacture of a medicament for the diagnosis or treatment of a disease or disorder.

In a thirteenth aspect, the invention provides a method of treating a disease in a patient
15 comprising administering to the patient a polypeptide of the first aspect of the invention, or a nucleic acid molecule of the second or third aspect of the invention, or a vector of the fourth aspect of the invention, or a host cell of the fifth aspect of the invention, or a ligand of the sixth aspect of the invention, or a compound of the seventh aspect of the invention.

For diseases or disorders in which the expression of a natural gene encoding a polypeptide
20 of the first aspect of the invention, or in which the activity of a polypeptide of the first aspect of the invention, is lower in a diseased patient or a patient affected by a disorder when compared to the level of expression or activity in a healthy patient, the polypeptide, nucleic acid molecule, ligand or compound administered to the patient should be an agonist. Conversely, for diseases or disorders in which the expression of the natural gene
25 or activity of the polypeptide is higher in a diseased patient or in a patient affected by a disorder when compared to the level of expression or activity in a healthy patient, the polypeptide, nucleic acid molecule, ligand or compound administered to the patient should be an antagonist. Examples of such antagonists include antisense nucleic acid molecules, ribozymes and ligands, such as antibodies.

30 In a fourteenth aspect, the invention provides transgenic or knockout non-human animals that have been transformed to express higher, lower or absent levels of a polypeptide of the first aspect of the invention. Such transgenic animals are very useful models for the study

of disease/disorders and may also be used in screening regimes for the identification of compounds that are effective in the treatment or diagnosis of such a disease/disorder.

~~A summary of standard techniques and procedures which may be employed in order to~~
utilise the invention is given below. It will be understood that this invention is not limited
5 to the particular methodology, protocols, cell lines, vectors and reagents described. It is
also to be understood that the terminology used herein is for the purpose of describing
particular embodiments only and it is not intended that this terminology should limit the
scope of the present invention. The extent of the invention is limited only by the terms of
the appended claims.

10 Standard abbreviations for nucleotides and amino acids are used in this specification.

The practice of the present invention will employ, unless otherwise indicated, conventional techniques of molecular biology, microbiology, recombinant DNA technology and immunology, which are within the skill of those working in the art.

Such techniques are explained fully in the literature. Examples of particularly suitable texts
15 for consultation include the following: Sambrook Molecular Cloning; A Laboratory
Manual, Second Edition (1989); DNA Cloning, Volumes I and II (D.N Glover ed. 1985);
Oligonucleotide Synthesis (M.J. Gait ed. 1984); Nucleic Acid Hybridization (B.D. Hames
& S.J. Higgins eds. 1984); Transcription and Translation (B.D. Hames & S.J. Higgins eds.
1984); Animal Cell Culture (R.I. Freshney ed. 1986); Immobilized Cells and Enzymes
20 (IRL Press, 1986); B. Perbal, A Practical Guide to Molecular Cloning (1984); the Methods
in Enzymology series (Academic Press, Inc.), especially volumes 154 & 155; Gene
Transfer Vectors for Mammalian Cells (J.H. Miller and M.P. Calos eds. 1987, Cold Spring
Harbor Laboratory); Immunochemical Methods in Cell and Molecular Biology (Mayer and
Walker, eds. 1987, Academic Press, London); Scopes, (1987) Protein Purification:
25 Principles and Practice, Second Edition (Springer Verlag, N.Y.); and Handbook of
Experimental Immunology, Volumes I-IV (D.M. Weir and C. C. Blackwell eds. 1986).

As used herein, the term "polypeptide" includes any peptide or protein comprising two or
more amino acids joined to each other by peptide bonds or modified peptide bonds, i.e.
peptide isosteres. This term refers both to short chains (peptides and oligopeptides) and to
30 longer chains (proteins).

The polypeptide of the present invention may be in the form of a mature protein or may be a pre-, pro- or prepro- protein that can be activated by cleavage of the pre-, pro- or prepro- portion to produce an active mature polypeptide. In such polypeptides, the pre-, pro- or prepro- sequence may be a leader or secretory sequence or may be a sequence that is
5 employed for purification of the mature polypeptide sequence.

The polypeptide of the first aspect of the invention may form part of a fusion protein. For example, it is often advantageous to include one or more additional amino acid sequences which may contain secretory or leader sequences, pro-sequences, sequences which aid in purification, or sequences that confer higher protein stability, for example during
10 recombinant production. Alternatively or additionally, the mature polypeptide may be fused with another compound, such as a compound to increase the half-life of the polypeptide (for example, polyethylene glycol).

Polypeptides may contain amino acids other than the 20 gene-encoded amino acids, modified either by natural processes, such as by post-translational processing or by
15 chemical modification techniques which are well known in the art. Among the known modifications which may commonly be present in polypeptides of the present invention are glycosylation, lipid attachment, sulphation, gamma-carboxylation, for instance of glutamic acid residues, hydroxylation and ADP-ribosylation. Other potential modifications include acetylation, acylation, amidation, covalent attachment of flavin, covalent
20 attachment of a haeme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulphide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation, GPI anchor formation, iodination, methylation, myristoylation, oxidation,
25 proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination.

Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. In fact, blockage of the amino or carboxyl terminus in a polypeptide, or both, by a covalent modification is common in
30 naturally-occurring and synthetic polypeptides and such modifications may be present in polypeptides of the present invention.

The modifications that occur in a polypeptide often will be a function of how the polypeptide is made. For polypeptides that are made recombinantly, the nature and extent of the modifications in large part will be determined by the post-translational modification capacity of the particular host cell and the modification signals that are present in the amino acid sequence of the polypeptide in question. For instance, glycosylation patterns vary between different types of host cell.

The polypeptides of the present invention can be prepared in any suitable manner. Such polypeptides include isolated naturally-occurring polypeptides (for example purified from cell culture), recombinantly-produced polypeptides (including fusion proteins), synthetically-produced polypeptides or polypeptides that are produced by a combination of these methods.

The functionally-equivalent polypeptides of the first aspect of the invention may be polypeptides that are homologous to the INSP081, INSP082 and INSP091 polypeptides. Two polypeptides are said to be "homologous", as the term is used herein, if the sequence of one of the polypeptides has a high enough degree of identity or similarity to the sequence of the other polypeptide. "Identity" indicates that at any particular position in the aligned sequences, the amino acid residue is identical between the sequences. "Similarity" indicates that, at any particular position in the aligned sequences, the amino acid residue is of a similar type between the sequences. Degrees of identity and similarity can be readily calculated (Computational Molecular Biology, Lesk, A.M., ed., Oxford University Press, New York, 1988; Biocomputing. Informatics and Genome Projects, Smith, D.W., ed., Academic Press, New York, 1993; Computer Analysis of Sequence Data, Part 1, Griffin, A.M., and Griffin, H.G., eds., Humana Press, New Jersey, 1994; Sequence Analysis in Molecular Biology, von Heinje, G., Academic Press, 1987; and Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991).

Homologous polypeptides therefore include natural biological variants (for example, allelic variants or geographical variations within the species from which the polypeptides are derived) and mutants (such as mutants containing amino acid substitutions, insertions or deletions) of the INSP081, INSP082 and INSP091 polypeptides. Such mutants may include polypeptides in which one or more of the amino acid residues are substituted with a conserved or non-conserved amino acid residue (preferably a conserved amino acid residue) and such substituted amino acid residue may or may not be one encoded by the

genetic code. Typical such substitutions are among Ala, Val, Leu and Ile; among Ser and Thr; among the acidic residues Asp and Glu; among Asn and Gln; among the basic residues Lys and Arg; or among the aromatic residues Phe and Tyr. Particularly preferred are variants in which several, i.e. between 5 and 10, 1 and 5, 1 and 3, 1 and 2 or just 1 amino acids are substituted, deleted or added in any combination. Especially preferred are silent substitutions, additions and deletions, which do not alter the properties and activities of the protein. Also especially preferred in this regard are conservative substitutions. Such mutants also include polypeptides in which one or more of the amino acid residues includes a substituent group.

- 10 Typically, greater than 30% identity between two polypeptides is considered to be an indication of functional equivalence. Preferably, functionally equivalent polypeptides of the first aspect of the invention have a degree of sequence identity with the INSP081, INSP082 or INSP091 polypeptides, or with active fragments thereof, of greater than 80%. More preferred polypeptides have degrees of identity of greater than 85%, 90%, 95%, 98%
15 or 99%, respectively.

- The functionally-equivalent polypeptides of the first aspect of the invention may also be polypeptides which have been identified using one or more techniques of structural alignment. For example, the Inpharmatica Genome Threader technology that forms one aspect of the search tools used to generate the Biopendium™ search database may be used
20 (see PCT application WO 01/69507) to identify polypeptides of presently-unknown function which, while having low sequence identity as compared to the INSP081, INSP082 and INSP091 polypeptides, are predicted to be members of the Germinal Center Kinase (GCK) subfamily of the STE20 family of protein kinases, preferably NIK-like kinases and more preferably NIK-like embryo specific kinases (NESK), by virtue of sharing significant
25 structural homology with the INSP081, INSP082 and INSP091 polypeptide sequences. By "significant structural homology" is meant that the Inpharmatica Genome Threader predicts two proteins to share structural homology with a certainty of 10% and above.

- The polypeptides of the first aspect of the invention also include fragments of the INSP081, INSP082 and INSP091 polypeptides and fragments of the functional equivalents
30 of the INSP081, INSP082 and INSP091 polypeptides, provided that those fragments are members of the Germinal Center Kinase (GCK) subfamily of the STE20 family of protein kinases, preferably NIK-like kinases and more preferably NIK-like embryo specific

kinases (NESK) or have an antigenic determinant in common with the INSP081, INSP082 and INSP091 polypeptides.

As used herein, the term "fragment" refers to a polypeptide having an amino acid sequence

that is the same as part, but not all, of the amino acid sequence of the INSP081, INSP082
5 and INSP091 polypeptides or one of their functional equivalents. The fragments should comprise at least n consecutive amino acids from the sequence and, depending on the particular sequence, n preferably is 7 or more (for example, 8, 10, 12, 14, 16, 18, 20 or more). Small fragments may form an antigenic determinant.

Fragments of the full length INSP081 polypeptides may comprise combinations of 2, 3, 4,
10 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 neighbouring exon sequences in the INSP081 polypeptide sequences (for example, they may consist of a fragment having the sequence given in exons 1 and 2, in exons 6, 7 and 8, in exons 10, 11, 12, 13, 14, 15 and 16 and so forth).

Fragments of the full length INSP082 polypeptides may comprise combinations of 2, 3, 4,
15 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27 or 28 neighbouring exon sequences in the INSP082 polypeptide sequences.

Fragments of the full length INSP091 polypeptides may comprise combinations of 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27 or 28 neighbouring exon sequences in the INSP091 polypeptide sequences.

20 Such fragments may be "free-standing", i.e. not part of or fused to other amino acids or polypeptides, or they may be comprised within a larger polypeptide of which they form a part or region. When comprised within a larger polypeptide, the fragment of the invention most preferably forms a single continuous region. For instance, certain preferred embodiments relate to a fragment having a pre- and/or pro- polypeptide region fused to the
25 amino terminus of the fragment and/or an additional region fused to the carboxyl terminus of the fragment. However, several fragments may be comprised within a single larger polypeptide.

The polypeptides of the present invention or their immunogenic fragments (comprising at least one antigenic determinant) can be used to generate ligands, such as polyclonal or
30 monoclonal antibodies, that are immunospecific for the polypeptides. Such antibodies may be employed to isolate or to identify clones expressing the polypeptides of the invention or

to purify the polypeptides by affinity chromatography. The antibodies may also be employed as diagnostic or therapeutic aids, amongst other applications, as will be apparent to the skilled reader.

The term "immunospecific" means that the antibodies have substantially greater affinity
5 for the polypeptides of the invention than their affinity for other related polypeptides in the prior art. As used herein, the term "antibody" refers to intact molecules as well as to fragments thereof, such as Fab, F(ab')₂ and Fv, which are capable of binding to the antigenic determinant in question. Such antibodies thus bind to the polypeptides of the first aspect of the invention.

10 If polyclonal antibodies are desired, a selected mammal, such as a mouse, rabbit, goat or horse, may be immunised with a polypeptide of the first aspect of the invention. The polypeptide used to immunise the animal can be derived by recombinant DNA technology or can be synthesized chemically. If desired, the polypeptide can be conjugated to a carrier protein. Commonly used carriers to which the polypeptides may be chemically coupled
15 include bovine serum albumin, thyroglobulin and keyhole limpet haemocyanin. The coupled polypeptide is then used to immunise the animal. Serum from the immunised animal is collected and treated according to known procedures, for example by immunoaffinity chromatography.

Monoclonal antibodies to the polypeptides of the first aspect of the invention can also be
20 readily produced by one skilled in the art. The general methodology for making monoclonal antibodies using hybridoma technology is well known (see, for example, Kohler, G. and Milstein, C., *Nature* 256: 495-497 (1975); Kozbor *et al.*, *Immunology Today* 4: 72 (1983); Cole *et al.*, 77-96 in *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, Inc. (1985).

25 Panels of monoclonal antibodies produced against the polypeptides of the first aspect of the invention can be screened for various properties, i.e., for isotype, epitope, affinity, etc. Monoclonal antibodies are particularly useful in purification of the individual polypeptides against which they are directed. Alternatively, genes encoding the monoclonal antibodies of interest may be isolated from hybridomas, for instance by PCR techniques known in the
30 art, and cloned and expressed in appropriate vectors.

Chimeric antibodies, in which non-human variable regions are joined or fused to human constant regions (see, for example, Liu *et al.*, *Proc. Natl. Acad. Sci. USA*, 84, 3439

(1987)), may also be of use.

The antibody may be modified to make it less immunogenic in an individual, for example by humanisation (see Jones *et al.*, Nature, 321, 522 (1986); Verhoeyen *et al.*, Science, 239,

- 1534 (1988); Kabat *et al.*, J. Immunol., 147, 1709 (1991); Queen *et al.*, Proc. Natl Acad. Sci. USA, 86, 10029 (1989); Gorman *et al.*, Proc. Natl Acad. Sci. USA, 88, 34181 (1991); and Hodgson *et al.*, Bio/Technology, 9, 421 (1991)). The term "humanised antibody", as used herein, refers to antibody molecules in which the CDR amino acids and selected other amino acids in the variable domains of the heavy and/or light chains of a non-human donor antibody have been substituted in place of the equivalent amino acids in a human antibody.
- 10 The humanised antibody thus closely resembles a human antibody but has the binding ability of the donor antibody.

In a further alternative, the antibody may be a "bispecific" antibody, that is an antibody having two different antigen binding domains, each domain being directed against a different epitope.

- 15 Phage display technology may be utilised to select genes which encode antibodies with binding activities towards the polypeptides of the invention either from repertoires of PCR amplified V-genes of lymphocytes from humans screened for possessing the relevant antibodies, or from naive libraries (McCafferty, J. *et al.*, (1990), Nature 348, 552-554; Marks, J. *et al.*, (1992) Biotechnology 10, 779-783). The affinity of these antibodies can
- 20 also be improved by chain shuffling (Clackson, T. *et al.*, (1991) Nature 352, 624-628).

Antibodies generated by the above techniques, whether polyclonal or monoclonal, have additional utility in that they may be employed as reagents in immunoassays, radioimmunoassays (RIA) or enzyme-linked immunosorbent assays (ELISA). In these applications, the antibodies can be labelled with an analytically-detectable reagent such as

25 a radioisotope, a fluorescent molecule or an enzyme.

Preferred nucleic acid molecules of the second and third aspects of the invention are those which encode a polypeptide sequence as recited in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID

30 NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:60,

SEQ ID NO:62, SEQ ID NO:64, SEQ ID NO:66, SEQ ID NO:68, SEQ ID NO:70, SEQ ID NO:72, SEQ ID NO:74, SEQ ID NO:76, SEQ ID NO:78, SEQ ID NO:80, SEQ ID NO:82, SEQ ID NO:84, SEQ ID NO:86, SEQ ID NO:88, SEQ ID NO:90, SEQ ID NO:92, SEQ ID NO:94, SEQ ID NO:96, SEQ ID NO:98, SEQ ID NO:100, SEQ ID NO:102, SEQ ID NO:104, SEQ ID NO:106, SEQ ID NO:108, SEQ ID NO:110, SEQ ID NO:112, SEQ ID NO:114, SEQ ID NO:116, SEQ ID NO:118, SEQ ID NO:120, SEQ ID NO:122, SEQ ID NO:124, SEQ ID NO:126, SEQ ID NO:128, SEQ ID NO:130, SEQ ID NO:132, SEQ ID NO:134, SEQ ID NO:136, SEQ ID NO:138, SEQ ID NO:140, SEQ ID NO:142, SEQ ID NO:144, SEQ ID NO:146, SEQ ID NO:148, SEQ ID NO:150, SEQ ID NO:152, SEQ ID NO:154, SEQ ID NO:156 and/or SEQ ID NO:158 and functionally equivalent polypeptides. These nucleic acid molecules may be used in the methods and applications described herein. The nucleic acid molecules of the invention preferably comprise at least *n* consecutive nucleotides from the sequences disclosed herein where, depending on the particular sequence, *n* is 10 or more (for example, 12, 14, 15, 18, 20, 25, 30, 35, 40 or more).

The nucleic acid molecules of the invention also include sequences that are complementary to nucleic acid molecules described above (for example, for antisense or probing purposes).

Nucleic acid molecules of the present invention may be in the form of RNA, such as mRNA, or in the form of DNA, including, for instance cDNA, synthetic DNA or genomic DNA. Such nucleic acid molecules may be obtained by cloning, by chemical synthetic techniques or by a combination thereof. The nucleic acid molecules can be prepared, for example, by chemical synthesis using techniques such as solid phase phosphoramidite chemical synthesis, from genomic or cDNA libraries or by separation from an organism. RNA molecules may generally be generated by the *in vitro* or *in vivo* transcription of DNA sequences.

The nucleic acid molecules may be double-stranded or single-stranded. Single-stranded DNA may be the coding strand, also known as the sense strand, or it may be the non-coding strand, also referred to as the anti-sense strand.

The term "nucleic acid molecule" also includes analogues of DNA and RNA, such as those containing modified backbones, and peptide nucleic acids (PNA). The term "PNA", as used herein, refers to an antisense molecule or an anti-gene agent which comprises an

oligonucleotide of at least five nucleotides in length linked to a peptide backbone of amino acid residues, which preferably ends in lysine. The terminal lysine confers solubility to the composition. PNAs may be pegylated to extend their lifespan in a cell, where they preferentially bind complementary single stranded DNA and RNA and stop transcript

5 elongation (Nielsen, P.E. *et al.* (1993) *Anticancer Drug Des.* 8:53-63).

A nucleic acid molecule which encodes a polypeptide of this invention may be identical to the coding sequence of one or more of the nucleic acid molecules disclosed herein.

These molecules also may have a different sequence which, as a result of the degeneracy of the genetic code, encodes a polypeptide SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6,
 10 SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:60, SEQ ID
 15 NO:62, SEQ ID NO:64, SEQ ID NO:66, SEQ ID NO:68, SEQ ID NO:70, SEQ ID NO:72, SEQ ID NO:74, SEQ ID NO:76, SEQ ID NO:78, SEQ ID NO:80, SEQ ID NO:82, SEQ ID NO:84, SEQ ID NO:86, SEQ ID NO:88, SEQ ID NO:90, SEQ ID NO:92, SEQ ID NO:94, SEQ ID NO:96, SEQ ID NO:98, SEQ ID NO:100, SEQ ID NO:102, SEQ ID NO:104, SEQ ID NO:106, SEQ ID NO:108, SEQ ID NO:110, SEQ ID NO:112, SEQ ID NO:114, SEQ ID
 20 NO:116, SEQ ID NO:118, SEQ ID NO:120, SEQ ID NO:122, SEQ ID NO:124, SEQ ID NO:126, SEQ ID NO:128, SEQ ID NO:130, SEQ ID NO:132, SEQ ID NO:134, SEQ ID NO:136, SEQ ID NO:138, SEQ ID NO:140, SEQ ID NO:142, SEQ ID NO:144, SEQ ID NO:146, SEQ ID NO:148, SEQ ID NO:150, SEQ ID NO:152, SEQ ID NO:154, SEQ ID NO:156 and/or SEQ ID NO:158. Such nucleic acid molecules may include, but are not
 25 limited to, the coding sequence for the mature polypeptide by itself; the coding sequence for the mature polypeptide and additional coding sequences, such as those encoding a leader or secretory sequence, such as a pro-, pre- or prepro- polypeptide sequence; the coding sequence of the mature polypeptide, with or without the aforementioned additional coding sequences, together with further additional, non-coding sequences, including non-
 30 coding 5' and 3' sequences, such as the transcribed, non-translated sequences that play a role in transcription (including termination signals), ribosome binding and mRNA stability. The nucleic acid molecules may also include additional sequences which encode additional amino acids, such as those which provide additional functionalities.

The nucleic acid molecules of the second and third aspects of the invention may also encode the fragments or the functional equivalents of the polypeptides and fragments of the first aspect of the invention. Such a nucleic acid molecule may be a naturally-occurring variant such as a naturally-occurring allelic variant, or the molecule may be a variant that
5 is not known to occur naturally. Such non-naturally occurring variants of the nucleic acid molecule may be made by mutagenesis techniques, including those applied to nucleic acid molecules, cells or organisms.

Among variants in this regard are variants that differ from the aforementioned nucleic acid molecules by nucleotide substitutions, deletions or insertions. The substitutions, deletions
10 or insertions may involve one or more nucleotides. The variants may be altered in coding or non-coding regions or both. Alterations in the coding regions may produce conservative or non-conservative amino acid substitutions, deletions or insertions.

The nucleic acid molecules of the invention can also be engineered, using methods generally known in the art, for a variety of reasons, including modifying the cloning,
15 processing, and/or expression of the gene product (the polypeptide). DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides are included as techniques which may be used to engineer the nucleotide sequences. Site-directed mutagenesis may be used to insert new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, introduce
20 mutations and so forth.

Nucleic acid molecules which encode a polypeptide of the first aspect of the invention may be ligated to a heterologous sequence so that the combined nucleic acid molecule encodes a fusion protein. Such combined nucleic acid molecules are included within the second or third aspects of the invention. For example, to screen peptide libraries for inhibitors of the
25 activity of the polypeptide, it may be useful to express, using such a combined nucleic acid molecule, a fusion protein that can be recognised by a commercially-available antibody. A fusion protein may also be engineered to contain a cleavage site located between the sequence of the polypeptide of the invention and the sequence of a heterologous protein so that the polypeptide may be cleaved and purified away from the heterologous protein.

30 The nucleic acid molecules of the invention also include antisense molecules that are partially complementary to nucleic acid molecules encoding polypeptides of the present invention and that therefore hybridize to the encoding nucleic acid molecules

(hybridization). Such antisense molecules, such as oligonucleotides, can be designed to recognise, specifically bind to and prevent transcription of a target nucleic acid encoding a polypeptide of the invention, as will be known by those of ordinary skill in the art (see, for example, Cohen, J.S., Trends in Pharm. Sci., 10, 435 (1989), Okano, J. Neurochem. 56, 560 (1991); O'Connor, J. Neurochem 56, 560 (1991); Lee *et al.*, Nucleic Acids Res 6, 3073 (1979); Cooney *et al.*, Science 241, 456 (1988); Dervan *et al.*, Science 251, 1360 (1991).

The term "hybridization" as used here refers to the association of two nucleic acid molecules with one another by hydrogen bonding. Typically, one molecule will be fixed to a solid support and the other will be free in solution. Then, the two molecules may be placed in contact with one another under conditions that favour hydrogen bonding. Factors that affect this bonding include: the type and volume of solvent; reaction temperature; time of hybridization; agitation; agents to block the non-specific attachment of the liquid phase molecule to the solid support (Denhardt's reagent or BLOTTO); the concentration of the molecules; use of compounds to increase the rate of association of molecules (dextran sulphate or polyethylene glycol); and the stringency of the washing conditions following hybridization (see Sambrook *et al.* [*supra*]).

The inhibition of hybridization of a completely complementary molecule to a target molecule may be examined using a hybridization assay, as known in the art (see, for example, Sambrook *et al.* [*supra*]). A substantially homologous molecule will then compete for and inhibit the binding of a completely homologous molecule to the target molecule under various conditions of stringency, as taught in Wahl, G.M. and S.L. Berger (1987; Methods Enzymol. 152:399-407) and Kimmel, A.R. (1987; Methods Enzymol. 152:507-511).

"Stringency" refers to conditions in a hybridization reaction that favour the association of very similar molecules over association of molecules that differ. High stringency hybridisation conditions are defined as overnight incubation at 42°C in a solution comprising 50% formamide, 5XSSC (150mM NaCl, 15mM trisodium citrate), 50mM sodium phosphate (pH7.6), 5x Denhardts solution, 10% dextran sulphate, and 20 microgram/ml denatured, sheared salmon sperm DNA, followed by washing the filters in 0.1X SSC at approximately 65°C. Low stringency conditions involve the hybridisation reaction being carried out at 35°C (see Sambrook *et al.* [*supra*]). Preferably, the conditions used for hybridization are those of high stringency.

Preferred embodiments of this aspect of the invention are nucleic acid molecules that are at least 70% identical over their entire length to a nucleic acid molecule encoding the INSP081, INSP082 or INSP091 polypeptides and nucleic acid molecules that are substantially complementary to such nucleic acid molecules. Preferably, a nucleic acid molecule according to this aspect of the invention comprises a region that is at least 80% identical over its entire length to such coding sequences, or is a nucleic acid molecule that is complementary thereto. In this regard, nucleic acid molecules at least 90%, preferably at least 95%, more preferably at least 98%, 99% or more identical over their entire length to the same are particularly preferred. Preferred embodiments in this respect are nucleic acid molecules that encode polypeptides which retain substantially the same biological function or activity as the INSP081, INSP082 or INSP091 polypeptides.

The invention also provides a process for detecting a nucleic acid molecule of the invention, comprising the steps of: (a) contacting a nucleic probe according to the invention with a biological sample under hybridizing conditions to form duplexes; and (b) detecting any such duplexes that are formed.

As discussed additionally below in connection with assays that may be utilised according to the invention, a nucleic acid molecule as described above may be used as a hybridization probe for RNA, cDNA or genomic DNA, in order to isolate full-length cDNAs and genomic clones encoding the INSP081, INSP082 or INSP091 polypeptides and to isolate cDNA and genomic clones of homologous or orthologous genes that have a high sequence similarity to the gene encoding this polypeptide.

In this regard, the following techniques, among others known in the art, may be utilised and are discussed below for purposes of illustration. Methods for DNA sequencing and analysis are well known and are generally available in the art and may, indeed, be used to practice many of the embodiments of the invention discussed herein. Such methods may employ such enzymes as the Klenow fragment of DNA polymerase I, Sequenase (US Biochemical Corp, Cleveland, OH), Taq polymerase (Perkin Elmer), thermostable T7 polymerase (Amersham, Chicago, IL), or combinations of polymerases and proof-reading exonucleases such as those found in the ELONGASE Amplification System marketed by Gibco/BRL (Gaithersburg, MD). Preferably, the sequencing process may be automated using machines such as the Hamilton Micro Lab 2200 (Hamilton, Reno, NV), the Peltier Thermal Cycler (PTC200; MJ Research, Watertown, MA) and the ABI Catalyst and 373

and 377 DNA Sequencers (Perkin Elmer).

One method for isolating a nucleic acid molecule encoding a polypeptide with an equivalent function to that of the INSP081, INSP082 or INSP091 polypeptides is to probe

a genomic or cDNA library with a natural or artificially-designed probe using standard
 5 procedures that are recognised in the art (see, for example, "Current Protocols in Molecular Biology", Ausubel *et al.* (eds). Greene Publishing Association and John Wiley Interscience, New York, 1989,1992). Probes comprising at least 15, preferably at least 30, and more preferably at least 50, contiguous bases that correspond to, or are complementary to, nucleic acid sequences from the appropriate encoding gene (SEQ ID NO:1, SEQ ID
 10 NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:57,
 15 SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:65, SEQ ID NO:67, SEQ ID NO:69, SEQ ID NO:71, SEQ ID NO:73, SEQ ID NO:75, SEQ ID NO:77, SEQ ID NO:79, SEQ ID NO:81, SEQ ID NO:83, SEQ ID NO:85, SEQ ID NO:87, SEQ ID NO:89, SEQ ID NO:91, SEQ ID NO:93, SEQ ID NO:95, SEQ ID NO:97, SEQ ID NO:99, SEQ ID NO:101, SEQ ID NO:103, SEQ ID NO:105, SEQ ID NO:107, SEQ ID NO:109, SEQ ID NO:111,
 20 SEQ ID NO:113, SEQ ID NO:115, SEQ ID NO:117, SEQ ID NO:119, SEQ ID NO:121, SEQ ID NO:123, SEQ ID NO:125, SEQ ID NO:127, SEQ ID NO:129, SEQ ID NO:131, SEQ ID NO:133, SEQ ID NO:135, SEQ ID NO:137, SEQ ID NO:139, SEQ ID NO:141, SEQ ID NO:143, SEQ ID NO:145, SEQ ID NO:147, SEQ ID NO:149, SEQ ID NO:151, SEQ ID NO:153, SEQ ID NO:155 and SEQ ID NO:157) are particularly useful probes.
 25 Such probes may be labelled with an analytically-detectable reagent to facilitate their identification. Useful reagents include, but are not limited to, radioisotopes, fluorescent dyes and enzymes that are capable of catalysing the formation of a detectable product. Using these probes, the ordinarily skilled artisan will be capable of isolating complementary copies of genomic DNA, cDNA or RNA polynucleotides encoding
 30 proteins of interest from human, mammalian or other animal sources and screening such sources for related sequences, for example, for additional members of the family, type and/or subtype.

In many cases, isolated cDNA sequences will be incomplete, in that the region encoding the polypeptide will be cut short, normally at the 5' end. Several methods are available to obtain full length cDNAs, or to extend short cDNAs. Such sequences may be extended utilising a partial nucleotide sequence and employing various methods known in the art to detect upstream sequences such as promoters and regulatory elements. For example, one method which may be employed is based on the method of Rapid Amplification of cDNA Ends (RACE; see, for example, Frohman *et al.*, PNAS USA 85, 8998-9002, 1988). Recent modifications of this technique, exemplified by the MarathonTM technology (Clontech Laboratories Inc.), for example, have significantly simplified the search for longer cDNAs.

A slightly different technique, termed "restriction-site" PCR, uses universal primers to retrieve unknown nucleic acid sequence adjacent a known locus (Sarkar, G. (1993) PCR Methods Applic. 2:318-322). Inverse PCR may also be used to amplify or to extend sequences using divergent primers based on a known region (Triglia, T. *et al.* (1988) Nucleic Acids Res. 16:8186). Another method which may be used is capture PCR which involves PCR amplification of DNA fragments adjacent a known sequence in human and yeast artificial chromosome DNA (Lagerstrom, M. *et al.* (1991) PCR Methods Applic., 1, 111-119). Another method which may be used to retrieve unknown sequences is that of Parker, J.D. *et al.* (1991); Nucleic Acids Res. 19:3055-3060). Additionally, one may use PCR, nested primers, and PromoterFinderTM libraries to walk genomic DNA (Clontech, Palo Alto, CA). This process avoids the need to screen libraries and is useful in finding intron/exon junctions.

When screening for full-length cDNAs, it is preferable to use libraries that have been size-selected to include larger cDNAs. Also, random-primed libraries are preferable, in that they will contain more sequences that contain the 5' regions of genes. Use of a randomly primed library may be especially preferable for situations in which an oligo d(T) library does not yield a full-length cDNA. Genomic libraries may be useful for extension of sequence into 5' non-transcribed regulatory regions.

In one embodiment of the invention, the nucleic acid molecules of the present invention may be used for chromosome localisation. In this technique, a nucleic acid molecule is specifically targeted to, and can hybridize with, a particular location on an individual human chromosome. The mapping of relevant sequences to chromosomes according to the present invention is an important step in the confirmatory correlation of those sequences with the gene-associated disease. Once a sequence has been mapped to a precise

chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. Such data are found in, for example, V. McKusick, Mendelian Inheritance in Man (available on-line through Johns Hopkins University Welch

Medical Library). The relationships between genes and diseases that have been mapped to
5 the same chromosomal region are then identified through linkage analysis (coinheritance of physically adjacent genes). This provides valuable information to investigators searching for disease genes using positional cloning or other gene discovery techniques. Once the disease or syndrome has been crudely localised by genetic linkage to a particular genomic region, any sequences mapping to that area may represent associated or
10 regulatory genes for further investigation. The nucleic acid molecule may also be used to detect differences in the chromosomal location due to translocation, inversion, etc. among normal, carrier, or affected individuals.

The nucleic acid molecules of the present invention are also valuable for tissue localisation. Such techniques allow the determination of expression patterns of the
15 polypeptide in tissues by detection of the mRNAs that encode them. These techniques include *in situ* hybridization techniques and nucleotide amplification techniques, such as PCR. Results from these studies provide an indication of the normal functions of the polypeptide in the organism. In addition, comparative studies of the normal expression pattern of mRNAs with that of mRNAs encoded by a mutant gene provide valuable
20 insights into the role of mutant polypeptides in disease/disorders. Such inappropriate expression may be of a temporal, spatial or quantitative nature.

The vectors of the present invention comprise nucleic acid molecules of the invention and may be cloning or expression vectors. The host cells of the invention, which may be transformed, transfected or transduced with the vectors of the invention may be
25 prokaryotic or eukaryotic.

The polypeptides of the invention may be prepared in recombinant form by expression of their encoding nucleic acid molecules in vectors contained within a host cell. Such expression methods are well known to those of skill in the art and many are described in detail by Sambrook *et al.* (*supra*) and Fernandez & Hoeffler (1998, eds. "Gene expression
30 systems. Using nature for the art of expression". Academic Press, San Diego, London, Boston, New York, Sydney, Tokyo, Toronto).

Generally, any system or vector that is suitable to maintain, propagate or express nucleic acid molecules to produce a polypeptide in the required host may be used. The appropriate nucleotide sequence may be inserted into an expression system by any of a variety of well-known and routine techniques, such as, for example, those described in Sambrook *et al.*,
5 (*supra*). Generally, the encoding gene can be placed under the control of a control element such as a promoter, ribosome binding site (for bacterial expression) and, optionally, an operator, so that the DNA sequence encoding the desired polypeptide is transcribed into RNA in the transformed host cell.

Examples of suitable expression systems include, for example, chromosomal, episomal and
10 virus-derived systems, including, for example, vectors derived from: bacterial plasmids, bacteriophage, transposons, yeast episomes, insertion elements, yeast chromosomal elements, viruses such as baculoviruses, papova viruses such as SV40, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses and retroviruses, or combinations thereof, such as those derived from plasmid and bacteriophage genetic elements, including
15 cosmids and phagemids. Human artificial chromosomes (HACs) may also be employed to deliver larger fragments of DNA than can be contained and expressed in a plasmid.

Particularly suitable expression systems include microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with virus
20 expression vectors (for example, baculovirus); plant cell systems transformed with virus expression vectors (for example, cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or with bacterial expression vectors (for example, Ti or pBR322 plasmids); or animal cell systems. Cell-free translation systems can also be employed to produce the polypeptides of the invention.

25 Introduction of nucleic acid molecules encoding a polypeptide of the present invention into host cells can be effected by methods described in many standard laboratory manuals, such as Davis *et al.*, Basic Methods in Molecular Biology (1986) and Sambrook *et al.*, (*supra*). Particularly suitable methods include calcium phosphate transfection, DEAE-dextran mediated transfection, transfection, microinjection, cationic lipid-mediated transfection,
30 electroporation, transduction, scrape loading, ballistic introduction or infection (see Sambrook *et al.*, 1989 [*supra*]; Ausubel *et al.*, 1991 [*supra*]; Spector, Goldman & Leinwald, 1998). In eukaryotic cells, expression systems may either be transient (for

example, episomal) or permanent (chromosomal integration) according to the needs of the system.

The encoding nucleic acid molecule may or may not include a sequence encoding a control sequence, such as a signal peptide or leader sequence, as desired, for example, for
 5 secretion of the translated polypeptide into the lumen of the endoplasmic reticulum, into the periplasmic space or into the extracellular environment. These signals may be endogenous to the polypeptide or they may be heterologous signals. Leader sequences can be removed by the bacterial host in post-translational processing.

In addition to control sequences, it may be desirable to add regulatory sequences that allow
 10 for regulation of the expression of the polypeptide relative to the growth of the host cell. Examples of regulatory sequences are those which cause the expression of a gene to be increased or decreased in response to a chemical or physical stimulus, including the presence of a regulatory compound or to various temperature or metabolic conditions. Regulatory sequences are those non-translated regions of the vector, such as enhancers,
 15 promoters and 5' and 3' untranslated regions. These interact with host cellular proteins to carry out transcription and translation. Such regulatory sequences may vary in their strength and specificity. Depending on the vector system and host utilised, any number of suitable transcription and translation elements, including constitutive and inducible promoters, may be used. For example, when cloning in bacterial systems, inducible
 20 promoters such as the hybrid lacZ promoter of the Bluescript phagemid (Stratagene, LaJolla, CA) or pSport1™ plasmid (Gibco BRL) and the like may be used. The baculovirus polyhedrin promoter may be used in insect cells. Promoters or enhancers derived from the genomes of plant cells (for example, heat shock, RUBISCO and storage protein genes) or from plant viruses (for example, viral promoters or leader sequences) may be cloned into
 25 the vector. In mammalian cell systems, promoters from mammalian genes or from mammalian viruses are preferable. If it is necessary to generate a cell line that contains multiple copies of the sequence, vectors based on SV40 or EBV may be used with an appropriate selectable marker.

An expression vector is constructed so that the particular nucleic acid coding sequence is
 30 located in the vector with the appropriate regulatory sequences, the positioning and orientation of the coding sequence with respect to the regulatory sequences being such that the coding sequence is transcribed under the "control" of the regulatory sequences, i.e.,

RNA polymerase which binds to the DNA molecule at the control sequences transcribes the coding sequence. In some cases it may be necessary to modify the sequence so that it may be attached to the control sequences with the appropriate orientation; i.e., to maintain the reading frame.

- 5 The control sequences and other regulatory sequences may be ligated to the nucleic acid coding sequence prior to insertion into a vector. Alternatively, the coding sequence can be cloned directly into an expression vector that already contains the control sequences and an appropriate restriction site.

For long-term, high-yield production of a recombinant polypeptide, stable expression is preferred. For example, cell lines which stably express the polypeptide of interest may be transformed using expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the introduction of the vector, cells may be allowed to grow for 1-2 days in an enriched media before they are switched to selective media. The purpose of the
15 selectable marker is to confer resistance to selection, and its presence allows growth and recovery of cells that successfully express the introduced sequences. Resistant clones of stably transformed cells may be proliferated using tissue culture techniques appropriate to the cell type.

Mammalian cell lines available as hosts for expression are known in the art and include
20 many immortalised cell lines available from the American Type Culture Collection (ATCC) including, but not limited to, Chinese hamster ovary (CHO), HeLa, baby hamster kidney (BHK), monkey kidney (COS), C127, 3T3, BHK, HEK 293, Bowes melanoma and human hepatocellular carcinoma (for example Hep G2) cells and a number of other cell lines.

- 25 In the baculovirus system, the materials for baculovirus/insect cell expression systems are commercially available in kit form from, *inter alia*, Invitrogen, San Diego CA (the "MaxBac" kit). These techniques are generally known to those skilled in the art and are described fully in Summers and Smith, Texas Agricultural Experiment Station Bulletin No. 1555 (1987). Particularly suitable host cells for use in this system include insect cells such
30 as *Drosophila* S2 and *Spodoptera* Sf9 cells.

There are many plant cell culture and whole plant genetic expression systems known in the art. Examples of suitable plant cellular genetic expression systems include those described

in US 5,693,506; US 5,659,122; and US 5,608,143. Additional examples of genetic expression in plant cell culture has been described by Zenk, *Phytochemistry* 30, 3861-3863 (1991).

In particular, all plants from which protoplasts can be isolated and cultured to give whole
5 regenerated plants can be utilised, so that whole plants are recovered which contain the transferred gene. Practically all plants can be regenerated from cultured cells or tissues, including but not limited to all major species of sugar cane, sugar beet, cotton, fruit and other trees, legumes and vegetables.

Examples of particularly preferred bacterial host cells include *streptococci*, *staphylococci*,
10 *E. coli*, *Streptomyces* and *Bacillus subtilis* cells.

Examples of particularly suitable host cells for fungal expression include yeast cells (for example, *S. cerevisiae*) and *Aspergillus* cells.

Any number of selection systems are known in the art that may be used to recover transformed cell lines. Examples include the herpes simplex virus thymidine kinase
15 (Wigler, M. *et al.* (1977) *Cell* 11:223-32) and adenine phosphoribosyltransferase (Lowy, I. *et al.* (1980) *Cell* 22:817-23) genes that can be employed in tk^- or $aprt^+$ cells, respectively.

Also, antimetabolite, antibiotic or herbicide resistance can be used as the basis for selection; for example, dihydrofolate reductase (DHFR) that confers resistance to methotrexate (Wigler, M. *et al.* (1980) *Proc. Natl. Acad. Sci.* 77:3567-70); npt, which
20 confers resistance to the aminoglycosides neomycin and G-418 (Colbere-Garapin, F. *et al.* (1981) *J. Mol. Biol.* 150:1-14) and als or pat, which confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively. Additional selectable genes have been described, examples of which will be clear to those of skill in the art.

Although the presence or absence of marker gene expression suggests that the gene of
25 interest is also present, its presence and expression may need to be confirmed. For example, if the relevant sequence is inserted within a marker gene sequence, transformed cells containing the appropriate sequences can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a sequence encoding a polypeptide of the invention under the control of a single promoter. Expression of the
30 marker gene in response to induction or selection usually indicates expression of the tandem gene as well.

Alternatively, host cells that contain a nucleic acid sequence encoding a polypeptide of the invention and which express said polypeptide may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations and protein bioassays, for example, fluorescence
5 activated cell sorting (FACS) or immunoassay techniques (such as the enzyme-linked immunosorbent assay [ELISA] and radioimmunoassay [RIA]), that include membrane, solution, or chip based technologies for the detection and/or quantification of nucleic acid or protein (see Hampton, R. *et al.* (1990) *Serological Methods, a Laboratory Manual*, APS Press, St Paul, MN) and Maddox, D.E. *et al.* (1983) *J. Exp. Med.*, 158, 1211-1216).

- 10 A wide variety of labels and conjugation techniques are known by those skilled in the art and may be used in various nucleic acid and amino acid assays. Means for producing labelled hybridization or PCR probes for detecting sequences related to nucleic acid molecules encoding polypeptides of the present invention include oligolabelling, nick translation, end-labelling or PCR amplification using a labelled polynucleotide.
- 15 Alternatively, the sequences encoding the polypeptide of the invention may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesise RNA probes *in vitro* by addition of an appropriate RNA polymerase such as T7, T3 or SP6 and labelled nucleotides. These procedures may be conducted using a variety of commercially available kits (Pharmacia &
20 Upjohn, (Kalamazoo, MI); Promega (Madison WI); and U.S. Biochemical Corp., Cleveland, OH)).

Suitable reporter molecules or labels, which may be used for ease of detection, include radionuclides, enzymes and fluorescent, chemiluminescent or chromogenic agents as well as substrates, cofactors, inhibitors, magnetic particles, and the like.

- 25 Nucleic acid molecules according to the present invention may also be used to create transgenic animals, particularly rodent animals. Such transgenic animals form a further aspect of the present invention. This may be done locally by modification of somatic cells, or by germ line therapy to incorporate heritable modifications. Such transgenic animals may be particularly useful in the generation of animal models for drug molecules effective
30 as modulators of the polypeptides of the present invention.

The polypeptide can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulphate or ethanol precipitation, acid extraction,

anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. High performance liquid chromatography is particularly useful for purification. Well known techniques for refolding proteins may be employed to regenerate an active conformation when the polypeptide is denatured during isolation and or purification.

Specialised vector constructions may also be used to facilitate purification of proteins, as desired, by joining sequences encoding the polypeptides of the invention to a nucleotide sequence encoding a polypeptide domain that will facilitate purification of soluble proteins. Examples of such purification-facilitating domains include metal chelating peptides such as histidine-tryptophan modules that allow purification on immobilised metals, protein A domains that allow purification on immobilised immunoglobulin, and the domain utilised in the FLAGS extension/affinity purification system (Immunex Corp., Seattle, WA). The inclusion of cleavable linker sequences such as those specific for Factor XA or enterokinase (Invitrogen, San Diego, CA) between the purification domain and the polypeptide of the invention may be used to facilitate purification. One such expression vector provides for expression of a fusion protein containing the polypeptide of the invention fused to several histidine residues preceding a thioredoxin or an enterokinase cleavage site. The histidine residues facilitate purification by IMAC (immobilised metal ion affinity chromatography as described in Porath, J. *et al.* (1992), Prot. Exp. Purif. 3: 263-281) while the thioredoxin or enterokinase cleavage site provides a means for purifying the polypeptide from the fusion protein. A discussion of vectors which contain fusion proteins is provided in Kroll, D.J. *et al.* (1993; DNA Cell Biol. 12:441-453).

If the polypeptide is to be expressed for use in screening assays, generally it is preferred that it be produced at the surface of the host cell in which it is expressed. In this event, the host cells may be harvested prior to use in the screening assay, for example using techniques such as fluorescence activated cell sorting (FACS) or immunoaffinity techniques. If the polypeptide is secreted into the medium, the medium can be recovered in order to recover and purify the expressed polypeptide. If polypeptide is produced intracellularly, the cells must first be lysed before the polypeptide is recovered.

The polypeptide of the invention can be used to screen libraries of compounds in any of a variety of drug screening techniques. Such compounds may activate (agonise) or inhibit

(antagonise) the level of expression of the gene or the activity of the polypeptide of the invention and form a further aspect of the present invention. Preferred compounds are effective to alter the expression of a natural gene which encodes a polypeptide of the first aspect of the invention or to regulate the activity of a polypeptide of the first aspect of the invention.

Agonist or antagonist compounds may be isolated from, for example, cells, cell-free preparations, chemical libraries or natural product mixtures. These agonists or antagonists may be natural or modified substrates, ligands, enzymes, receptors or structural or functional mimetics. For a suitable review of such screening techniques, see Coligan *et al.*, Current Protocols in Immunology 1(2):Chapter 5 (1991).

Compounds that are most likely to be good antagonists are molecules that bind to the polypeptide of the invention without inducing the biological effects of the polypeptide upon binding to it. Potential antagonists include small organic molecules, peptides, polypeptides and antibodies that bind to the polypeptide of the invention and thereby inhibit or extinguish its activity. In this fashion, binding of the polypeptide to normal cellular binding molecules may be inhibited, such that the normal biological activity of the polypeptide is prevented.

The polypeptide of the invention that is employed in such a screening technique may be free in solution, affixed to a solid support, borne on a cell surface or located intracellularly. In general, such screening procedures may involve using appropriate cells or cell membranes that express the polypeptide that are contacted with a test compound to observe binding, or stimulation or inhibition of a functional response. The functional response of the cells contacted with the test compound is then compared with control cells that were not contacted with the test compound. Such an assay may assess whether the test compound results in a signal generated by activation of the polypeptide, using an appropriate detection system. Inhibitors of activation are generally assayed in the presence of a known agonist and the effect on activation by the agonist in the presence of the test compound is observed.

A preferred method for identifying an agonist or antagonist compound of a polypeptide of the present invention comprises:

(a) contacting a cell expressing on the surface thereof the polypeptide according to the first aspect of the invention, the polypeptide being associated with a second component capable

of providing a detectable signal in response to the binding of a compound to the polypeptide, with a compound to be screened under conditions to permit binding to the polypeptide; and

- (b) determining whether the compound binds to and activates or inhibits the polypeptide by
5 measuring the level of a signal generated from the interaction of the compound with the polypeptide.

A further preferred method for identifying an agonist or antagonist of a polypeptide of the invention comprises:

- (a) contacting a cell expressing on the surface thereof the polypeptide, the polypeptide
10 being associated with a second component capable of providing a detectable signal in response to the binding of a compound to the polypeptide, with a compound to be screened under conditions to permit binding to the polypeptide; and

- (b) determining whether the compound binds to and activates or inhibits the polypeptide by
comparing the level of a signal generated from the interaction of the compound with the
15 polypeptide with the level of a signal in the absence of the compound.

In further preferred embodiments, the general methods that are described above may further comprise conducting the identification of agonist or antagonist in the presence of labelled or unlabelled ligand for the polypeptide.

- In another embodiment of the method for identifying an agonist or antagonist of a
20 polypeptide of the present invention comprises:

- determining the inhibition of binding of a ligand to cells which have a polypeptide of the invention on the surface thereof, or to cell membranes containing such a polypeptide, in the presence of a candidate compound under conditions to permit binding to the polypeptide, and determining the amount of ligand bound to the polypeptide. A compound
25 capable of causing reduction of binding of a ligand is considered to be an agonist or antagonist. Preferably the ligand is labelled.

More particularly, a method of screening for a polypeptide antagonist or agonist compound comprises the steps of:

- (a) incubating a labelled ligand with a whole cell expressing a polypeptide according to the
30 invention on the cell surface, or a cell membrane containing a polypeptide of the invention,

- (b) measuring the amount of labelled ligand bound to the whole cell or the cell membrane;
- (c) adding a candidate compound to a mixture of labelled ligand and the whole cell or the cell membrane of step (a) and allowing the mixture to attain equilibrium;
- (d) measuring the amount of labelled ligand bound to the whole cell or the cell membrane
- 5 after step (c); and
- (e) comparing the difference in the labelled ligand bound in step (b) and (d), such that the compound which causes the reduction in binding in step (d) is considered to be an agonist or antagonist.

Assays suitable for examining the biological activity of the INSP081 and INSP082

10 polypeptides include assays for kinase activity and MAP kinase pathway activation assays, as described in Nakano *et al.* JBC, (2000) 275, 27, 20533-20539.

In certain of the embodiments described above, simple binding assays may be used, in which the adherence of a test compound to a surface bearing the polypeptide is detected by means of a label directly or indirectly associated with the test compound or in an assay

15 involving competition with a labelled competitor. In another embodiment, competitive drug screening assays may be used, in which neutralising antibodies that are capable of binding the polypeptide specifically compete with a test compound for binding. In this manner, the antibodies can be used to detect the presence of any test compound that possesses specific binding affinity for the polypeptide.

20 Assays may also be designed to detect the effect of added test compounds on the production of mRNA encoding the polypeptide in cells. For example, an ELISA may be constructed that measures secreted or cell-associated levels of polypeptide using monoclonal or polyclonal antibodies by standard methods known in the art, and this can be used to search for compounds that may inhibit or enhance the production of the

25 polypeptide from suitably manipulated cells or tissues. The formation of binding complexes between the polypeptide and the compound being tested may then be measured.

Another technique for drug screening which may be used provides for high throughput screening of compounds having suitable binding affinity to the polypeptide of interest (see International patent application WO84/03564). In this method, large numbers of different

30 small test compounds are synthesised on a solid substrate, which may then be reacted with the polypeptide of the invention and washed. One way of immobilising the polypeptide is

to use non-neutralising antibodies. Bound polypeptide may then be detected using methods that are well known in the art. Purified polypeptide can also be coated directly onto plates for use in the aforementioned drug screening techniques.

The polypeptide of the invention may be used to identify membrane-bound or soluble
5 receptors, through standard receptor binding techniques that are known in the art, such as ligand binding and crosslinking assays in which the polypeptide is labelled with a radioactive isotope, is chemically modified, or is fused to a peptide sequence that facilitates its detection or purification, and incubated with a source of the putative receptor (for example, a composition of cells, cell membranes, cell supernatants, tissue extracts, or
10 bodily fluids). The efficacy of binding may be measured using biophysical techniques such as surface plasmon resonance and spectroscopy. Binding assays may be used for the purification and cloning of the receptor, but may also identify agonists and antagonists of the polypeptide, that compete with the binding of the polypeptide to its receptor. Standard methods for conducting screening assays are well understood in the art.

15 The invention also includes a screening kit useful in the methods for identifying agonists, antagonists, ligands, receptors, substrates, enzymes, that are described above.

The invention includes the agonists, antagonists, ligands, receptors, substrates and enzymes, and other compounds which modulate the activity or antigenicity of the polypeptide of the invention discovered by the methods that are described above.

20 The invention also provides pharmaceutical compositions comprising a polypeptide, nucleic acid, ligand or compound of the invention in combination with a suitable pharmaceutical carrier. These compositions may be suitable as therapeutic or diagnostic reagents, as vaccines, or as other immunogenic compositions, as outlined in detail below.

According to the terminology used herein, a composition containing a polypeptide, nucleic
25 acid, ligand or compound [X] is "substantially free of" impurities [herein, Y] when at least 85% by weight of the total X+Y in the composition is X. Preferably, X comprises at least about 90% by weight of the total of X+Y in the composition, more preferably at least about 95%, 98% or even 99% by weight.

The pharmaceutical compositions should preferably comprise a therapeutically effective
30 amount of the polypeptide, nucleic acid molecule, ligand, or compound of the invention.

The term "therapeutically effective amount" as used herein refers to an amount of a

therapeutic agent needed to treat, ameliorate, or prevent a targeted disease or condition, or to exhibit a detectable therapeutic or preventative effect. For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays, for example, of neoplastic cells, or in animal models, usually mice, rabbits, dogs, or pigs. The
5 animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.

The precise effective amount for a human subject will depend upon the severity of the disease state, general health of the subject, age, weight, and gender of the subject, diet,
10 time and frequency of administration, drug combination(s), reaction sensitivities, and tolerance/response to therapy. This amount can be determined by routine experimentation and is within the judgement of the clinician. Generally, an effective dose will be from 0.01 mg/kg to 50 mg/kg, preferably 0.05 mg/kg to 10 mg/kg. Compositions may be administered individually to a patient or may be administered in combination with other
15 agents, drugs or hormones.

A pharmaceutical composition may also contain a pharmaceutically acceptable carrier, for administration of a therapeutic agent. Such carriers include antibodies and other polypeptides, genes and other therapeutic agents such as liposomes, provided that the carrier does not itself induce the production of antibodies harmful to the individual
20 receiving the composition, and which may be administered without undue toxicity. Suitable carriers may be large, slowly metabolised macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers and inactive virus particles.

Pharmaceutically acceptable salts can be used therein, for example, mineral acid salts such
25 as hydrochlorides, hydrobromides, phosphates, sulphates, and the like; and the salts of organic acids such as acetates, propionates, malonates, benzoates, and the like. A thorough discussion of pharmaceutically acceptable carriers is available in Remington's Pharmaceutical Sciences (Mack Pub. Co., N.J. 1991).

Pharmaceutically acceptable carriers in therapeutic compositions may additionally contain
30 liquids such as water, saline, glycerol and ethanol. Additionally, auxiliary substances, such as wetting or emulsifying agents, pH buffering substances, and the like, may be present in such compositions. Such carriers enable the pharmaceutical compositions to be formulated

as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for ingestion by the patient.

Once formulated, the compositions of the invention can be administered directly to the subject. The subjects to be treated can be animals; in particular, human subjects can be
5 treated.

The pharmaceutical compositions utilised in this invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, transdermal or transcutaneous applications (for example, see WO98/20734), subcutaneous, intraperitoneal, intranasal,
10 enteral, topical, sublingual, intravaginal or rectal means. Gene guns or hyposprays may also be used to administer the pharmaceutical compositions of the invention. Typically, the therapeutic compositions may be prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid vehicles prior to injection may also be prepared.

15 Direct delivery of the compositions will generally be accomplished by injection, subcutaneously, intraperitoneally, intravenously or intramuscularly, or delivered to the interstitial space of a tissue. The compositions can also be administered into a lesion. Dosage treatment may be a single dose schedule or a multiple dose schedule.

If the activity of the polypeptide of the invention is in excess in a particular disease state,
20 several approaches are available. One approach comprises administering to a subject an inhibitor compound (antagonist) as described above, along with a pharmaceutically acceptable carrier in an amount effective to inhibit the function of the polypeptide, such as by blocking the binding of ligands, substrates, enzymes, receptors, or by inhibiting a second signal, and thereby alleviating the abnormal condition. Preferably, such antagonists
25 are antibodies. Most preferably, such antibodies are chimeric and/or humanised to minimise their immunogenicity, as described previously.

In another approach, soluble forms of the polypeptide that retain binding affinity for the ligand, substrate, enzyme, receptor, in question, may be administered. Typically, the polypeptide may be administered in the form of fragments that retain the relevant portions.

30 In an alternative approach, expression of the gene encoding the polypeptide can be inhibited using expression blocking techniques, such as the use of antisense nucleic acid

molecules (as described above), either internally generated or separately administered. Modifications of gene expression can be obtained by designing complementary sequences or antisense molecules (DNA, RNA, or PNA) to the control, 5' or regulatory regions (signal sequence, promoters, enhancers and introns) of the gene encoding the polypeptide.

- 5 Similarly, inhibition can be achieved using "triple helix" base-pairing methodology. Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules. Recent therapeutic advances using triplex DNA have been described in the literature (Gee, J.E. *et al.* (1994) In: Huber, B.E. and B.I. Carr, Molecular and Immunologic Approaches, Futura Publishing Co., Mt. Kisco, NY). The complementary sequence or antisense molecule may also be designed to block translation of mRNA by preventing the transcript from binding to ribosomes. Such oligonucleotides may be administered or may be generated *in situ* from expression *in vivo*.

- 15 In addition, expression of the polypeptide of the invention may be prevented by using ribozymes specific to its encoding mRNA sequence. Ribozymes are catalytically active RNAs that can be natural or synthetic (see for example Usman, N, *et al.*, Curr. Opin. Struct. Biol (1996) 6(4), 527-33). Synthetic ribozymes can be designed to specifically cleave mRNAs at selected positions thereby preventing translation of the mRNAs into functional polypeptide. Ribozymes may be synthesised with a natural ribose phosphate backbone and natural bases, as normally found in RNA molecules. Alternatively the ribozymes may be synthesised with non-natural backbones, for example, 2'-O-methyl RNA, to provide protection from ribonuclease degradation and may contain modified bases.

- RNA molecules may be modified to increase intracellular stability and half-life. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5' and/or 3' ends of the molecule or the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase linkages within the backbone of the molecule. This concept is inherent in the production of PNAs and can be extended in all of these molecules by the inclusion of non-traditional bases such as inosine, queosine and butosine, as well as acetyl-, methyl-, thio- and similarly modified forms of adenine, cytidine, guanine, thymine and uridine which are not as easily recognised by endogenous endonucleases.

For treating abnormal conditions related to an under-expression of the polypeptide of the invention and its activity, several approaches are also available. One approach comprises administering to a subject a therapeutically effective amount of a compound that activates the polypeptide, i.e., an agonist as described above, to alleviate the abnormal condition.

- 5 Alternatively, a therapeutic amount of the polypeptide in combination with a suitable pharmaceutical carrier may be administered to restore the relevant physiological balance of polypeptide.

Gene therapy may be employed to effect the endogenous production of the polypeptide by the relevant cells in the subject. Gene therapy is used to treat permanently the inappropriate
10 production of the polypeptide by replacing a defective gene with a corrected therapeutic gene.

Gene therapy of the present invention can occur *in vivo* or *ex vivo*. *Ex vivo* gene therapy requires the isolation and purification of patient cells, the introduction of a therapeutic gene and introduction of the genetically altered cells back into the patient. In contrast, *in*
15 *vivo* gene therapy does not require isolation and purification of a patient's cells.

The therapeutic gene is typically "packaged" for administration to a patient. Gene delivery vehicles may be non-viral, such as liposomes, or replication-deficient viruses, such as adenovirus as described by Berkner, K.L., in Curr. Top. Microbiol. Immunol., 158, 39-66 (1992) or adeno-associated virus (AAV) vectors as described by Muzyczka, N., in Curr.
20 Top. Microbiol. Immunol., 158, 97-129 (1992) and U.S. Patent No. 5,252,479. For example, a nucleic acid molecule encoding a polypeptide of the invention may be engineered for expression in a replication-defective retroviral vector. This expression construct may then be isolated and introduced into a packaging cell transduced with a retroviral plasmid vector containing RNA encoding the polypeptide, such that the
25 packaging cell now produces infectious viral particles containing the gene of interest. These producer cells may be administered to a subject for engineering cells *in vivo* and expression of the polypeptide *in vivo* (see Chapter 20, Gene Therapy and other Molecular Genetic-based Therapeutic Approaches, (and references cited therein) in Human Molecular Genetics (1996), T Strachan and A P Read, BIOS Scientific Publishers Ltd).

- 30 Another approach is the administration of "naked DNA" in which the therapeutic gene is directly injected into the bloodstream or muscle tissue.

In situations in which the polypeptides or nucleic acid molecules of the invention are disease-causing agents, the invention provides that they can be used in vaccines to raise antibodies against the disease causing agent.

Vaccines according to the invention may either be prophylactic (i.e. to prevent infection) or therapeutic (i.e. to treat disease after infection). Such vaccines comprise immunising antigen(s), immunogen(s), polypeptide(s), protein(s) or nucleic acid, usually in combination with pharmaceutically-acceptable carriers as described above, which include any carrier that does not itself induce the production of antibodies harmful to the individual receiving the composition. Additionally, these carriers may function as immunostimulating agents ("adjuvants"). Furthermore, the antigen or immunogen may be conjugated to a bacterial toxoid, such as a toxoid from diphtheria, tetanus, cholera, *H. pylori*, and other pathogens.

Since polypeptides may be broken down in the stomach, vaccines comprising polypeptides are preferably administered parenterally (for instance, subcutaneous, intramuscular, intravenous, or intradermal injection). Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain antioxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the recipient, and aqueous and non-aqueous sterile suspensions which may include suspending agents or thickening agents.

The vaccine formulations of the invention may be presented in unit-dose or multi-dose containers. For example, sealed ampoules and vials and may be stored in a freeze-dried condition requiring only the addition of the sterile liquid carrier immediately prior to use. The dosage will depend on the specific activity of the vaccine and can be readily determined by routine experimentation.

This invention also relates to the use of nucleic acid molecules according to the present invention as diagnostic reagents. Detection of a mutated form of the gene characterised by the nucleic acid molecules of the invention which is associated with a dysfunction will provide a diagnostic tool that can add to, or define, a diagnosis of a disease, or susceptibility to a disease, which results from under-expression, over-expression or altered spatial or temporal expression of the gene. Individuals carrying mutations in the gene may be detected at the DNA level by a variety of techniques.

Nucleic acid molecules for diagnosis may be obtained from a subject's cells, such as from blood, urine, saliva, tissue biopsy or autopsy material. The genomic DNA may be used directly for detection or may be amplified enzymatically by using PCR, ligase chain

reaction (LCR), strand displacement amplification (SDA), or other amplification techniques (see Saiki *et al.*, Nature, 324, 163-166 (1986); Bej, *et al.*, Crit. Rev. Biochem. Molec. Biol., 26, 301-334 (1991); Birkenmeyer *et al.*, J. Virol. Meth., 35, 117-126 (1991); Van Brunt, J., Bio/Technology, 8, 291-294 (1990)) prior to analysis.

In one embodiment, this aspect of the invention provides a method of diagnosing a disease or disorder in a patient, comprising assessing the level of expression of a natural gene encoding a polypeptide according to the invention and comparing said level of expression to a control level, wherein a level that is different to said control level is indicative of disease. The method may comprise the steps of:

a) contacting a sample of tissue from the patient with a nucleic acid probe under stringent conditions that allow the formation of a hybrid complex between a nucleic acid molecule of the invention and the probe;

b) contacting a control sample with said probe under the same conditions used in step a);

c) and detecting the presence of hybrid complexes in said samples;

wherein detection of levels of the hybrid complex in the patient sample that differ from levels of the hybrid complex in the control sample is indicative of disease.

A further aspect of the invention comprises a diagnostic method comprising the steps of:

a) obtaining a tissue sample from a patient being tested for a disease;

b) isolating a nucleic acid molecule according to the invention from said tissue sample; and

c) diagnosing the patient for disease by detecting the presence of a mutation in the nucleic acid molecule which is associated with disease.

To aid the detection of nucleic acid molecules in the above-described methods, an amplification step, for example using PCR, may be included.

Deletions and insertions can be detected by a change in the size of the amplified product in comparison to the normal genotype. Point mutations can be identified by hybridizing amplified DNA to labelled RNA of the invention or alternatively, labelled antisense DNA sequences of the invention. Perfectly-matched sequences can be distinguished from

mismatched duplexes by RNase digestion or by assessing differences in melting temperatures. The presence or absence of the mutation in the patient may be detected by contacting DNA with a nucleic acid probe that hybridises to the DNA under stringent conditions to form a hybrid double-stranded molecule, the hybrid double-stranded molecule having an unhybridised portion of the nucleic acid probe strand at any portion corresponding to a mutation associated with disease; and detecting the presence or absence of an unhybridised portion of the probe strand as an indication of the presence or absence of a disease-associated mutation in the corresponding portion of the DNA strand.

Such diagnostics are particularly useful for prenatal and even neonatal testing.

Point mutations and other sequence differences between the reference gene and "mutant" genes can be identified by other well-known techniques, such as direct DNA sequencing or single-strand conformational polymorphism, (see Orita *et al.*, Genomics, 5, 874-879 (1989)). For example, a sequencing primer may be used with double-stranded PCR product or a single-stranded template molecule generated by a modified PCR. The sequence determination is performed by conventional procedures with radiolabelled nucleotides or by automatic sequencing procedures with fluorescent-tags. Cloned DNA segments may also be used as probes to detect specific DNA segments. The sensitivity of this method is greatly enhanced when combined with PCR. Further, point mutations and other sequence variations, such as polymorphisms, can be detected as described above, for example, through the use of allele-specific oligonucleotides for PCR amplification of sequences that differ by single nucleotides.

DNA sequence differences may also be detected by alterations in the electrophoretic mobility of DNA fragments in gels, with or without denaturing agents, or by direct DNA sequencing (for example, Myers *et al.*, Science (1985) 230:1242). Sequence changes at specific locations may also be revealed by nuclease protection assays, such as RNase and S1 protection or the chemical cleavage method (see Cotton *et al.*, Proc. Natl. Acad. Sci. USA (1985) 85: 4397-4401).

In addition to conventional gel electrophoresis and DNA sequencing, mutations such as microdeletions, aneuploidies, translocations, inversions, can also be detected by *in situ* analysis (see, for example, Keller *et al.*, DNA Probes, 2nd Ed., Stockton Press, New York, N.Y., USA (1993)), that is, DNA or RNA sequences in cells can be analysed for mutations without need for their isolation and/or immobilisation onto a membrane. Fluorescence *in*

situ hybridization (FISH) is presently the most commonly applied method and numerous reviews of FISH have appeared (see, for example, Trachuck *et al.*, Science, 250, 559-562 (1990), and Trask *et al.*, Trends, Genet., 7, 149-154 (1991)).

- In another embodiment of the invention, an array of oligonucleotide probes comprising a nucleic acid molecule according to the invention can be constructed to conduct efficient screening of genetic variants, mutations and polymorphisms. Array technology methods are well known and have general applicability and can be used to address a variety of questions in molecular genetics including gene expression, genetic linkage, and genetic variability (see for example: M.Chee *et al.*, Science (1996), Vol 274, pp 610-613).
- 10 In one embodiment, the array is prepared and used according to the methods described in PCT application WO95/11995 (Chee *et al.*; Lockhart, D. J. *et al.* (1996) Nat. Biotech. 14: 1675-1680); and Schena, M. *et al.* (1996) Proc. Natl. Acad. Sci. 93: 10614-10619). Oligonucleotide pairs may range from two to over one million. The oligomers are synthesized at designated areas on a substrate using a light-directed chemical process. The
- 15 substrate may be paper, nylon or other type of membrane, filter, chip, glass slide or any other suitable solid support. In another aspect, an oligonucleotide may be synthesized on the surface of the substrate by using a chemical coupling procedure and an ink jet application apparatus, as described in PCT application W095/25116 (Baldeschweiler *et al.*). In another aspect, a "gridded" array analogous to a dot (or slot) blot may be used to arrange
- 20 and link cDNA fragments or oligonucleotides to the surface of a substrate using a vacuum system, thermal, UV, mechanical or chemical bonding procedures. An array, such as those described above, may be produced by hand or by using available devices (slot blot or dot blot apparatus), materials (any suitable solid support), and machines (including robotic instruments), and may contain 8, 24, 96, 384, 1536 or 6144 oligonucleotides, or any other
- 25 number between two and over one million which lends itself to the efficient use of commercially-available instrumentation.

In addition to the methods discussed above, diseases may be diagnosed by methods comprising determining, from a sample derived from a subject, an abnormally decreased or increased level of polypeptide or mRNA. Decreased or increased expression can be

30 measured at the RNA level using any of the methods well known in the art for the quantitation of polynucleotides, such as, for example, nucleic acid amplification, for instance PCR, RT-PCR, RNase protection, Northern blotting and other hybridization

methods.

Assay techniques that can be used to determine levels of a polypeptide of the present invention in a sample derived from a host are well-known to those of skill in the art and are discussed in some detail above (including radioimmunoassays, competitive-binding assays, 5 Western Blot analysis and ELISA assays). This aspect of the invention provides a diagnostic method which comprises the steps of: (a) contacting a ligand as described above with a biological sample under conditions suitable for the formation of a ligand-polypeptide complex; and (b) detecting said complex.

10 Protocols such as ELISA, RIA, and FACS for measuring polypeptide levels may additionally provide a basis for diagnosing altered or abnormal levels of polypeptide expression. Normal or standard values for polypeptide expression are established by combining body fluids or cell extracts taken from normal mammalian subjects, preferably humans, with antibody to the polypeptide under conditions suitable for complex formation. The amount of standard complex formation may be quantified by various methods, such as 15 by photometric means.

Antibodies which specifically bind to a polypeptide of the invention may be used for the diagnosis of conditions or diseases characterised by expression of the polypeptide, or in assays to monitor patients being treated with the polypeptides, nucleic acid molecules, ligands and other compounds of the invention. Antibodies useful for diagnostic purposes 20 may be prepared in the same manner as those described above for therapeutics. Diagnostic assays for the polypeptide include methods that utilise the antibody and a label to detect the polypeptide in human body fluids or extracts of cells or tissues. The antibodies may be used with or without modification, and may be labelled by joining them, either covalently or non-covalently, with a reporter molecule. A wide variety of reporter molecules known 25 in the art may be used, several of which are described above.

Quantities of polypeptide expressed in subject, control and disease samples from biopsied tissues are compared with the standard values. Deviation between standard and subject values establishes the parameters for diagnosing disease. Diagnostic assays may be used to distinguish between absence, presence, and excess expression of polypeptide and to 30 monitor regulation of polypeptide levels during therapeutic intervention. Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal studies, in clinical trials or in monitoring the treatment of an individual patient.

A diagnostic kit of the present invention may comprise:

(a) a nucleic acid molecule of the present invention;

~~(b) a polypeptide of the present invention; or~~

(c) a ligand of the present invention.

- 5 In one aspect of the invention, a diagnostic kit may comprise a first container containing a nucleic acid probe that hybridises under stringent conditions with a nucleic acid molecule according to the invention; a second container containing primers useful for amplifying the nucleic acid molecule; and instructions for using the probe and primers for facilitating the diagnosis of disease. The kit may further comprise a third container holding an agent for
10 digesting unhybridised RNA.

In an alternative aspect of the invention, a diagnostic kit may comprise an array of nucleic acid molecules, at least one of which may be a nucleic acid molecule according to the invention.

- To detect polypeptide according to the invention, a diagnostic kit may comprise one or
15 more antibodies that bind to a polypeptide according to the invention; and a reagent useful for the detection of a binding reaction between the antibody and the polypeptide.

- Such kits will be of use in diagnosing a disease or susceptibility to disease in which members of the Germinal Center Kinase (GCK) subfamily of the STE20 family of protein kinases, preferably NIK-like kinases and more preferably NIK-like embryo specific
20 kinases (NESK) are implicated. Such diseases may include cell proliferative disorders, including neoplasm, melanoma, lung, colorectal, breast, pancreas, head and neck and other solid tumours; myeloproliferative disorders, such as leukemia, non-Hodgkin lymphoma, leukopenia, thrombocytopenia, angiogenesis disorder, Kaposi's sarcoma; autoimmune/inflammatory disorders, including allergy, inflammatory bowel disease,
25 arthritis, psoriasis and respiratory tract inflammation, asthma, and organ transplant rejection; cardiovascular disorders, including hypertension, oedema, angina, atherosclerosis, thrombosis, sepsis, shock, reperfusion injury, and ischemia; neurological disorders including central nervous system disease, Alzheimer's disease, brain injury, amyotrophic lateral sclerosis, and pain; developmental disorders; metabolic disorders
30 including diabetes mellitus, osteoporosis, and obesity; AIDS and renal disease; infections including viral infection, bacterial infection, fungal infection and parasitic infection and

other pathological conditions and in particular developmental disorders of late embryogenesis and neural tube defects such as spina bifida.

Various aspects and embodiments of the present invention will now be described in more detail by way of example, with particular reference to the INSP081, INSP082 and
5 INSP091 polypeptides.

It will be appreciated that modification of detail may be made without departing from the scope of the invention.

Brief description of the Figures

Figure 1: Top ten results from BLAST against NCBI non-redundant database using SEQ ID
10 NO:42 (INSP081 full protein sequence).

Figure 2: Alignment generated by BLAST between SEQ ID NO:42 (INSP081 full protein sequence) and the top hit, (AB035267) Nck-interacting kinase-like embryo specific kinase from *Mus. musculus*.

Figure 3: Top ten results from BLAST against NCBI non-redundant database using SEQ ID
15 NO:100 (INSP082 full protein sequence).

Figure 4: Alignment generated by BLAST between SEQ ID NO:100 (INSP082 full protein sequence) and the top hit, (AB035267) Nck-interacting kinase-like embryo specific kinase from *Mus. musculus*.

Figure 5: Top ten results from BLAST against NCBI non-redundant database using SEQ ID
20 NO:158 (INSP091 full protein sequence).

Figure 6: Alignment generated by BLAST between SEQ ID NO:158 (INSP091 full protein sequence) and the top hit, (AB035267) Nck-interacting kinase-like embryo specific kinase from *Mus. musculus*.

Examples

25 Example 1: INSP081 Protein BLAST Results

The INSP081 polypeptide sequence, shown in SEQ ID NO:42, was used as a BLAST query against the NCBI non-redundant sequence database. As can be seen in Figure 1, the top hit is to Nck-interacting kinase-like embryo specific kinase (NESK) from *Mus. musculus*. INSP081 has 57% identity over its 1132 residues to the top hit. The majority of
30 this identity occurs at the N-terminal of the protein. This is because INSP082 contains the NESK-like kinase domain at its N-terminal. The top hit has an expectation value of 0.

The closest human BLASTP homologue is the fifth top hit, (NM_004834) mitogen-activated protein kinase kinase kinase 4, HPK/GCK-like kinase. INSP081 has 58% identity to this human homologue over 326 of its residues. The closest human hit has an expectation value of e^{-108} .

- 5 The fact that all the top ten hits are from NESK or NIK-like kinases together with the expectation values given for these hits (the top four hits have expectation values of zero whilst the top ten hits all have an expectation value of e^{-107} or less, which is extremely low), indicates that INSP081 is a member of the Germinal Center Kinase (GCK) subfamily of the STE20 family of protein kinases and is preferably a NIK-like kinase and is even
10 more preferably a NIK-like embryo specific kinase (NESK).

Example 2: INSP082 Protein BLAST Results

- The INSP082 polypeptide sequence, shown in SEQ ID NO:100, was used as a BLAST query against the NCBI non-redundant sequence database. As can be seen in Figure 3, the top hits is to Nck-interacting kinase-like embryo specific kinase (NESK) from *Mus.*
15 *musculus* and hits two to ten are all from NESK or NIK-like kinases. The top four hits have expectation values of zero whilst the top ten hits all have an expectation value of e^{-107} or less, which is extremely low. This therefore indicates that INSP082 is a member of the Germinal Center Kinase (GCK) subfamily of the STE20 family of protein kinases, preferably a NIK-like kinase and is even more preferably a NIK-like embryo specific
20 kinase (NESK).

Example 3: INSP091 Protein BLAST Results

- The INSP082 polypeptide sequence, shown in SEQ ID NO:158, was used as a BLAST query against the NCBI non-redundant sequence database. As can be seen in Figure 5, the top hits is to Nck-interacting kinase-like embryo specific kinase (NESK) from *Mus.*
25 *musculus* and hits two to ten are all from NESK or NIK-like kinases. The top four hits have expectation values of zero whilst the top ten hits all have an expectation value of e^{-107} or less, which is extremely low. This therefore indicates that INSP091 is a member of the Germinal Center Kinase (GCK) subfamily of the STE20 family of protein kinases, preferably a NIK-like kinase and is even more preferably a NIK-like embryo specific
30 kinase (NESK).

Sequence Listing:**SEQ ID NO:1 (INSP081 exon 1 nucleotide sequence)**

1 ATGGCGGGAC CTGGGGGCTG GAGGGACAGG GAGGTCACGG ATCTGGGCCA CCTGCCG

5 SEQ ID NO: 2 (INSP081 exon 1 polypeptide sequence)

1 MAGPGGWRDR EVTDLGHLR

SEQ ID NO: 3 (INSP081 exon 2 nucleotide sequence)

1 GATCCAACCTG GAATATTCTC ACTAGATAAA ACCATTGGCC TTGGTACTTA TGGCAGAATC
61 TATTTG

10 SEQ ID NO:4 (INSP081 exon 2 polypeptide sequence)

1 DPTGIFSLDK TIGLGTYGRI YL

SEQ ID NO: 5 (INSP081 exon 3 nucleotide sequence)

1 GGACTTCATG AGAAGACTGG TGCATTTACA GCTGTAAAG TGATGAACGC TCGTAAG

SEQ ID NO:6 (INSP081 exon 3 polypeptide sequence)

15 1 GLHEKTGAFT AVKVMNARK

SEQ ID NO: 7 (INSP081 exon 4 nucleotide sequence)

1 ACCCCTTTAC CTGAAATAGG AAGGCGAGTG AGAGTGAATA AATATCAAAA ATCTGTTGGG
61 TGGAGATACA GT

SEQ ID NO:8 (INSP081 exon 4 polypeptide sequence)

20 1 TPLPEIGRRV RVNKYQKSVG WRYS

SEQ ID NO: 9 (INSP081 exon 5 nucleotide sequence)

1 GATGAGGAAG AGGATCTCAG GACTGAACTC AACCTTCTGA GGAAGTACTC TTTCCACAAA
61 AACATTGTGT CCTTCTATGG AGCATTTTTC AAGCTGAGTC CCCCTGGTCA GCGGCACCAA
121 CTTTGG

25 SEQ ID NO:10 (INSP081 exon 5 polypeptide sequence)

1 DEEDLRTTEL NLLRKYSFHK NIVSFYGAFF KLSPPGQRHQ LW

SEQ ID NO: 11 (INSP081 exon 6 nucleotide sequence)

1 ATGGTGATGG AGTTATGTGC AGCAGGTTTC GTCAGTGATG TAGTGAGAAT GACCAGTAAT
61 CAGAGTTTAA AAGAAGATTG GATTGCTTAT ATCTGCCGAG AAATCCTTCA G

SEQ ID NO:12 (INSP081 exon 6 polypeptide sequence)

1 MVMELCAAGS VTDVVRMTSN QSLKEDWIAI ICREILQ

SEQ ID NO:13 (INSP081 exon 7 nucleotide sequence)

1 GGCTTAGCTC ACCTTCACGC ACACCGAGTA ATTACCCGGG ACATCAAAGG TCAGAATGTG
5 61 CTGCTGACTC ATAATGCTGA AGTAAACTG G

SEQ ID NO:14 (INSP081 exon 7 polypeptide sequence)

1 GLAHLHAHRV IHRDIKGQNV LLTHNAEVKL V

SEQ ID NO:15 (INSP081 exon 8 nucleotide sequence)

1 TTGATTTTGG AGTGAGTGCC CAGGTGAGCA GAACTAATGG AAGAAGGAAT AGTTTCATTG
10 61 GGACACCATA CTGGATGGCA CCTGAGGTGA TTGACTGTGA TGAGGACCCA AGACGCTCCT
121 ATGATTACAG A

SEQ ID NO:16 (INSP081 exon 8 polypeptide sequence)

1 DFGVSAQVSR TNGRRNSFIG TPYWMAPEVI DCDEDPRRSY DYR

SEQ ID NO:17 (INSP081 exon 9 nucleotide sequence)

15 1 AGTGATGTGT GGTCTGTGGG AATTACTGCC ATTGAAATGG CTGAAGGAGC CCCTC

SEQ ID NO:18 (INSP081 exon 9 polypeptide sequence)

1 SDVWSVGITA IEMAEGAPP

SEQ ID NO:19 (INSP081 exon 10 nucleotide sequence)

1 CTCTGTGTA CCTTCAACCC TTGGAAGCTC TCTTCGTTAT TTTGCGGGAA TCTGCTCCCA
20 61 CAGTCAAATC CAGCGGATG

SEQ ID NO:20 (INSP081 exon 10 polypeptide sequence)

1 LCNLQPLEAL FVILRESAPT VKSSGW

SEQ ID NO:21 (INSP081 exon 11 nucleotide sequence)

1 GTCCCGTAAG TTCCACAATT TCATGGAAAA GTGTACGATA AAAAATTTCC TGTTTCGTCC
25 61 TACTTCTGCA AACATGCTTC AACACCCATT TGTTCTGGGAT ATAAAAAATG AACGACATGT
121 TGTGAGTCA TTAACAAGGC ATCTTACTGG AATCATTTAAA AAAAGACAGA AAAAAG

SEQ ID NO:22 (INSP081 exon 11 polypeptide sequence)

1 SRKFHNFMEK CTIKNFLFRP TSANMLQHPF VRDIKNERHV VESLTRHLTG IIKKRQKKG

SEQ ID NO: 23 (INSP081 exon 12 nucleotide sequence)

1 GAATACCTTT GATCTTTGAA AGAGAAGAAG CTATTAAGGA ACAGTACACC GTGAGAAGAT
61 TCAG

SEQ ID NO:24 (INSP081 exon 12 polypeptide sequence)

5 1 IPLIFEREEA IKEQYTVRRF R

SEQ ID NO: 25 (INSP081 exon 13 nucleotide sequence)

1 AGGACCCTCT TGCACTCACG AGCTTCTGAG ATTGCCAACC AGCAGCAGAT GCAGACCACT
61 TAGAGTCCTG CATGGGGAAC CCTCTCAGCC AAGGTGGCTA CCTGATCGAG AAGAGCCACA
121 GGTCCAGGCA CTTCAGCAGC TACAGGGAGC AGCCAGGGTA TTCATGCCAC TGCAGGCTCT
10 181 GGACAGTGCA CCTAAGCCTC TAAAGGGGCA GGCTCAGGCA CCTCAACGAC TACAAGGGGC
241 AGCTCGGGTG TTCATGCCAC TACAGGCTCA GGTGAAGGCT AAAGCCTCTA AACCTCTACA
301 AATGCAGATT AAGGCACCTC CACGACTACG GAGGGCAGCC AGGGTGCTCA TGCCACTACA
361 GGCACAGGTT AGGGCACCTA GGCTTCTGCA GGTACAGTCC CAGGTATCCA AAAAGCAGCA
421 GGCCAGACC CAGACATCAG AACCACAAGA TTTGGACCAG GTACCAGAGG AATTTAGGG
15 481 TCAAGATCAG GTACCCGAAC AACAAAGGCA GGGCCAGGCC CCTGAACAAC AGCAGAGGCA
541 CAACCAGGTG CCTGAACAAG AGCTGGAGCA GAACCAGGCA CCTGAACAGC CAGAGGTACA
601 GGAACAGGCT GCCGAGCCTG CACAGGCAGA GACTGAGGCA GAGGAACCTG AGTCATTACG
661 AGTAAATGCC CAGGTATTTT TGCCCTGCT ATCACAAGAT CACCATGTGC TGTTGCCACT
721 ACATTTGGAT ACTCAGGTGC TCATTCCAGT AGAGGGGCAA ACTGAAGGAT CACCTCAGGC
20 781 ACAGGCTTGG AACTAGAAC CCCACAGGC AATTGGCTCA GTTCAAGCAC TGATAGAGGG
841 ACTATCAAGA GACTTGCTTC GGGCACCAAA CTCAAATAAC TCAAAGCCAC TTGGTCCGTT
901 GCAAACCTG ATGGAAAATC TGTCATCAA TAGGTTTAC TCACAACCAG AACAGGCACG
961 GGAGAAAAAA TCAAAGTTT CTACTCTGAG GCAAGCACTG GCAAAAAGAC TATCACCAAA
1021 GAGGTTTCAGG GCAAAGTCAT CATGGAGACC TGAAAAGCTT GAACTCTCGG ATTTAGAAGC
25 1081 CCGCAGGCAA AGGCGCCAAC GCAGATGGGA AGATATCTTT AATCAGCATG AGGAAGAATT
1141 GAGACAAGTT GATAAA

SEQ ID NO:26 (INSP081 exon 13 polypeptide sequence)

1 GPSCTHELLR LPTSSRCRPL RVLHGEPSQP RWLPDREEPQ VQALQQQLQA ARVFMPLQAL
61 DSAPKPLKGQ AQAPQRLQGA ARVFMPLQAQ VKAKASKPLQ MQIKAPPLR RAARVLMPLQ
30 121 AQVRAPRLQ VQSQVSKKQ AQTQTSEPQD LDQVPEEFQ QDQVPEQQRQ GOAPEQQQRH
181 NQVPEQELEQ NQAPEQPEVQ EQAAEPAQAE TEAEPEPSLR VNAQVFLPLL SQDHHVLLPL
241 HLDQVLIPV EGQTEGSPQA QAWTLEPPQA IGSVQALIEG LSRDLLRAPN SNNSKPLGPL
301 QTLMENLSSN RFYSQPEQAR EKKSIVSTLR QALAKRLSPK RFRAKSSWRP EKLELSDLEA

361 RRQRRQRRWE DIFNQHEEEL RQVDK

SEQ ID NO: 27 (INSP081 exon 14 nucleotide sequence)

1 GACAAAGAAG ATGAATCATC AGACAATGAT GAAGTATTTT ATTGATTCA GGCTGAAGTC
61 CAGATAGAGC CATTGAAGCC ATACATTTCA AATCCTAAAA AAATTGAG

5 SEQ ID NO:28 (INSP081 exon 14 polypeptide sequence)

1 DKEDESSDND EVFHSIQAEV QIEPLKPYIS NPKKIE

SEQ ID NO: 29 (INSP081 exon 15 nucleotide sequence)

1 GTTCAAGAGA GATCTCCTTC TGTGCCTAAC AACCAGGATC ATGCACATCA TGTCAGTTC
61 TCTTCAAG

10 SEQ ID NO:30 (INSP081 exon 15 polypeptide sequence)

1 VQERSPSVPN NQDHAHVKF SSR

SEQ ID NO: 31 (INSP081 exon 16 nucleotide sequence)

1 GACATGGCAC ATGCTTTTCT GTCTTTTCAT TAGCGTTCCT CAGCGGTCTC TTTTGGAACA
61 AGCTCAGAAG CCCATTGACA TCAGACAAAG GAGTTCGCAA AATCGTCAAA ATTGGCTGGC
15 121 AGCATCAG

SEQ ID NO:32 (INSP081 exon 16 polypeptide sequence)

1 TWHMLFCLFI SVPQSLLEQ AQKPDIRQR SSQNRQNWLA ASE

SEQ ID NO: 33 (INSP081 exon 17 nucleotide sequence)

1 AATCTTCTTC TGAGGAAGAA AGTCCTGTGA CTGGAAGGAG GTCTCAGTCA TCACCACCTT
20 61 ATTCTACTAT TGATCAGAAG TTGCTGGTTG ACATCCAT

SEQ ID NO:34 (INSP081 exon 17 polypeptide sequence)

1 SSSEEEESPVT GRRSQSSPPY STIDQKLLVD IH

SEQ ID NO: 35 (INSP081 exon 18 nucleotide sequence)

1 GTTCCAGATG GATTTAAAGT AGGAAAAATA TCACCCCTG TATACTTGAC AAACGAATGG
25 61 GTAGGCTATA ATGCACTCTC TGAAATCTTC CGGAATGATT GGTAACTCC GGCACCTGTC
121 ATTCAGCCAC CTGAAGAGGA TGGTGATTAT GTTGAACCTCT ATGATGCCAG TGCTGATACT
181 GATGGTGATG ATGATGATGA GTCTAATGAT ACTTTTGAAG ATACCTATGA TCATGCCAAT
241 GGCAATGATG ACTTGATAA CCAGGTTGAT CAGGCTAATG ATGTTTGTAAG AGACCATGAT
301 GATGACAACA ATAAGTTTGT TGATGATGTA AATAATAATT ATTATGAGGC GCCTAGTTGT
30 361 CCAAG

SEQ ID NO:36 (INSP081 exon 18 polypeptide sequence)

1 VPDGFKVGKI SPPVYLTNEW VGYNALSEIF RNDWLTPAPV IQPPEEDGDY VELYDASADT
 61 DGDDDDDESND TFEDTYDHAN GNDDLNDQVD QANDVCKDHD DDNNKFVDDV NNNYYEAPSC
 121 PR

5 SEQ ID NO: 37 (INSP081 exon 19 nucleotide sequence)

1 GGCAAGCTAT GGCAGAGATG GAAGCTGCAA GCAAGATGGT TATGATGGAA GTCGTGGAAA
 61 AGAGGAAGCC TACAGAGGCT ATGGAAGCCA TACAGCCAAT AGAAGCCATG GAGGAAGTGC
 121 AGCCAGTGAG GACAATGCAG CCATTGGAGA TCAGGAAGAA CATGCAGCCA ATATAGGCAG
 181 TGAAAGAAGA GGCAGTGAGG GTGATGGAG

10 SEQ ID NO:38 (INSP081 exon 19 polypeptide sequence)

1 ASYGRDGSCK QDGYDGSRGK EEAYRGYGSB TANRSHGGSB ASEDNAAIGD QEEHAANIGS
 61 ERRGSEGDGG

SEQ ID NO: 39 (INSP081 exon 20 nucleotide sequence)

1 GTGGTGGAAA TGAGGCCTCA AATGCCATTG ACTCAGGTGC TGCACCGTCA GCACCTGATC
 15 61 ATGAGAGTGA CAATAAGGAC ATATCAGAAT CATCAACACA ATCAGATTTT TCTGCCAATC
 121 ACTCATCTCC TTCCAAAGGT TCTGGGATGT CTGCTGATGC TAACTTTGCC AGTGCCATCT
 181 AA

SEQ ID NO:40 (INSP081 exon 20 polypeptide sequence)

1 GGNEASNAID SGAAPSAPDH ESDNKDISES STQSDFSANH SSPSKGSGMS ADANFASAI

20 SEQ ID NO:41 (INSP081 nucleotide sequence)

1 ATGGCGGGAC CTGGGGGCTG GAGGGACAGG GAGGTCACGG ATCTGGGCCA CCTGCCGGAT
 61 CCAACTGGAA TATTCTCACT AGATAAAACC ATTGGCCTTG GTACTTATGG CAGAATCTAT
 121 TTGGGACTTC ATGAGAAGAC TGGTGCATTT ACAGCTGTTA AAGTGATGAA CGCTCGTAAG
 181 ACCCCTTTAC CTGAAATAGG AAGGCGAGTG AGAGTGAATA AATATCAAAA ATCTGTTGGG
 25 241 TGGAGATACA GTGATGAGGA AGAGGATCTC AGGACTGAAC TCAACCTTCT GAGGAAGTAC
 301 TCTTTCCACA AAAACATTGT GTCCTTCTAT GGAGCATTTT TCAAGCTGAG TCCCCCTGGT
 361 CAGCGGCACC AACTTTGGAT GGTGATGGAG TTATGTGCAG CAGGTTCCGGT CACTGATGTA
 421 GTGAGAATGA CCAGTAATCA GAGTTTAAAA GAAGATTGGA TTGCTTATAT CTGCCGAGAA
 481 ATCCTTCAGG GCTTAGCTCA CCTTCACGCA CACCGAGTAA TTCACGGGA CATCAAAGGT
 30 541 CAGAATGTGC TGCTGACTCA TAATGCTGAA GTAAACTGG TTGATTTTGG AGTGAGTGCC
 601 CAGGTGAGCA GAACTAATGG AAGAAGGAAT AGTTTCATTG GGACACCATA CTGGATGGCA
 661 CCTGAGGTGA TTGACTGTGA TGAGGACCCA AGACGCTCCT ATGATTACAG AAGTGATGTG

721 TGGTCTGTGG GAATTACTGC CATTGAAATG GCTGAAGGAG CCCCTCCTCT GTGTAACCTT
 781 CAACCCTTGG AAGCTCTCTT CGTTATTTTG CGGGAATCTG CTCCCACAGT CAAATCCAGC
 841 GGATGGTCCC GTAAGTTCCA CAATTTTCATG GAAAAGTGTA CGATAAAAAA TTTCCTGTTT

 901 CGTCCTACTT CTGCAAACAT GCTTCAACAC CCATTTGTTC GGGATATAAA AAATGAACGA
 5 961 CATGTTGTTG AGTCATTAAC AAGGCATCTT ACTGGAATCA TTAAAAAAG ACAGAAAAAA
 1021 GGAATACCTT TGATCTTTGA AAGAGAAGAA GCTATTAAGG AACAGTACAC CGTGAGAAGA
 1081 TTCAGAGGAC CCTCTTGCAC TCACGAGCTT CTGAGATTGC CAACCAGCAG CAGATGCAGA
 1141 CCACTTAGAG TCCTGCATGG GGAACCCCTCT CAGCCAAGGT GGCTACCTGA TCGAGAAGAG
 1201 CCACAGGTCC AGGCACTTCA GCAGCTACAG GGAGCAGCCA GGGTATTCAT GCCACTGCAG
 10 1261 GCTCTGGACA GTGCACCTAA GCCTCTAAAG GGGCAGGCTC AGGCACCTCA ACGACTACAA
 1321 GGGGCAGCTC GGGTGTTCAT GCCACTACAG GCTCAGGTGA AGGCTAAAGC CTCTAAACCT
 1381 CTACAAATGC AGATTAAGGC ACCTCCACGA CTACGGAGGG CAGCCAGGGT GCTCATGCCA
 1441 CTACAGGCAC AGGTTAGGGC ACCTAGGCTT CTGCAGGTAC AGTCCCAGGT ATCCAAAAAG
 1501 CAGCAGGCCC AGACCCAGAC ATCAGAACCA CAAGATTTGG ACCAGGTACC AGAGGAATTT
 15 1561 CAGGGTCAAG ATCAGGTACC CGAACAACAA AGGCAGGGCC AGGCCCCTGA ACAACAGCAG
 1621 AGGCACAACC AGGTGCCTGA ACAAGAGCTG GAGCAGAACC AGGCACCTGA ACAGCCAGAG
 1681 GTACAGGAAC AGGCTGCCGA GCCTGCACAG GCAGAGACTG AGGCAGAGGA ACCTGAGTCA
 1741 TTACGAGTAA ATGCCCAGGT ATTTCTGCCC CTGCTATCAC AAGATCACCA TGTGCTGTTG
 1801 CCACTACATT TGGATACTCA GGTGCTCATT CCAGTAGAGG GGCAAACCTGA AGGATCACCT
 20 1861 CAGGCACAGG CTTGGACACT AGAACCCCCA CAGGCAATTG GCTCAGTTCA AGCACTGATA
 1921 GAGGGACTAT CAAGAGACTT GCTTCGGGCA CCAAACCTCA AATACTCAA GCCACTTGGT
 1981 CCGTTGCAAA CCCTGATGGA AAATCTGTCA TCAAATAGGT TTTACTCACA ACCAGAACAG
 2041 GCACGGGAGA AAAAATCAAA AGTTTCTACT CTGAGGCAAG CACTGGCAAA AAGACTATCA
 2101 CCAAAGAGGT TCAGGGCAAA GTCATCATGG AGACCTGAAA AGCTTGAACT CTCGGATTTA
 25 2161 GAAGCCCGCA GGCAAAGGCG CCAACGCAGA TGGGAAGATA TCTTTAATCA GCATGAGGAA
 2221 GAATTGAGAC AAGTTGATAA AGACAAAGAA GATGAATCAT CAGACAATGA TGAAGTATTT
 2281 CATTCGATTC AGGCTGAAGT CCAGATAGAG CCATTGAAGC CATACATTTT AAATCCTAAA
 2341 AAAATTGAGG TTCAAGAGAG ATCTCCTTCT GTGCCTAACA ACCAGGATCA TGCACATCAT
 2401 GTCAAGTTCT CTTCAAGGAC ATGGCACATG CTTTCTGTG TTTTCATTAG CGTTCCTCAG
 30 2461 CGGTCTCTTT TGGAACAAGC TCAGAAGCCC ATTGACATCA GACAAAGGAG TTCGCAAAAT
 2521 CGTCAAAATT GGCTGGCAGC ATCAGAATCT TCTTCTGAGG AAGAAAGTCC TGTGACTGGA
 2581 AGGAGGTCTC AGTCATCACC ACCTTATTCT ACTATTGATC AGAAGTTGCT GGTGACATC
 2641 CATGTTCCAG ATGGATTTAA AGTAGGAAAA ATATCACCCC CTGTATACTT GACAAACGAA
 2701 TGGGTAGGCT ATAATGCACT CTCTGAAATC TTCCGGAATG ATTGGTTAAC TCCGGCACCT
 35 2761 GTCATTACAG CACCTGAAGA GGATGGTGAT TATGTTGAAC TCTATGATGC CAGTGCTGAT

2821 ACTGATGGTG ATGATGATGA TGAGTCTAAT GATACTTTTG AAGATACCTA TGATCATGCC
 2881 AATGGCAATG ATGACTTGGA TAACCAGGTT GATCAGGCTA ATGATGTTTG TAAAGACCAT
 2941 GATGATGACA ACAATAAGTT TGTTGATGAT GTAAATAATA ATTATTATGA GGCGCCTAGT
 3001 TGTCCAAGGG CAAGCTATGG CAGAGATGGA AGCTGCAAGC AAGATGGTTA TGATGGAAGT
 5 3061 CGTGGAAAAG AGGAAGCCTA CAGAGGCTAT GGAAGCCATA CAGCCAATAG AAGCCATGGA
 3121 GGAAGTGCAG CCAGTGAGGA CAATGCAGCC ATTGGAGATC AGGAAGAACA TGCAGCCAAT
 3181 ATAGGCAGTG AAAGAAGAGG CAGTGAGGGT GATGGAGGTG GTGGAAATGA GGCCTCAAAT
 3241 GCCATTGACT CAGGTGCTGC ACCGTCAGCA CCTGATCATG AGAGTGACAA TAAGGACATA
 3301 TCAGAATCAT CAACACAATC AGATTTTTCT GCCAATCACT CATCTCCTTC CAAAGGTCTC
 10 3361 GGGATGTCTG CTGATGCTAA CTTTGCCAGT GCCATC

SEQ ID NO:42 (INSP081 polypeptide sequence)

1 MAGPGGWRDR EVTDLGHLPD PTGIFSLDKT IGLGTYGRIY LGLHEKTGAF TAVKVMNARK
 61 TPLPEIGRRV RVNKYQKSVG WRYSDEEEDL RTELNLLRKY SFHKNIVSFY GAFFKLSPPG
 121 QRHQLWMVME LCAAGSVTDV VRMTSNQSLK EDWIAYICRE ILQGLAHLHA HRVIHRDIKG
 15 181 QNVLLTHNAE VKLVDFGVSA QVSRTNGRRN SFIGTPYWMA PEVIDCDEDP RRSYDYRSDV
 241 WSVGITAIEA AEGAPPLCNL QPLEALFVIL RESAPTVKSS GWSRKPHNFM EKCTIKNFLF
 301 RPTSANMLQH PFVRDIKNER HVVESLTRHL TGIKKRQKK GIPLIFEREE AIKEQYTVRR
 361 FRGPSCTHEL LRLPTSSRCR PLRVLHGEPs QPRWLPDREE PQVQALQQQLQ GAARVFMPLQ
 421 ALDSAPKPLK GQAQAPQRLQ GAARVFMPLQ AQVKAKASKP LQMGIKAPPR LRRARVLMPL
 20 481 LQAQVRAPRL LQVQSQVSKK QQAQTQTSEP QDLQVPEEF QGQDQVPEQQ RQGQAPEQQQ
 541 RHNQVPEQEL EQNQAPEQPE VQEQAAPPAQ AETEAEEPES LRVNAQVFLP LLSQDHHVLL
 601 PLHLDQTQVLI PVEGQTEGSP QAQAWTLEPP QAIGSVQALI EGLSRDLLRA PNSNNSKPLG
 661 PLQTLMENLS SNRFYSQPEQ AREKSKSVST LRQALAKRLS PKRFRAKSSW RPEKLELSDL
 721 EARRQRRQRR WEDIFNQHEE ELRQVDKDE DESSDNDEVF HSIQAEVQIE PLKPYISNPK
 25 781 KIEVQERSPS VPMNQDHAHH VKFSSRTWHM LFCLFISVPQ RSLLEQAQKP IDIRQRSSQN
 841 RQNWLAASES SSEEESPVTG RRSQSSPPYS TIDQKLLVDI HVPDGFVKVGK ISPPVYLTNE
 901 WVGYNALSEI FRNDWLTPAP VIQPPEEDGD YVELYDASAD TDGDDDDDES DTFEDTYDHA
 961 NGNDLDLNOV DQANDVCKDH DDDNNKFVDD VNNNYEAPS CPRASYGRDG SCKQDGYDGS
 1021 RGKEEAYRGY GSHTANRSHG GSAASEDNAA IGDQEEHAAN IGSERRGSEG DGGGGNEASN
 30 1081 AIDSGAAPSA PDHESDNKDI SESSTQSDFS ANHSSPSKGS GMSADANFAS AI

SEQ ID NO:43 (INSP082 exon 1 nucleotide sequence)

1 ATGGCGGGAC CTGGGGGCTG GAGGGACAGG GAGGTCACGG ATCTGGGCCA CCTGCCG

SEQ ID NO:44 (INSP082 exon 1 polypeptide sequence)

1 MAGPGGWRDR EVTDLGHL P

SEQ ID NO:45 (INSP082 exon 2 nucleotide sequence)

1 GATCCAAC TGAATATTCTC ACTAGATAAA ACCATTGGCC TTGGTACTTA TGGCAGAATC
5 61 TATTTG

SEQ ID NO:46 (INSP082 exon 2 polypeptide sequence)

1 DPTGIFSLDK TIGLGTYGRI YL

SEQ ID NO:47 (INSP082 exon 3 nucleotide sequence)

1 GGACTTCATG AGAAGACTGG TGCATTTACA GCTGTAAAG TGATGAACGC TCGTAAG

10 SEQ ID NO:48 (INSP082 exon 3 polypeptide sequence)

1 GLHEKTGAFT AVKVMNARK

SEQ ID NO:49 (INSP082 exon 4 nucleotide sequence)

1 ACCCCTTTAC CTGAAATAGG AAGGCGAGTG AGAGTGAATA AATATCAAAA ATCTGTTGGG
61 TGGAGATACA GT

15 SEQ ID NO:50 (INSP082 exon 4 polypeptide sequence)

1 TPLPEIGRRV RVNKYQKSVG WRYS

SEQ ID NO:51 (INSP082 exon 5 nucleotide sequence)

1 GATGAGGAAG AGGATCTCAG GACTGAACTC AACCTTCTGA GGAAGTACTC TTTCCACAAA
61 AACATTGTGT CCTTCTATGG AGCATTTTTC AAGCTGAGTC CCCCTGGTCA GCGGCACCAA
20 121 CTTTGG

SEQ ID NO:52 (INSP082 exon 5 polypeptide sequence)

1 DEEEDLRTEL NLLRKYSFHK NIVSFYGAFF KLSPPGQRHQ LW

SEQ ID NO:53 (INSP082 exon 6 nucleotide sequence)

1 ATGGTGATGG AGTTATGTGC AGCAGGTTTCG GTCAGTATG TAGTGAGAAT GACCAGTAAT
25 61 CAGAGTTTAA AAGAAGATTG GATTGCTTAT ATCTGCCGAG AAATCCTTCA G

SEQ ID NO:54 (INSP082 exon 6 polypeptide sequence)

1 VMELCAAGS VTDVVRMTSN QSLKEDWIA Y ICREILQ

SEQ ID NO:55 (INSP082 exon 7 nucleotide sequence)

1 GGCTTAGCTC ACCTTCACGC ACACCGAGTA ATTCACCGGG ACATCAAAGG TCAGAATGTG
30 61 CTGCTGACTC ATAATGCTGA AGTAAACTG G

SEQ ID NO:56 (INSP082 exon 7 polypeptide sequence)

1 GLAHLHAHRV IHRDIKGQNV LLTHNAEVKL V

SEQ ID NO:57 (INSP082 exon 8 nucleotide sequence)

1 TTGATTTTGG AGTGAGTGCC CAGGTGAGCA GAACTAATGG AAGAAGGAAT AGTTTCATTG
5 61 GGACACCATA CTGGATGGCA CCTGAGGTGA TTGACTGTGA TGAGGACCCA AGACGCTCCT
121 ATGATTACAG A

SEQ ID NO:58 (INSP082 exon 8 polypeptide sequence)

1 DFGVSAQVSR TNGRRNSFIG TPYWMAPEVI DCDDEPRRSY DYS

SEQ ID NO:59 (INSP082 exon 9 nucleotide sequence)

10 1 AGTGATGTGT GGTCTGTGGG AATTACTGCC ATTGAAATGG CTGAAGGAGC CCCTC

SEQ ID NO:60 (INSP082 exon 9 polypeptide sequence)

1 SDVWSVGITA IEMAEGAPP

SEQ ID NO:61 (INSP082 exon 10 nucleotide sequence)

1 CTCTGTGTAA CCTTCAACCC TTGGAAGCTC TCTTCGTTAT TTTGCGGGAA TCTGCTCCCA
15 61 CAGTCAAATC CAGCGGATG

SEQ ID NO:62 (INSP082 exon 10 polypeptide sequence)

1 LCNLQPLEAL FVILRESAPT VKSSGW

SEQ ID NO:63 (INSP082 exon 11 nucleotide sequence)

1 GTCCCGTAAG TTCCACAATT TCATGGAAAA GTGTACGATA AAAAATTTC TGTTCGTCC
20 61 TACTTCTGCA AACATGCTTC AACACCCATT TGTTCGGGAT ATAAAAAATG AACGACATGT
121 TGTTGAGTCA TTAACAAGGC ATCTTACTGG AATCATTTAA AAAAGACAGA AAAAAG

SEQ ID NO:64 (INSP082 exon 11 polypeptide sequence)

1 SRKFHNFMEK CTIKNFLFRP TSANMLQHPF VRDIKNERHV VESLTRHLTG IIKKRQKKG

SEQ ID NO:65 (INSP082 exon 12 nucleotide sequence)

25 1 GAATACCTTT GATCTTTGAA AGAGAAGAAG CTATTAAGGA ACAGTACACC GTGAGAAGAT
61 TCAG

SEQ ID NO:66 (INSP082 exon 12 polypeptide sequence)

1 IPLIFEREEA IKEQYTVRRF R

SEQ ID NO:67 (INSP082 exon 13 nucleotide sequence)

1 AGGACCCTCT TGCCTCAGC AGCTTCTGAG ATTGCCAACC AGCAGCAGAT GCAGACCACT
 61 TAGAGTCCTG CATGGGGAAC CCTCTCAGCC AAGGTGGCTA CCTGATCGAG AAGAGCCACA
 121 GGTCCAGGCA CTTACAGCAGC TACAGGGAGC AGCCAGGGTA TTCATGCCAC TGCAGGCTCT
 5 181 GGACAGTGCA CCTAAGCCTC TAAAGGGGCA GGCTCAGGCA CCTCAACGAC TACAAGGGGC
 241 AGCTCGGGTG TTCATGCCAC TACAGGCTCA GGTGAAGGCT AAAGCCTCTA AACCTCTACA
 301 AATGCAGATT AAGGCACCTC CACGACTACG GAGGGCAGCC AGGGTGCTCA TGCCACTACA
 361 GGCACAGGTT AGGGCACCTA GGCTTCTGCA GGTACAGTCC CAGGTATCCA AAAAGCAGCA
 421 GGCCCAGACC CAGACATCAG AACCACAAGA TTTGGACCAG GTACCAGAGG AATTTACAGG
 10 481 TCAAGATCAG GTACCCGAAC AACAAAGGCA GGGCCAGGCC CCTGAACAAC AGCAGAGGCA
 541 CAACCAGGTG CCTGAACAAG AGCTGGAGCA GAACCAGGCA CCTGAACAGC CAGAGGTACA
 601 GGAACAGGCT GCCGAGCCTG CACAGGCAGA GACTGAGGCA GAGGAACCTG AGTCATTACG
 661 AGTAAATGCC CAGGTATTTT TGCCCTGCT ATCACAAGAT CACCATGTGC TGTTCGCACT
 721 ACATTTGGAT ACTCAGGTGC TCATTCCAGT AGAGGGGCAA ACTGAAGGAT CACCTCAGGC
 15 781 ACAGGCTTGG AACTAGAAC CCCACAGGC AATTGGCTCA GTTCAAGCAC TGATAGAGGG
 841 ACTATCAAGA GACTTGCTTC GGGCACCAA CTCAAATAAC TCAAAGCCAC TTGGTCCGTT
 901 GCAAACCCTG ATGGAATATC TGTCATCAA TAGGTTTTAC TCACAACCAG AACAGGCACG
 961 GGAGAAAAAA TCAAAAGTTT CTACTCTGAG GCAAGCACTG GCAAAAAGAC TATCACCAAA
 1021 GAGGTTTCAGG GCAAAGTCAT CATGGAGACC TGAAAAGCTT GAACTCTCGG ATTTAGAAGC
 20 1081 CCGCAGGCAA AGGCGCCAAC GCAGATGGGA AGATATCTTT AATCAGCATG AGGAAGAATT
 1141 GAGACAAGTT GATAAA

SEQ ID NO:68 (INSP082 exon 13 polypeptide sequence)

1 GPSCTHELLR LPTSSRCRPL RVLHGEPSPQ RWLPDREEPO VQALQQLQGA ARVFMPLQAL
 61 DSAPKPLKGQ AQAPQRLQGA ARVFMPLQAG VKAKASKPLQ MQIKAPPRLR RAARVLMPLQ
 25 121 AQVRAPRLLO VQSQVSKKQQ AQTQTSEPOD LDQVPEEFQD QDQVPEQQRQ GQAPEQQQRH
 181 NQVPEQELEQ NQAPEQPEVQ EQAAEPAQAE TEAEPEPESLR VNAQVFLPLL SQDHHVLLPL
 241 HLDTOVLIPV EGQTEGSPQA QAWTLEPPQA IGSVQALIEG LSRDLLRAPN SNNSKPLGPL
 301 QTLMENLSSN RFYSQPEQAR EKSKVSTLR QALAKRLSPK RFRAKSSWRP EKLELSDLEA
 361 RRQRQRWE DIFNQHEEEL RQVDK

30 SEQ ID NO:69 (INSP082 exon 14 nucleotide sequence)

1 GACAAAGAAG ATGAATCATC AGACAATGAT GAAGTATTTT ATTCGATTCA GGCTGAAGTC
 61 CAGATAGAGC CATTGAAGCC ATACATTTCA AATCCTAAAA AAATTGAG

SEQ ID NO:70 (INSP082 exon 14 polypeptide séquence)

1 DKEDESSDND EVFHSIQAEV QIEPLKPYIS NPKKIE

SEQ ID NO:71 (INSP082 exon 15 nucleotide sequence)

1 GTTCAAGAGA GATCTCCTTC TGTGCCTAAC AACCAGGATC ATGCACATCA TGTCAAGTTC
5 61 TCTTCAAG

SEQ ID NO:72 (INSP082 exon 15 polypeptide sequence)

1 VQERSPSVFN NQDHAHHVKF SSR

SEQ ID NO:73 (INSP082 exon 16 nucleotide sequence)

1 GACATGGCAC ATGCTTTTCT GTCTTTTCAT TAGCGTTCCT CAGCGGTCTC TTTTGGAACA
10 61 AGCTCAGAAG CCCATTGACA TCAGACAAAG GAGTTCGCAA AATCGTCAAA ATTGGCTGGC
121 AGCATCAG

SEQ ID NO:74 (INSP082 exon 16 polypeptide sequence)

1 TWHMLFCLFI SVPQRSLEQ AQKPDIRQR SSQNRQNWLA ASE

SEQ ID NO:75 (INSP082 exon 17 nucleotide sequence)

15 1 AATCTTCTTC TGAGGAAGAA AGTCCTGTGA CTGGAAGGAG GTCTCAGTCA TCACCACCTT
61 ATTCTACTAT TGATCAGAAG TTGCTGGTTG ACATCCAT

SEQ ID NO:76 (INSP082 exon 17 polypeptide sequence)

1 SSSEESPVF GRRSQSSPPY STIDQKLLVD IH

SEQ ID NO:77 (INSP082 exon 18 nucleotide sequence)

20 1 GTTCCAGATG GATTTAAAGT AGGAAAAATA TCACCCCTG TATACTTGAC AAACGAATGG
61 GTAGGCTATA ATGCACTCTC TGAAATCTTC CGGAATGATT GGTAACTCC GGCACCTGTC
121 ATTCAGCCAC CTGAAGAGGA TGGTGATTAT GTTGAACCTCT ATGATGCCAG TGCTGATACT
181 GATGGTGATG ATGATGATGA GTCTAATGAT ACTTTTGAAG ATACCTATGA TCATGCCAAT
241 GGCAATGATG ACTTGATAA CCAGGTTGAT CAGGCTAATG ATGTTTGTA AGACCATGAT
25 301 GATGACAACA ATAAGTTTGT TGATGATGTA AATAATAATT ATTATGAGGC GCCTAGTTGT
361 CCAAG

SEQ ID NO:78 (INSP082 exon 18 polypeptide sequence)

1 VPDGFKVGKI SPPVYLTNEW VGYNALSEIF RNDWLTPAPV IQPPEEDGDY VELYDASADT
61 DGDDDDDESND TFEDTYDHAN GNDDLNDQVD QANDVCKDHD DDNNKFVDDV NNNYYEAPSC
30 121 PR

SEQ ID NO:79 (INSP082 exon 19 nucleotide sequence)

1 GGCAAGCTAT GGCAGAGATG GAAGCTGCAA GCAAGATGGT TATGATGGAA GTCGTGGAAA
 61 AGAGGAAGCC TACAGAGGCT ATGGAAGCCA TACAGCCAAT AGAAGCCATG GAGGAAGTGC
 121 AGCCAGTGAG GACAATGCAG CCATTGGAGA TCAGGAAGAA CATGCAGCCA ATATAGGCAG
 5 181 TGAAAGAAGA GGCAGTGAGG GTGATGGAG

SEQ ID NO:80 (INSP082 exon 19 polypeptide sequence)

1 ASYGRDGSCK QDGYDGSRGK EEAYRGYGSN TANRSHGGS ASEDNAAIGD QEEHAANIGS
 61 ERRGSEGDGG

SEQ ID NO:81 (INSP082 exon 20 nucleotide sequence)

10 1 GTGGTGGAAA TGAGGCCTCA AATGCCATTG ACTCAGGTGC TGCACCGTCA GCACCTGATC
 61 ATGAGAGTGA CAATAAGGAC ATATCAGAAT CATCAACACA ATCAGATTTT TCTGCCAATC
 121 ACTCATCTCC TTCAAAGGT TCTGGGATGT CTGCTGATGC TAACTTTGCC AGTGCCATCT

SEQ ID NO: 82 (INSP082 exon 20 polypeptide sequence)

1 GGNEASNAID SGAAPSAPDH ESDNKDISES STQSDFSANH SSPSKGSGMS ADANFASAIL

15 SEQ ID NO:83 (INSP082 exon 21 nucleotide sequence)

1 TATACGCTGG ATTCGTAGAA GTACCTGAGG AATCACCTAAGCAACCCTCT GAAGTCAATG
 61 TTAACCCACT CTATGTCTCT CCTGCATGTA AAAAACCCT AATCCACATG TATGAAAAGG
 121 AGTTCACTTC TGAGATCTGC TGTGGTTCTT TGTGGG

SEQ ID NO:84 (INSP082 exon 21 polypeptide sequence)

20 1 YAGFVEVPPEE SPKQPSENVN NPLYVSPACK KPLIHMYEKE FTSEICCGSL WG

SEQ ID NO:85 (INSP082 exon 22 nucleotide sequence)

1 GAGTCAATTT GCTGTTGGGA ACCCGATCTA ATCTATATCT GATGGACAGA AGTGGAAGG
 61 CTGACATTAC TAACTTATA AGGCGAAGAC CATTCGCCA GATTCAAGTC TTAGAGCCAC
 121 TCAATTTGCT GATTACCATC TCAG

25 SEQ ID NO:86 (INSP082 exon 22 polypeptide sequence)

1 VNLLLGTRSN LYLMDRSGKA DITKLIRRRP FRQIQVLEPL NLLITISG

SEQ ID NO:87 (INSP082 exon 23 nucleotide sequence)

1 GTCATAAGAA CAGACTTCGG GTGTATCATC TGACCTGGTT GAGGAACAAG ATTTTGAATA
 61 ATGATCCAGA AAGTAAAAGA AGGCAAGAAG AAATGCTGAA GACAGAGGAA GCCTGCAAAG
 30 121 CTATTGATAA GTTAACAGGC TGTGAACACT TCAGTGTCC

SEQ ID NO:88 (INSP082 exon 23 polypeptide sequence)

1 HKNRLRVYHL TWLRNKILNN DPESKRRQEE MLKTEEACKA IDKLTGCEHF SVL

SEQ ID NO:89 (INSP082 exon 24 nucleotide sequence)

1 TCCAACATGA AGAAACAACA TATATTGCAA TTGCTTTGAA ATCATCAATT CACCTTTATG
5 61 CATGGGCACC AAAGTCCTTT GATGAAAGCA CTGCTATTAA A

SEQ ID NO:90 (INSP082 exon 24 polypeptide sequence)

1 QHEETTYIAI ALKSSIHLYA WAPKSFDEST AIK

SEQ ID NO:91 (INSP082 exon 25 nucleotide sequence)

1 GTATTTCCAA CACTTGATCA TAAGCCAGTG ACAGTTGACC TGGCTATTGG TTCTGAAAAA
10 61 AGACTAAAGA TTTTCTTCAG CTCAGCAGAT GGATATCACC TCATCGATGC AGAATCTGAG
121 GTTATGTCTG ATGTGACCCT GCCAAAGAAT

SEQ ID NO:92 INSP082 exon 25 polypeptide sequence)

1 VFPTLDHKPV TVDLAIGSEK RLKIFFSSAD GYHLIDAESE VMSDVTLPKN

SEQ ID NO:93 (INSP082 exon 26 nucleotide sequence)

15 1 CCCCTGGAAA TCATTATACC ACAGAATATC ATCATTTTAC CTGATTGCTT GGGAATTGGC
61 ATGATGCTCA CCTTCAATGC TGAAGCCCTC TCTGTGGAAG CAAATGAACA ACTCTTCAAG
121 AAGATCCTTG AAATGTGGAA AGACATACCA TCTTCTATAG

SEQ ID NO:94 INSP082 exon 26 polypeptide sequence)

1 PLEIIIPQNI IILPDCLGIG MMLTFNAEAL SVEANEQLFK KILEMWKDIP SSIA

20 SEQ ID NO:95 (INSP082 exon 27 nucleotide sequence)

1 CTTTTGAATG TACACAGCGA ACCACAGGAT GGGGCCAAAA GGCCATTGAA GTGCGCTCTT
61 TGCAATCCAG GGTTCTGGAA AGTGAGCTGA AGCGCAGGTC AATTAAGAAG CTGAGATTCC
121 TGTGCACCCG GGGTGACAAG

SEQ ID NO:96 INSP082 exon 27 polypeptide sequence)

25 1 FECTQRTTGW GQKAIEVRSL QSRVLESELK RRSIKKLRFL CTRGDK

SEQ ID NO:97 (INSP082 exon 28 nucleotide sequence)

1 CTGTTCTTTA CCTCTACCCT GCGCAATCAC CACAGCCGGG TTTACTTCAT GACACTTGGA
61 AAACCTGAAG AGCTCCAAAG CAATTATGAT GTC

SEQ ID NO:98 INSP082 exon 28 polypeptide sequence)

30 1 LFFTSTLRNH HSRVYFMTLG KLEELQSNYD V

SEQ ID NO:99

INSP082 nucleotide sequence

```

1  ATGGCGGGAC CTGGGGGCTG GAGGGACAGG GAGGTCACGG ATCTGGGCCA CCTGCCGGAT
61  CCAACTGGAA TATTCTCACT AGATAAAACC ATTGGCCTTG GTACTTATGG CAGAATCTAT
121 TTGGGACTTC ATGAGAAGAC TGGTGCAATTT ACAGCTGTTA AAGTGATGAA CGCTCGTAAG
5  181  ACCCCTTTAC CTGAAATAGG AAGGCGAGTG AGAGTGAATA AATATCAAAA ATCTGTTGGG
241 TGGAGATACA GTGATGAGGA AGAGGATCTC AGGACTGAAC TCAACCTTCT GAGGAAGTAC
301 TCTTTCACA AAAACATTGT GTCCTTCTAT GGAGCATTTT TCAAGCTGAG TCCCCCTGGT
361 CAGCGGCACC AACTTTGGAT GGTGATGGAG TTATGTGCAG CAGGTTCCGT CACTGATGTA
421 GTGAGAATGA CCAGTAATCA GAGTTTAAAA GAAGATTGGA TTGCTTATAT CTGCCGAGAA
10  481  ATCCTTCAGG GCTTAGCTCA CCTTCACGCA CACCGAGTAA TTCACCGGGA CATCAAAGGT
541 CAGAATGTGC TGCTGACTCA TAATGCTGAA GTAAACTGG TTGATTTTGG AGTGAGTGCC
601 CAGGTGAGCA GAACTAATGG AAGAAGGAAT AGTTTCATTG GGACACCATA CTGGATGGCA
661 CCTGAGGTGA TTGACTGTGA TGAGGACCCA AGACGCTCCT ATGATTACAG AAGTGATGTG
721 TGGTCTGTGG GAATTACTGC CATTGAAATG GCTGAAGGAG CCCCTCCTCT GTGTAACCTT
15  781  CAACCCTTGG AAGCTCTCTT CGTTATTTTG CGGGAATCTG CTCCCACAGT CAAATCCAGC
841 GGATGGTCCC GTAAGTTCCA CAATTTCATG GAAAAGTGTA CGATAAAAAA TTTCCTGTTT
901 CGTCCTACTT CTGCAAACAT GCTTCAACAC CCATTTGTTC GGGATATAAA AAATGAACGA
961 CATGTTGTG AGTCATTAAC AAGGCATCTT ACTGGAATCA TTAAAAAAG ACAGAAAAAA
1021 GGAATACCTT TGATCTTTGA AAGAGAAGAA GCTATTAAGG AACAGTACAC CGTGAGAAGA
20  1081 TTCAGAGGAC CCTCTTGCAC TCACGAGCTT CTGAGATTGC CAACCAGCAG CAGATGCAGA
1141 CCACTTAGAG TCCTGCATGG GGAACCCTCT CAGCCAAGGT GGCTACCTGA TCGAGAAGAG
1201 CCACAGGTCC AGGCACTTCA GCAGCTACAG GGAGCAGCCA GGGTATTCAT GCCACTGCAG
1261 GCTCTGGACA GTGCACCTAA GCCTCTAAAG GGGCAGGCTC AGGCACCTCA ACGACTACAA
1321 GGGGCAGCTC GGGTGTTTCA GCCACTACAG GCTCAGGTGA AGGCTAAAGC CTCTAAACCT
25  1381 CTACAAATGC AGATTAAGGC ACCTCCACGA CTACGGAGGG CAGCCAGGGT GCTCATGCCA
1441 CTACAGGCAC AGGTTAGGGC ACCTAGGCTT CTGCAGGTAC AGTCCCAGGT ATCCAAAAAG
1501 CAGCAGGCCC AGACCCAGAC ATCAGAACCA CAAGATTTGG ACCAGGTACC AGAGGAATTT
1561 CAGGGTCAAG ATCAGGTACC CGAACAACAA AGGCAGGGCC AGGCCCTGA ACAACAGCAG
1621 AGGCACAACC AGGTGCCTGA ACAAGAGCTG GAGCAGAACC AGGCACCTGA ACAGCCAGAG
30  1681 GTACAGGAAC AGGCTGCCGA GCCTGCACAG GCAGAGACTG AGGCAGAGGA ACCTGAGTCA
1741 TTACGAGTAA ATGCCAGGT ATTTCTGCCC CTGCTATCAC AAGATCACCA TGTGCTGTTG
1801 CCACTACATT TGGATACTCA GGTGCTCATT CCAGTAGAGG GGCAAACTGA AGGATCACCT
1861 CAGGCACAGG CTTGGACACT AGAACCCCCA CAGGCAATTG GCTCAGTTCA AGCACTGATA
1921 GAGGGACTAT CAAGAGACTT GCTTCGGGCA CCAAACCTCA ATAACCTAAA GCCACTTGGT

```

1981 CCGTTGCAAA CCCTGATGGA AAATCTGTCA TCAAATAGGT TTTACTCACA ACCAGAACAG
 2041 GCACGGGAGA AAAAATCAAA AGTTTCTACT CTGAGGCAAG CACTGGCAAA AAGACTATCA
 2101 CCAAAGAGGT TCAGGGCAAA GTCATCATGG AGACCTGAAA AGCTTGAACT CTCGGATTTA
 2161 GAAGCCCGCA GGCAAAGGCG CCAACGCAGA TGGGAAGATA TCTTTAATCA GCATGAGGAA
 5 2221 GAATTGAGAC AAGTTGATAA AGACAAAGAA GATGAATCAT CAGACAATGA TGAAGTATTT
 2281 CATTCGATTC AGGCTGAAGT CCAGATAGAG CCATTGAAGC CATACATTTT AAATCCTAAA
 2341 AAAATTGAGG TTCAAGAGAG ATCTCCTTCT GTGCCTAACA ACCAGGATCA TGCACATCAT
 2401 GTCAAGTTCT CTTCAAGGAC ATGGCACATG CTTTTCTGTC TTTTCATTAG CGTTCCTCAG
 2461 CGGTCTCTTT TGGAACAAGC TCAGAAGCCC ATTGACATCA GACAAAGGAG TTCGCAAAAT
 10 2521 CGTCAAAATT GGCTGGCAGC ATCAGAATCT TCTTCTGAGG AAGAAAGTCC TGTGACTGGA
 2581 AGGAGGTCTC AGTCATCACC ACCTTATTCT ACTATTGATC AGAAGTTGCT GGTGACATC
 2641 CATGTTCCAG ATGGATTTAA AGTAGGAAAA ATATCACCCC CTGTATACTT GACAAACGAA
 2701 TGGGTAGGCT ATAATGCACT CTCTGAAATC TTCCGGAATG ATTGGTTAAC TCCGGCACCT
 2761 GTCATTCAGC CACCTGAAGA GGATGGTGAT TATGTTGAAC TCTATGATGC CAGTGCTGAT
 15 2821 ACTGATGGTG ATGATGATGA TGAGTCTAAT GATACTTTTG AAGATACCTA TGATCATGCC
 2881 AATGGCAATG ATGACTTGGA TAACCAGGTT GATCAGGCTA ATGATGTTTG TAAAGACCAT
 2941 GATGATGACA ACAATAAGTT TGTGATGAT GTAAATAATA ATTATTATGA GGCGCCTAGT
 3001 TGTCCAAGGG CAAGCTATGG CAGAGATGGA AGCTGCAAGC AAGATGGTTA TGATGGAAGT
 3061 CGTGGAAGAG AGGAAGCCTA CAGAGGCTAT GGAAGCCATA CAGCCAATAG AAGCCATGGA
 20 3121 GGAAGTGCAG CCAGTGAGGA CAATGCAGCC ATTGGAGATC AGGAAGAACA TGCAGCCAAT
 3181 ATAGGCAGTG AAAGAAGAGG CAGTGAGGGT GATGGAGGTG GTGGAAATGA GGCCTCAAAT
 3241 GCCATTGACT CAGGTGCTGC ACCGTCAGCA CCTGATCATG AGAGTGACAA TAAGGACATA
 3301 TCAGAATCAT CAACACAATC AGATTTTCTT GCCAATCACT CATCTCCTTC CAAAGGTTCT
 3361 GGGATGTCTG CTGATGCTAA CTTTGCCAGT GCCATCTTAT ACGCTGGATT CGTAGAAGTA
 25 3421 CCTGAGGAAT CACCTAAGCA ACCCTCTGAA GTCAATGTTA ACCCACTCTA TGTCTCTCCT
 3481 GCATGTAAAA AACCCTAAT CCACATGTAT GAAAAGGAGT TCACTTCTGA GATCTGCTGT
 3541 GGTTCCTTGT GGGGAGTCAA TTTGCTGTTG GGAACCCGAT CTAATCTATA TCTGATGGAC
 3601 AGAAGTGGAA AGGCTGACAT TACTAACTT ATAAGGCGAA GACCATTCCG CCAGATTCAA
 3661 GTCTTAGAGC CACTCAATTT GCTGATTACC ATCTCAGGTC ATAAGAACAG ACTTCGGGTG
 30 3721 TATCATCTGA CCTGGTTGAG GAACAAGATT TTGAATAATG ATCCAGAAAG TAAAAGAAGG
 3781 CAAGAAGAAA TGCTGAAGAC AGAGGAAGCC TGCAAAGCTA TTGATAAGTT AACAGGCTGT
 3841 GAACACTTCA GTGTCCTCCA ACATGAAGAA ACAACATATA TTGCAATTGC TTTGAAATCA
 3901 TCAATTCAC CTTTATGCATG GGCACCAAAG TCCTTTGATG AAAGCACTGC TATTAAAGTA
 3961 TTTCCAACAC TTGATCATAA GCCAGTGACA GTTGACCTGG CTATTGGTTC TGAAAAAGA
 35 4021 CTAAAGATTT TCTTCAGCTC AGCAGATGGA TATCACCTCA TCGATGCAGA ATCTGAGGTT

4081 ATGTCTGATG TGACCCCTGCC AAAGAATCCC CTGGAAATCA TTATACCACA GAATATCATC
 4141 ATTTTACCTG ATTGCTTGGG AATTGGCATG ATGCTCACCT TCAATGCTGA AGCCCTCTCT
 4201 GTGGAAGCAA ATGAACAACT CTTCAAGAAG ATCCTTGAAA TGTGGAAAGA CATACCATCT
 4261 TCTATAGCTT TTGAATGTAC ACAGCGAACC ACAGGATGGG GCCAAAAGGC CATTTGAAGT
 5 4321 CGCTCTTTGC AATCCAGGGT TCTGGAAAGT GAGCTGAAGC GCAGGTCAAT TAAGAAGCTG
 4381 AGATTCCCTGT GCACCCGGGG TGACAAGCTG TTCTTTACCT CTACCCTGCG CAATCACCAC
 AGCCGGGTTT ACTTCATGAC ACTTGGAAAA CTTGAAGAGC TCCAAAGCAA TTATGATGTC

SEQ ID NO 100: INSP082 full polypeptide sequence

1 MAGPGGWRDR EVTDLGHLPD PTGIFSLDKT IGLGTYGRIY LGLHEKTGAF TAVKVMNARK
 10 61 TPLPEIGRRV RVNKYQKSVG WRYSDEEEDL RTELNLLRKY SFHKNIVSFY GAFFKLSPPG
 121 QRHQLWMVME LCAAGSVTDV VRMTSNQSLK EDWIAYICRE ILQGLAHLHA HRVIHRDIKG
 181 QNVLLTHNAE VKLVDFGVSA QVSRITNGRRN SFIGTPYWMA PEVIDCDEDP RRSYDYRSDV
 241 WSVGITAIEA AEGAPPLCNL QPLEALFVIL RESAPTVKSS GWSRKFHNFH EKCTIKNLF
 301 RPTSANMLQH PFVRDIKNER HVVESLTRHL TGIKKRQKK GIPLIFEREE AIKEQYTVRR
 15 361 FRGPSCTHEL LRLPTSSRCR PLRVLHGEPS QPRWLPDREE PQVQALQQLQ GAARVFMPLQ
 421 ALDSAPKPLK GQAQAPQRLQ GAARVFMPLQ AQVKAKASKP LQMGIKAPPR LRRARVLMPL
 481 LQAQVRAPRL LQVQSQVSKK QQAQTQTSEP QDLQVPEEF QGQDQVPEEQ RQGQAPEQQQ
 541 RHNQVPEQEL EQNQAPEQPE VQEQAEPAPQ AETEAEPEPS LRVNAQVFLP LLSQDHHVLL
 601 PLHLDTQVLI PVEGQTEGSP QAQAWTLEPP QAIGSVQALI EGLSRDLLRA PNSMNSKPLG
 20 661 PLQTLMENLS SNRFYSQPEQ AREKSKSVST LRQALAKRLS PKRFRAKSSW RPEKLELSDL
 721 EARRQRRQRR WEDIFNQHEE ELRQVDKDKE DESSDNDEVF HSIQAEVQIE PLKPYISNPK
 781 KIEVQERSPS VPNQDHAHH VKFSSRTWHM LFCLFISVPQ RSLLEQAQKP IDIRQSSQN
 841 RQNWLAASES SSEEESPVTV RRSQSSPPYS TIDQKLLVDI HVPDGFVKVGK ISPPVYLTNE
 901 WVGYNALSEI FRNDWLTPAP VIQPPEEDGD YVELYDASAD TDGDDDDDES DTFEDTYDHA
 25 961 NGNDDLDNQV DQANDVCKDH DDDNNKFVDD VNNNYEAPS CPRASYGRDG SCKQDGYDGS
 1021 RGKEEAYRGY GSHTANRSHG GSAASEDNAA IGDQEEHAAN IGSERRGSEG DGGGGNEASN
 1081 AIDSGAAPSA PDHESDNKDI SESSTQSDFS ANHSSPSKGS GMSADANFAS AILYAGFVEV
 1141 PEESPKQPSE VNVNPLYVSP ACKKPLIHY EKEFTSEICC GSLWGVNLLL GTRSNLYLMD
 1201 RSGKADITKL IRRRPFRQIQ VLEPLNLLIT ISGHKNRLRV YHLTWLRNKI LNNDPESKRR
 30 1261 QEEMLKTEEA CKAIKLTGK EHFVSLQHEE TTYIAIALKS SIHLYAWAPK SFDESTAIKV
 1321 FPTLDHKPVT VDLAIGSEKR LKIFFSSADG YHLIDAESEV MSDVTLKPNP LEIIPQNI
 1381 ILPDCLGIGM MLTFNAEALS VEANEQLFKK ILEMWKDIPS SIAFECTQRT TGWGQKAIEV
 1441 RSLQSRVLES ELKRRSIKKL RFLCTRQDKL FFTSTLRNHH SRVYFMTLKG LEELQSNYDV

SEQ ID NO:101 (INSP091 exon 1 nucleotide sequence)

35 1 ATGGCGGGAC CTGGGGGCTG GAGGGACAGG GAGGTCACGG ATCTGGGCCA CCTGCCG

SEQ ID NO:102 (INSP091 exon 1 polypeptide sequence)

1 MAGPGGWRDR EVTDLGHL P

SEQ ID NO:103 (INSP091 exon 2 nucleotide sequence)

1 GATCCAACTG GAATATTCTC ACTAGATAAA ACCATTGGCC TTGGTACTTA TGGCAGAATC
5 61 TATTTG

SEQ ID NO:104 (INSP091 exon 2 polypeptide sequence)

1 DPTGIFSLDK TIGLGTYGRI YL

SEQ ID NO:105 (INSP091 exon 3 nucleotide sequence)

1 GGACTTCATG AGAAGACTGG TGCATTTACA GCTGTAAAG TGATGAACGC TCGTAAG

10 SEQ ID NO:106 (INSP091 exon 3 polypeptide sequence)

1 GLHEKTGAFT AVKVMNARK

SEQ ID NO:107 (INSP091 exon 4 nucleotide sequence)

1 ACCCCTTTAC CTGAAATAGG AAGGCGAGTG AGAGTGAATA AATATCAAAA ATCTGTTGGG
61 TGGAGATACA GT

15 SEQ ID NO:108 (INSP091 exon 4 polypeptide sequence)

1 TPLPEIGRRV RVNKYQKSVG WRYS

SEQ ID NO:109 (INSP091 exon 5 nucleotide sequence)

1 GATGAGGAAG AGGATCTCAG GACTGAACTC AACCTTCTGA GGAAGTACTC TTTCCACAAA
61 AACATTGTGT CCTTCTATGG AGCATTTTTC AAGCTGAGTC CCCCTGGTCA GCGGCACCAA
20 121 CTTTGG

SEQ ID NO:110 (INSP091 exon 5 polypeptide sequence)

1 DEEEDLRTEL NLLRKYSFHK NIVSFYGAFF KLSPPGQRHQ LW

SEQ ID NO:111 (INSP091 exon 6 nucleotide sequence)

1 ATGGTGATGG AGTTATGTGC AGCAGGTTGC GTCACTGATG TAGTGAGAAT GACCAGTAAT
25 61 CAGAGTTTAA AAGAAGATTG GATTGCTTAT ATCTGCCGAG AAATCCTTCA G

SEQ ID NO:112 (INSP091 exon 6 polypeptide sequence)

1 MVMELCAAGS VTDVVRMTSN QSLKEDWIAY ICREILQ

SEQ ID NO:113 (INSP091 exon 7 nucleotide sequence)

1 GGCTTAGCTC ACCTTCACGC ACACCGAGTA ATTCACCGGG ACATCAAAGG TCAGAATGTG
30 61 CTGCTGACTC ATAATGCTGA AGTAAACTG G

SEQ ID NO:114 (INSP091 exon 7 polypeptide sequence)

1 GLAHLHAHRV IHRDIKGQNV LLTHNAEVKL V

SEQ ID NO:115 (INSP091 exon 8 nucleotide sequence)

1 TTGATTTTGG AGTGAGTGCC CAGGTGAGCA GAACTAATGG AAGAAGGAAT AGTTTCATTG

61 GGACACCATA CTGGATGGCA CCTGAGGTGA TTGACTGTGA TGAGGACCCA AGACGCTCCT
 121 .ATGATTACAG A

SEQ ID NO:116 (INSP091 exon 8 polypeptide sequence)

1 DFGVSAQVSR TNGRRNSFIG TPYWMAPEVI DCDEDPRRSY DYR

5 SEQ ID NO:117 (INSP091 exon 9 nucleotide sequence)

1 AGTGATGTGT GGTCTGTGGG AATTACTGCC ATTGAAATGG CTGAAGGAGC CCCTC

SEQ ID NO:118 (INSP091 exon 9 polypeptide sequence)

1 SDVWSVGITA IEMAEGAPP

SEQ ID NO:119 (INSP091 exon 10 nucleotide sequence)

10 1 CTCTGTGTAA CCTTCAACCC TTGGAAGCTC TCTTCGTTAT TTTGCGGGAA TCTGCTCCCA
 61 CAGTCAAATC CAGCGGATG

SEQ ID NO:120 (INSP091 exon 10 polypeptide sequence)

1 LCNLQPLEAL FVILRESAPT VKSSGW

SEQ ID NO:121 (INSP091 exon 11 nucleotide sequence)

15 1 GTCCCGTAAG TTCCACAATT TCATGGAAAA GTGTACGATA AAAAATTTCC TGTTTCGTCC
 61 TACTTCTGCA AACATGCTTC AACACCCATT TGTTTCGGGAT ATAAAAAATG AACGACATGT
 121 TGTTGAGTCA TTAACAAGGC ATCTTACTGG AATCATTAAG AAAAGACAGA AAAAAG

SEQ ID NO:122 (INSP091 exon 11 polypeptide sequence)

1 SRKFHNFMEK CTIKNFLFRP TSANMLQHPF VRDIKNERHV VESLTRHLTG IIKKRQKKG

20 SEQ ID NO:123 (INSP091 exon 12 nucleotide sequence)

1 GAATACCTTT GATCTTTGAA AGAGAAGAAG CTATTAAGGA ACAGTACACC GTGAGAAGAT
 61 TCAG

SEQ ID NO:124 (INSP091 exon 12 polypeptide sequence)

1 IPLIFEREEA IKEQYTVRRF R

25 SEQ ID NO:125 (INSP091 exon 13 nucleotide sequence)

1 AGGACCCTCT TGCACACACG AGCTTCTGAG ATTGCCAACC AGCAGCAGAT GCAGACCACT
 61 TAGAGTCCTG CATGGGGAAC CCTCTCAGCC AAGGTGGCTA CCTGATCGAG AAGAGCCACA
 121 GGTCCAGGCA CTTACAGCAGC TACAGGGAGC AGCCAGGGTA TTCATGCCAC TGCAGGCTCT
 181 GGACAGTGCA CCTAAGCCTC TAAAGGGGCA GGCTCAGGCA CCTCAACGAC TACAAGGGGC
 30 241 AGCTCGGGTG TTCATGCCAC TACAGGCTCA GGTGAAGGCT AAAGCCTCTA AACCTCTACA
 301 AATGCAGATT AAGGCACCTC CACGACTACG GAGGGCAGCC AGGGTGCTCA TGCCACTACA
 361 GGCACAGGTT AGGGCACCTA GGCTTCTGCA GGTACAGTCC CAGGTATCCA AAAAGCAGCA
 421 GGCCCAGACC CAGACATCAG AACCACAAGA TTTGGACCAG GTACCAGAGG AATTTTCAGG
 481 TCAAGATCAG GTACCCGAAC AACAAAGGCA GGGCCAGGCC CCTGAACAAC AGCAGAGGCA

541 CAACCAGGTG CCTGAACAAG AGCTGGAGCA GAACCAGGCA CCTGAACAGC CAGAGGTACA
 601 GGAACAGGCT GCCGAGCCTG CACAGGCAGA GACTGAGGCA GAGGAACCTG AGTCATTACG
 661 AGTAAATGCC CAGGTATTTT TCCCCCTGCT ATCACAAGAT CACCATGTGC TGTTGCCACT
 721 ACATTTGGAT ACTCAGGTGC TCATTCCAGT AGAGGGGGCAA ACTGAAGGAT CACCTCAGGC
 5 781 ACAGGCTTGG AACTAGAAC CCCACAGGC AATTGGCTCA GTTCAAGCAC TGATAGAGGG
 841 ACTATCAAGA GACTTGCTTC GGGCACCAAA CTCAAATAAC TCAAAGCCAC TTGGTCCGTT
 901 GCAAACCCTG ATGGAAAATC TGTCATCAAA TAGGTTTTAC TCACAACCAG AACAGGCACG
 961 GGAGAAAAAA TCAAAAGTTT CTACTCTGAG GCAAGCACTG GCAAAAAGAC TATCACCAAA
 1021 GAGGTTCAGG GCAAAGTCAT CATGGAGACC TGAAAAGCTT GAACTCTCGG ATTTAGAAGC
 10 1081 CCGCAGGCAA AGGCGCCAAC GCAGATGGGA AGATATCTTT AATCAGCATG AGGAAGAATT
 1141 GAGACAAGTT GATAAA

SEQ ID NO:126 (INSP091 exon 13 polypeptide sequence)

1 GPSCTHELLR LPTSSRCRPL RVLHGEPSPQ RWLPDREEPQ VQALQQLQGA ARVFMPLQAL
 61 DSAPKPLKGQ AQAPQRLQGA ARVFMPLQAQ VKAKASKPLQ MQIKAPPLR RAARVLMPLQ
 15 121 AQVRAPRLQ VQSQVSKKQQ AQTQTSEPQD LDQVPEEFQD QDQVPEQQRQ GOAPEQQQRH
 181 NQVPEQELEQ NQAPEQPEVQ EQAAEPAQAE TEAEEPESLR VNAQVFLPLL SQDHHVLLPL
 241 HLDTOVLIPV EGQTEGSPQA QAWTLEPPQA IGSVQALIEG LSRDLLRAPN SNNSKPLGPL
 301 QTLMENLSSN RFYSQPEQAR EKSKSVSTLR QALAKRLSPK RFRAKSSWRP EKLELSDLEA
 361 RRQRQRWE DIFNQHEEEL RQVDK

20 SEQ ID NO:127 (INSP091 exon 14 nucleotide sequence)

1 GACAAAGAAG ATGAATCATC AGACAATGAT GAAGTATTTT ATTCGATTCA GGCTGAAGTC
 61 CAGATAGAGC CATTGAAGCC ATACATTTC AATCCTAAAA AAATTGAG

SEQ ID NO:128 (INSP091 exon 14 polypeptide sequence)

1 DKEDESSDND EVFHSIQAEV QIEPLKPYIS NPKKIE

25 SEQ ID NO:129 (INSP091 exon 15 nucleotide sequence)

1 GTTCAAGAGA GATCTCCTTC TGTGCCTAAC AACCAGGATC ATGCACATCA TGTCAAGTTC
 61 TCTTCAAG

SEQ ID NO:130 (INSP091 exon 15 polypeptide sequence)

1 VQERSPSVPN NQDHAHHVKF SSS

30 SEQ ID NO:131 (INSP091 exon 16 nucleotide sequence)

1 CGTTCCTCAG CGGTCTCTTT TGGAACAAGC TCAGAAGCCC ATTGACATCA GACAAAGGAG
 61 TTCGCAAAAT CGTCAAAATT GGCTGGCAGC ATCAGGTGAT TCAAAGCACA AAATTTTAGC
 121 AGGCAAAACA CAGAGCTACT GTTTAACAAT TTATATTTCA GAAGTCAAGA AAGAAGAATT
 181 TCAAGAAGGA ATGAATCAAA AGTGTCAGGG AGCCCAAGTA GGATTAGGAC CTGAAGGCCA

241 TTGTATTTGG CAATTGGGTG

SEQ ID NO:132 (INSP091 exon 16 polypeptide sequence)

1 VPQRSLLLEQA QKPIDIRQRS SQNRQNLAA SGDSKHKILA GKTQSYCLTI YISEVKKEEF

61 QEGMNQKCQG AQVGLGPEGH CIWQLGE

5 SEQ ID NO:133 (INSP091 exon 17 nucleotide sequence)

1 AATCTTCTTC TGAGGAAGAA AGTCCTGTGA CTGGAAGGAG GTCTCAGTCA TCACCACCTT

61 ATTCTACTAT TGATCAGAAG TTGCTGGTTG ACATCCAT

SEQ ID NO:134 (INSP091 exon 17 polypeptide sequence)

1 SSSEESPVT GRRSQSSPPY STIDQKLLVD IH

10 SEQ ID NO:135 (INSP091 exon 18 nucleotide sequence)

1 GTTCCAGATG GATTTAAAGT AGGAAAAATA TCACCCCTG TATACTTGAC AAACGAATGG

61 GTAGGCTATA ATGCACTCTC TGAAATCTTC CGGAATGATT GGTTAACTCC GGCACCTGTC

121 ATTCAGCCAC CTGAAGAGGA TGGTGATTAT GTTGAACCTCT ATGATGCCAG TGCTGATACT

181 GATGGTGATG ATGATGATGA GTCTAATGAT ACTTTTGAAG ATACCTATGA TCATGCCAAT

15 241 GGCAATGATG ACTTGGATAA CCAGGTTGAT CAGGCTAATG ATGTTTGTAAG AGACCATGAT

301 GATGACAACA ATAAGTTTGT TGATGATGTA AATAATAATT ATTATGAGGC GCCTAGTTGT

361 CCAAG

SEQ ID NO:136 (INSP091 exon 18 polypeptide sequence)

1 VPDGFKVGKI SPPVYLNEW VGYNALSEIF RNDWLTPAPV IQPPEEDGDY VELYDASADT

20 61 DGDDDDDESND TFEDTYDHAN GNDDLDNQVD QANDVCKDHD DDNNKFVDDV NNNYYEAPSC

121 PR

SEQ ID NO:137 (INSP091 exon 19 nucleotide sequence)

1 GGCAAGCTAT GGCAGAGATG GAAGCTGCAA GCAAGATGGT TATGATGGAA GTCGTGGAAA

61 AGAGGAAGCC TACAGAGGCT ATGGAAGCCA TACAGCCAAT AGAAGCCATG GAGGAAGTGC

25 121 AGCCAGTGAG GACAATGCAG CCATTGGAGA TCAGGAAGAA CATGCAGCCA ATATAGGCAG

181 TGAAAGAAGA GGCAGTGAGG GTGATGGAGG TAAGGGAGTC GTTCGAACCA GTGAAGAGAG

241 TGGAGCCCTT GGAATCAATG GAGAAGAAAA TTGCTCAGAG ACAGATGGTC CAGGATTGAA

301 GAGACCTGCG TCTCAGGACT TTGAATATCT ACAGGAG

SEQ ID NO:138 (INSP091 exon 19 polypeptide sequence)

30 1 ASYGRDGSCK QDGYDGSRGK EEAYRGYGS TANRSHGGS ASEDNAAIGD QEEHAANIGS

61 ERRGSEGDGG KGVVRTSEES GALGLNGEEN CSETDGPGLK RPASQDFEYL QE

SEQ ID NO:139 (INSP091 exon 20 nucleotide sequence)

1 GAGCCAGGTG GTGAAATGA GGCCTCAAAT GCCATTGACT CAGGTGCTGC ACCGTCAGCA

61 CCTGATCATG AGAGTGACAA TAAGGACATA TCAGAATCAT CAACACAATC AGATTTTTCT

121 GCCAATCACT CATCTCCTTC CAAAGGTTCT GGGATGTCTG CTGATGCTAA CTTTGCCAGT
181 GCCATCT

SEQ ID NO:140 (INSP091 exon 20 polypeptide sequence)

1 EPGGGNEASN AIDSGAAPSA PDHESDNKDI SESSTQSDFS ANHSSPSKGS GMSADANFAS
5 61 AIL

SEQ ID NO:141 (INSP091 exon 21 nucleotide sequence)

1 TATACGCTGG ATTCGTAGAA GTACCTGAGG AATCACCTAA GCAACCCTCT GAAGTCAATG
61 TTAACCCACT CTATGTCTCT CCTGCATGTA AAAAACCCT AATCCACATG TATGAAAAGG
121 AGTTCACTTC TGAGATCTGC TGTGGTTCTT TGTGGG

10 SEQ ID NO:142 (INSP091 exon 21 polypeptide sequence)

1 YAGFVEVP EE SPKQPSEVNV NPLYVSPACK KPLIHMYEKE FTSEICCGSL WG

SEQ ID NO:143 (INSP091 exon 22 nucleotide sequence)

1 GAGTCAATTT GCTGTTGGGA ACCCGATCTA ATCTATATCT GATGGACAGA AGTGGAAGG
61 CTGACATTAC TAAACTTATA AGGCGAAGAC CATTCCGCCA GATTCAAGTC TTAGAGCCAC
15 121 TCAATTTGCT GATTACCATC TCAG

SEQ ID NO:144 (INSP091 exon 22 nucleotide sequence)

1 VNLLLGTRSN LYLMDRSGKA DITKLIRRRP FRQIQVLEPL NLLITISG

SEQ ID NO:145 (INSP091 exon 23 nucleotide sequence)

1 GTCATAAGAA CAGACTTCGG GTGTATCATC TGACCTGGTT GAGGAACAAG ATTTTGAATA
20 61 ATGATCCAGA AAGTAAAAGA AGGCAAGAAG AAATGCTGAA GACAGAGGAA GCCTGCAAAG
121 CTATTGATAA GTTAACAGGC TGTGAACACT TCAGTGTC

SEQ ID NO:146 (INSP091 exon 23 polypeptide sequence)

1 HKNRLRVYHL TWLRNKILNN DPESKRRQEE MLKTEEACKA IDKLTGCEHF SVL

SEQ ID NO:147 (INSP091 exon 24 nucleotide sequence)

25 1 TCCAACATGA AGAAACAACA TATATTGCAA TTGCTTTGAA ATCATCAATT CACCTTTATG
61 CATGGGCACC AAAGTCCTTT GATGAAAGCA CTGCTATTAA A

SEQ ID NO:148 (INSP091 exon 24 polypeptide sequence)

1 QHEETTYIAI ALKSSIHLYA WAPKSFDEST AIK

SEQ ID NO:149 (INSP091 exon 25 nucleotide sequence)

30 1 GTATTTCCAA CACTTGATCA TAAGCCAGTG ACAGTTGACC TGGCTATTGG TTCTGAAAAA
61 AGACTAAAGA TTTTCTTCAG CTCAGCAGAT GGATATCACC TCATCGATGC AGAATCTGAG
121 GTTATGTCTG ATGTGACCCT GCCAAAGAAT

SEQ ID NO:150 (INSP091 exon 25 polypeptide sequence)

1 VFPTLDHKPV TVDLAIGSEK RLKIFFSSAD GYHLIDAESE VMSDVTLPKN

SEQ ID NO:151 (INSP091 exon 26 nucleotide sequence)

1 CCCCTGGAAA TCATTATACC ACAGAAATATC ATCATTTTAC CTGATTGCTT GGAATTGGC
 61 ATGATGCTCA CCTTCAATGC TGAAGCCCTC TCTGTGGAAG CAAATGAACA ACTCTTCAAG
 121 AAGATCCTTG AAATGTGGAA AGACATACCA TCTTCTATAG

5 SEQ ID NO:152 (INSP091 exon 26 polypeptide sequence)

1 PLEIIIPQNI IILPDCLGIG MMLTFNAEAL SVEANEQLFK KILEMWKDIP SSIA

SEQ ID NO:153 (INSP091 exon 27 nucleotide sequence)

1 CTTTTGAATG TACACAGCGA ACCACAGGAT GGGGCCAAAA GGCCATTGAA GTGCGCTCTT
 61 TGCAATCCAG GGTTCCTGGAA AGTGAGCTGA AGCGCAGGTC AATTAAGAAG CTGAGATTCC
 10 121 TGTGCACCCG GGGTGACAAG

SEQ ID NO:154 (INSP091 exon 27 polypeptide sequence)

1 FECTQRTTGW GQKAIEVRSL QSRVLESELK RRSIKKLRF CTRGDK

SEQ ID NO:155 (INSP091 exon 28 nucleotide sequence)

1 CTGTTCTTTA CCTCTACCCT GCGCAATCAC CACAGCCGGG TTTACTTCAT GACACTTGGA
 15 61 AAACCTGAAG AGCTCCAAAG CAATTATGAT GTC

SEQ ID NO:156 (INSP091 exon 28 polypeptide sequence)

1 LFFTSTLRNH HSRVYFMTLG KLEELQSNYD V

SEQ ID NO: 157 (INSP091 nucleotide sequence)

1 ATGGCGGGAC CTGGGGGCTG GAGGGACAGG GAGGTCACGG ATCTGGGCCA CCTGCCGGAT
 20 61 CCAACTGGAA TATTCTCACT AGATAAAACC ATTGGCCTTG GTACTTATGG CAGAATCTAT
 121 TTGGGACTTC ATGAGAAGAC TGGTGCATTT ACAGCTGTTA AAGTGATGAA CGCTCGTAAG
 181 ACCCCTTTAC CTGAAATAGG AAGGCGAGTG AGAGTGAATA AATATCAAAA ATCTGTTGGG
 241 TGGAGATACA GTGATGAGGA AGAGGATCTC AGGACTGAAC TCAACCTTCT GAGGAAGTAC
 301 TCTTTCCACA AAAACATTGT GTCCTTCTAT GGAGCATTTT TCAAGCTGAG TCCCCCTGGT
 25 361 CAGCGGCACC AACTTTGGAT GGTGATGGAG TTATGTGCAG CAGGTTCCGGT CACTGATGTA
 421 GTGAGAATGA CCAGTAATCA GAGTTTAAAA GAAGATTGGA TTGCTTATAT CTGCCGAGAA
 481 ATCCTTCAGG GCTTAGCTCA CCTTCACGCA CACCGAGTAA TTCACCGGGA CATCAAAGGT
 541 CAGAATGTGC TGCTGACTCA TAATGCTGAA GTAAACTGG TTGATTTTGG AGTGAGTGCC
 601 CAGGTGAGCA GAACTAATGG AAGAAGGAAT AGTTTCATTG GGACACCATA CTGGATGGCA
 30 661 CCTGAGGTGA TTGACTGTGA TGAGGACCCA AGACGCTCCT ATGATTACAG AAGTGATGTG
 721 TGGTCTGTGG GAATTACTGC CATTGAAATG GCTGAAGGAG CCCCTCCTCT GTGTAACCTT
 781 CAACCCTTGG AAGCTCTCTT CGTTATTTTG CGGGAATCTG CTCCCACAGT CAAATCCAGC
 841 GGATGGTCCC GTAAGTTCCA CAATTTTCATG GAAAAGTGTA CGATAAAAAA TTTCTGTTT
 901 CGTCCTACTT CTGCAAACAT GCTTCAACAC CCATTGTGTC GGGATATAAA AAATGAACGA

961 CATGTTGTTG AGTCATTAAC AAGGCATCTT ACTGGAATCA TTAAAAAAG ACAGAAAAAA
 1021 GGAATACCTT TGATCTTTGA AAGAGAAGAA GCTATTAAGG AACAGTACAC CGTGAGAAGA
 1081 TTCAGAGGAC CCTCTTGCAC TCACGAGCTT CTGAGATTGC CAACCAGCAG CAGATGCAGA
 1141 CCACTTAGAG TCCTGCATGG GGAACCCTCT CAGCCAAGGT GGCTACCTGA TCGAGAAGAG
 5 1201 CCACAGGTCC AGGCACTTCA GCAGCTACAG GGAGCAGCCA GGGTATTCAT GCCACTGCAG
 1261 GCTCTGGACA GTGCACCTAA GCCTCTAAAG GGGCAGGCTC AGGCACCTCA ACGACTACAA
 1321 GGGGCAGCTC GGGTGTTCAT GCCACTACAG GCTCAGGTGA AGGCTAAAGC CTCTAAACCT
 1381 CTACAAATGC AGATTAAGGC ACCTCCACGA CTACGGAGGG CAGCCAGGGT GCTCATGCCA
 1441 CTACAGGCAC AGGTTAGGGC ACCTAGGCTT CTGCAGGTAC AGTCCCAGGT ATCCAAAAAG
 10 1501 CAGCAGGCCC AGACCCAGAC ATCAGAACCA CAAGATTTGG ACCAGGTACC AGAGGAATTT
 1561 CAGGGTCAAG ATCAGGTACC CGAACAACAA AGGCAGGGCC AGGCCCTGA ACAACAGCAG
 1621 AGGCACAACC AGGTGCCTGA ACAAGAGCTG GAGCAGAACC AGGCACCTGA ACAGCCAGAG
 1681 GTACAGGAAC AGGCTGCCGA GCCTGCACAG GCAGAGACTG AGGCAGAGGA ACCTGAGTCA
 1741 TTACGAGTAA ATGCCAGGT ATTTCTGCCC CTGCTATCAC AAGATCACCA TGTGCTGTTG
 15 1801 CCACTACATT TGGATACTCA GGTGCTCATT CCAGTAGAGG GGCAAATGA AGGATCACCT
 1861 CAGGCACAGG CTTGGACACT AGAACCCCCA CAGGCAATTG GCTCAGTTCA AGCACTGATA
 1921 GAGGGACTAT CAAGAGACTT GCTTCGGGCA CCAAACCTCAA ATAACCTAAA GCCACTTGGT
 1981 CCGTTGCAAA CCCTGATGGA AAATCTGTCA TCAAATAGGT TTTACTCACA ACCAGAACAG
 2041 GCACGGGAGA AAAAATCAAA AGTTTCTACT CTGAGGCAAG CACTGGCAAA AAGACTATCA
 20 2101 CCAAAGAGGT TCAGGGCAAA GTCATCATGG AGACCTGAAA AGCTTGAACCT CTCGGATTTA
 2161 GAAGCCCGCA GGCAAAGGCG CCAACGCAGA TGGGAAGATA TCTTTAATCA GCATGAGGAA
 2221 GAATTGAGAC AAGTTGATAA AGACAAAGAA GATGAATCAT CAGACAATGA TGAAGTATTT
 2281 CATTCGATTC AGGCTGAAGT CCAGATAGAG CCATTGAAGC CATACATTTT AAATCCTAAA
 2341 AAAATTGAGG TTCAAGAGAG ATCTCCTTCT GTGCCTAACA ACCAGGATCA TGCACATCAT
 25 2401 GTCAAGTTCT CTTCAAGCGT TCCTCAGCGG TCTCTTTTGG AACAAGCTCA GAAGCCCATT
 2461 GACATCAGAC AAAGGAGTTC GCAAAATCGT CAAAATTGGC TGGCAGCATC AGGTGATTCA
 2521 AAGCACAAAA TTTTAGCAGG CAAAACACAG AGCTACTGTT TAACAATTTA TATTTTCAGAA
 2581 GTCAAGAAAG AAGAATTTCA AGAAGGAATG AATCAAAAGT GTCAGGGAGC CCAAGTAGGA
 2641 TTAGGACCTG AAGGCCATTG TATTTGGCAA TTGGGTGAAT CTTCTTCTGA GGAAGAAAGT
 30 2701 CCTGTGACTG GAAGGAGGTC TCAGTCATCA CCACCTTATT CTACTATTGA TCAGAAGTTG
 2761 CTGGTTGACA TCCATGTTCC AGATGGATTT AAAGTAGGAA AAATATCACC CCCTGTATAC
 2821 TTGACAAAAC AATGGGTAGG CTATAATGCA CTCTCTGAAA TCTTCCGGAA TGATTGGTTA
 2881 ACTCCGGCAC CTGTCATTCA GCCACCTGAA GAGGATGGTG ATTATGTTGA ACTCTATGAT
 2941 GCCAGTGCTG ATACTGATGG TGATGATGAT GATGAGTCTA ATGATACTTT TGAAGATACC
 35 3001 TATGATCATG CCAATGGCAA TGATGACTTG GATAACCAGG TTGATCAGGC TAATGATGTT

3061 TGTAAAGACC ATGATGATGA CAACAATAAG TTTGTTGATG ATGTAAATAA TAATTATTAT
 3121 GAGGCGCCTA GTTGTCCAAG GGCAAGCTAT GGCAGAGATG GAAGCTGCAA GCAAGATGGT
 3181 TATGATGGAA GTCGTGGAAA AGAGGAAGCC TACAGAGGCT ATGGAAGCCA TACAGCCAAT

 3241 AGAAGCCATG GAGGAAGTGC AGCCAGTGAG GACAATGCAG CCATTGGAGA TCAGGAAGAA
 5 3301 CATGCAGCCA ATATAGGCAG TGAAAGAAGA GGCAGTGAGG GTGATGGAGG TAAGGGAGTC
 3361 GTTCGAACCA GTGAAGAGAG TGGAGCCCTT GGAATCAATG GAGAAGAAAA TTGCTCAGAG
 3421 ACAGATGGTC CAGGATTGAA GAGACCTGCG TCTCAGGACT TTGAATATCT ACAGGAGGAG
 3481 CCAGGTGGTG GAAATGAGGC CTCAAATGCC ATTGACTCAG GTGCTGCACC GTCAGCACCT
 3541 GATCATGAGA GTGACAATAA GGACATATCA GAATCATCAA CACAATCAGA TTTTCTGCC
 10 3601 AATCACTCAT CTCCTTCCAA AGGTTCTGGG ATGTCTGCTG ATGCTAACTT TGCCAGTGCC
 3661 ATCTTATACG CTGGATTCGT AGAAGTACCT GAGGAATCAC CTAAGCAACC CTCTGAAGTC
 3721 AATGTTAACC CACTCTATGT CTCTCTGCA TGTAATAAAC CACTAATCCA CATGTATGAA
 3781 AAGGAGTTCA CTTCTGAGAT CTGCTGTGGT TCTTTGTGGG GAGTCAATTT GCTGTTGGGA
 3841 ACCCGATCTA ATCTATATCT GATGGACAGA AGTGGAAAGG CTGACATTAC TAAACTTATA
 15 3901 AGGCGAAGAC CATTCCGCCA GATTCAGTC TTAGAGCCAC TCAATTTGCT GATTACCATC
 3961 TCAGGTCATA AGAACAGACT TCGGGTGTAT CATCTGACCT GGTGAGGAA CAAGATTTTG
 4021 AATAATGATC CAGAAAGTAA AAGAAGGCAA GAAGAAATGC TGAAGACAGA GGAAGCCTGC
 4081 AAAGCTATTG ATAAGTTAAC AGGCTGTGAA CACTTCAGTG TCCTCCAACA TGAAGAAACA
 4141 ACATATATTG CAATTGCTTT GAAATCATCA ATTACCTTT ATGCATGGGC ACCAAAGTCC
 20 4201 TTTGATGAAA GCACTGCTAT TAAAGTATTT CCAACACTTG ATCATAAGCC AGTGACAGTT
 4261 GACCTGGCTA TTGGTTCTGA AAAAAGACTA AAGATTTTCT TCAGCTCAGC AGATGGATAT
 4321 CACCTCATCG ATGCAGAATC TGAGGTTATG TCTGATGTGA CCCTGCCAAA GAATCCCCTG
 4381 GAAATCATTA TACCACAGAA TATCATCATT TTACCTGATT GCTTGGGAAT TGGCATGATG
 4441 CTCACCTTCA ATGCTGAAGC CCTCTCTGTG GAAGCAAATG AACAACTCTT CAAGAAGATC
 25 4501 CTTGAAATGT GGAAAGACAT ACCATCTTCT ATAGCTTTTG AATGTACACA GCGAACCACA
 4561 GGATGGGGCC AAAAGGCCAT TGAAGTGC GC TCTTTGCAAT CCAGGGTTCT GGAAAGTGAG
 4621 CTGAAGCGCA GGTCAATTAA GAAGCTGAGA TTCCTGTGCA CCCGGGGTGA CAAGCTGTTC
 4681 TTTACCTCTA CCCTGCGCAA TCACCACAGC CGGGTTTACT TCATGACACT TGGAACCTT
 4741 GAAGAGCTCC AAAGCAATTA TGATGTC

30 SEQ ID NO:158 (INSP091 polypeptide sequence)

1 MAGPGGWDRD EVTDLGHLPD PTGIFSLDKT IGLGTYGRIY LGLHEKTGAF TAVKVMNARK
 61 TPLPEIGRRV RVNKYQKSVG WRYSDEEEDL RTELNLLRKY SFHKNIVSFY GAFFKLSPPG
 121 QRHQLWMVME LCAAGSVTDV VRMTSNQSLK EDWIAYICRE ILQGLAHLHA HRVIHRDIKG
 181 QNVLLTHNAE VKLVDFGVSA QVSRTNGRRN SFIGTPYWMA PEVIDCDEDP RRSYDYRSVD
 35 241 WSVGITAIEM AEGAPPLCNL QPLEALFVIL RESAPT VKSS GWSRKFNFM EKCTIKNELF

301 RPTSANMLQH PFVRDIKNER HVVESLTRHL TGIKKRQKK GIPLIFEREE AIKEQYTVRR
 361 FRGPSCTHEL LRLPTSSRCR PLRVLHGEPs QPRWLPDREE PQVQALQQLQ GAARVFMPLQ
 421 ALDSAPKPLK GQAQAPQRLQ GAARVFMPLQ AQVKAKASKP LQMQIKAPPR LRRARVLMPL
 481 LQAQVRAPRL LQVQSQVSKK QQAQTQTSEP QDLQDVPEEF QGQDVPEQQ RQGQAPEQQQ
 5 541 RHNQVPEQEL EQNQAPEQPE VQEQAAPAQ AETEAEEPES LRVNAQVFLP LLSQDHHVLL
 601 PLHLDTQVLI PVEGQTEGSP QAQAWTLEPP QAIGSVQALI EGLSRDLLRA PNSNNSKPLG
 661 PLQTLMENLS SNRFYSQPEQ AREKSKSVST LRQALAKRLS PKRFRAKSSW RPEKLELSDL
 721 EARRQRRQRR WEDIFNQHEE ELRQVDKDKK DESSDNDEVF HSIQAEVQIE PLKPYISNPK
 781 KIEVQERSPS VPNNQDHAHH VKFSSSVQR SLLEQAQKPI DIRQRSSQNR QNWLAASGDS
 10 841 KHKILAGKTQ SYCLTIYISE VKKEEFQEGM NQKCQGAQVG LGPEGHCWQ LGESSESSEES
 901 PVTGRRSQSS PPYSTIDQKL LVDIHVPDGF KVGKISPPVY LTNEWVGYNAL LSEIFRNDWL
 961 TPAPVIQPPPE EDGDYVELYD ASADTDGDDD DESNDTFEDT YDHANGNDDL DNQVDQANDV
 1021 CKDHDDNNK FVDDVNNNYE EAPSCPRASY GRDGSKQDG YDGSRGKEEA YRGYGSHTAN
 1081 RSHGGSAAASE DNAAIGDQEE HAANIGSERR GSEGDGKGK VRTSEESGAL GLNGEENCSE
 15 1141 TDGPGLKRPA SQDFEYLQEE PGGGNEASNA IDSGAAPSAP DHESDNKDIS ESSTQSDFA
 1201 NHSSPSKSGS MSADANFASA ILYAGFVEVP EESPKQPSV NVNPLYVSPA CKKPLIHYE
 1261 KEFTSEICCG SLWGVNLLLG TRSNLYLMDR SGKADITKLI RRRPFRQIQV LEPLNLLITI
 1321 SGHKNRLRVY HLTWLRNKIL NNDPESKRRQ EEMLKTEEAC KAIDKLTGCE HFSVLQHEET
 1381 TYIAIALKSS IHLIYAWAPKS FDESTAIKVF PTLDHKPVTV DLAIGSEKRL KIFFSSADGY
 20 1441 HLIDAESEVM SDVTLPKNPL EIIIPQNIII LPDCLGIGMM LTFNAEALSV EANEQLFKKI
 1501 LEMWKDIPSS IAFECTQRTT GWGQKAIEVR SLQSRVLESE LKRRSIKKLR FLCTRGDKLF
 1561 FTSTLRNHHS RVYFMTLGKL EELQSNYDV

CLAIMS

1. A polypeptide, which polypeptide:

- (i) ~~comprises the amino acid sequence as recited in SEQ ID NO:2, SEQ ID NO:4,~~
 SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14,
 5 SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID
 NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ
 ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40 and/or SEQ ID
 NO:42;
- (ii) is a fragment thereof which is a member of the Germinal Center Kinase (GCK)
 10 subfamily of the STE20 family of protein kinases, preferably a NIK-like kinase
 and more preferably a NIK-like embryo specific kinase (NESK), or having an
 antigenic determinant in common with the polypeptide of (i); or
- (iii) is a functional equivalent of (i) or (ii).

2. A polypeptide according to claim 1 which:

- 15 (i) comprises the amino acid sequence as recited in SEQ ID NO:42;
- (ii) is a fragment thereof which is a member of the Germinal Center Kinase (GCK)
 subfamily of the STE20 family of protein kinases, preferably a NIK-like kinase
 and more preferably a NIK-like embryo specific kinase (NESK), or having an
 antigenic determinant in common with the polypeptide of (i); or
- 20 (iii) is a functional equivalent of (i) or (ii).

3. A polypeptide according to claim 1 or 2 which:

- (i) consists of the amino acid sequence as recited in SEQ ID NO:2, SEQ ID NO:4,
 SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14,
 SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID
 25 NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ
 ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40 and/or SEQ ID
 NO:42;
- (ii) is a fragment thereof which is a member of the Germinal Center Kinase (GCK)
 subfamily of the STE20 family of protein kinases, preferably a NIK-like kinase
 and more preferably a NIK-like embryo specific kinase (NESK), or having an
 30

antigenic determinant in common with the polypeptide of (i); or

(iii) is a functional equivalent of (i) or (ii).

4. A polypeptide, which polypeptide:

(i) comprises the amino acid sequence as recited in SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:64, SEQ ID NO:66, SEQ ID NO:68, SEQ ID NO:70, SEQ ID NO:72, SEQ ID NO:74, SEQ ID NO:76, SEQ ID NO:78, SEQ ID NO:80, SEQ ID NO:82, SEQ ID NO:84, SEQ ID NO:86, SEQ ID NO:88, SEQ ID NO:90, SEQ ID NO:92, SEQ ID NO:94, SEQ ID NO:96, SEQ ID NO:98 and/or SEQ ID NO:100;

(ii) is a fragment thereof which is a member of the Germinal Center Kinase (GCK) subfamily of the STE20 family of protein kinases, preferably a NIK-like kinase and more preferably a NIK-like embryo specific kinase (NESK), or having an antigenic determinant in common with the polypeptide of (i); or

(iii) is a functional equivalent of (i) or (ii).

5. A polypeptide, which polypeptide:

(i) comprises the amino acid sequence as recited in SEQ ID NO:100;

(ii) is a fragment thereof which is a member of the Germinal Center Kinase (GCK) subfamily of the STE20 family of protein kinases, preferably a NIK-like kinase and more preferably a NIK-like embryo specific kinase (NESK), or having an antigenic determinant in common with the polypeptide of (i); or

(iii) is a functional equivalent of (i) or (ii).

6. A polypeptide according to claim 4 or claim 5 which:

(i) consists of the amino acid sequence as recited in SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:64, SEQ ID NO:66, SEQ ID NO:68, SEQ ID NO:70, SEQ ID NO:72, SEQ ID NO:74, SEQ ID NO:76, SEQ ID NO:78, SEQ ID NO:80, SEQ ID NO:82, SEQ ID NO:84, SEQ ID NO:86, SEQ ID NO:88, SEQ ID NO:90, SEQ ID NO:92, SEQ ID NO:94, SEQ ID NO:96, SEQ ID NO:98 and/or SEQ ID NO:100;

- (ii) is a fragment thereof which is a member of the Germinal Center Kinase (GCK) subfamily of the STE20 family of protein kinases, preferably a NIK-like kinase and more preferably a Nik-like embryo specific kinase (NESK), or having an antigenic determinant in common with the polypeptide of (i); or

- 5 (iii) is a functional equivalent of (i) or (ii).

7. A polypeptide, which polypeptide:

- (i) comprises the amino acid sequence as recited in SEQ ID NO:102, SEQ ID NO:104, SEQ ID NO:106, SEQ ID NO:108, SEQ ID NO:110, SEQ ID NO:112, SEQ ID NO:114, SEQ ID NO:116, SEQ ID NO:118, SEQ ID NO:120, SEQ ID
10 NO:122, SEQ ID NO:124, SEQ ID NO:126, SEQ ID NO:128, SEQ ID NO:130, SEQ ID NO:132, SEQ ID NO:134, SEQ ID NO:136, SEQ ID NO:138, SEQ ID NO:140, SEQ ID NO:142, SEQ ID NO:144, SEQ ID NO:146, SEQ ID NO:148, SEQ ID NO:150, SEQ ID NO:152, SEQ ID NO:154, SEQ ID NO:156 and/or SEQ ID NO:158;

- 15 (ii) is a fragment thereof which is a member of the Germinal Center Kinase (GCK) subfamily of the STE20 family of protein kinases, preferably a NIK-like kinase and more preferably a NIK-like embryo specific kinase (NESK), or having an antigenic determinant in common with the polypeptide of (i); or

- (iii) is a functional equivalent of (i) or (ii).

20 8. A polypeptide, which polypeptide:

- (i) comprises the amino acid sequence as recited in SEQ ID NO:158;

- (ii) is a fragment thereof which is a member of the Germinal Center Kinase (GCK) subfamily of the STE20 family of protein kinases, preferably a NIK-like kinase and more preferably a NIK-like embryo specific kinase (NESK), or having an
25 antigenic determinant in common with the polypeptide of (i); or

- (iii) is a functional equivalent of (i) or (ii).

9. A polypeptide according to claim 7 or claim 8 which:

- (i) consists of the amino acid sequence as recited in SEQ ID NO:102, SEQ ID NO:104, SEQ ID NO:106, SEQ ID NO:108, SEQ ID NO:110, SEQ ID NO:112, SEQ ID NO:114, SEQ ID NO:116, SEQ ID NO:118, SEQ ID NO:120, SEQ ID
30

NO:122, SEQ ID NO:124, SEQ ID NO:126, SEQ ID NO:128, SEQ ID NO:130, SEQ ID NO:132, SEQ ID NO:134, SEQ ID NO:136, SEQ ID NO:138, SEQ ID NO:140, SEQ ID NO:142, SEQ ID NO:144, SEQ ID NO:146, SEQ ID NO:148, SEQ ID NO:150, SEQ ID NO:152, SEQ ID NO:154, SEQ ID NO:156 and/or SEQ ID NO:158;

(ii) is a fragment thereof which is a member of the Germinal Center Kinase (GCK) subfamily of the STE20 family of protein kinases, preferably a NIK-like kinase and more preferably a Nik-like embryo specific kinase (NESK), or having an antigenic determinant in common with the polypeptide of (i); or

(iii) is a functional equivalent of (i) or (ii).

10. A polypeptide which is a functional equivalent according to part (iii) of any of the above claims, characterised in that it is homologous to the amino acid sequence as recited in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:64, SEQ ID NO:66, SEQ ID NO:68, SEQ ID NO:70, SEQ ID NO:72, SEQ ID NO:74, SEQ ID NO:76, SEQ ID NO:78, SEQ ID NO:80, SEQ ID NO:82, SEQ ID NO:84, SEQ ID NO:86, SEQ ID NO:88, SEQ ID NO:90, SEQ ID NO:92, SEQ ID NO:94, SEQ ID NO:96, SEQ ID NO:98, SEQ ID NO:100, SEQ ID NO:102, SEQ ID NO:104, SEQ ID NO:106, SEQ ID NO:108, SEQ ID NO:110, SEQ ID NO:112, SEQ ID NO:114, SEQ ID NO:116, SEQ ID NO:118, SEQ ID NO:120, SEQ ID NO:122, SEQ ID NO:124, SEQ ID NO:126, SEQ ID NO:128, SEQ ID NO:130, SEQ ID NO:132, SEQ ID NO:134, SEQ ID NO:136, SEQ ID NO:138, SEQ ID NO:140, SEQ ID NO:142, SEQ ID NO:144, SEQ ID NO:146, SEQ ID NO:148, SEQ ID NO:150, SEQ ID NO:152, SEQ ID NO:154, SEQ ID NO:156 or SEQ ID NO:158 and is a member of the Germinal Center Kinase (GCK) subfamily of the STE20 family of protein kinases, preferably a NIK-like kinase and more preferably a NIK-like embryo specific kinase (NESK).

11. A polypeptide which is a fragment or a functional equivalent as recited in any one of claims 1 to 10, which has greater than 80% sequence identity with the amino acid sequence recited in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:64, SEQ ID NO:66, SEQ ID NO:68, SEQ ID NO:70, SEQ ID NO:72, SEQ ID NO:74, SEQ ID NO:76, SEQ ID NO:78, SEQ ID NO:80, SEQ ID NO:82, SEQ ID NO:84, SEQ ID NO:86, SEQ ID NO:88, SEQ ID NO:90, SEQ ID NO:92, SEQ ID NO:94, SEQ ID NO:96, SEQ ID NO:98, SEQ ID NO:100, SEQ ID NO:102, SEQ ID NO:104, SEQ ID NO:106, SEQ ID NO:108, SEQ ID NO:110, SEQ ID NO:112, SEQ ID NO:114, SEQ ID NO:116, SEQ ID NO:118, SEQ ID NO:120, SEQ ID NO:122, SEQ ID NO:124, SEQ ID NO:126, SEQ ID NO:128, SEQ ID NO:130, SEQ ID NO:132, SEQ ID NO:134, SEQ ID NO:136, SEQ ID NO:138, SEQ ID NO:140, SEQ ID NO:142, SEQ ID NO:144, SEQ ID NO:146, SEQ ID NO:148, SEQ ID NO:150, SEQ ID NO:152, SEQ ID NO:154, SEQ ID NO:156 or SEQ ID NO:158 or with an active fragment thereof, preferably greater than 85%, 90%, 95%, 98% or 99% sequence identity.

12. A polypeptide which is a functional equivalent as recited in any one of claims 1 to 11, which exhibits significant structural homology with a polypeptide having the amino acid sequence recited in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:64, SEQ ID NO:66, SEQ ID NO:68, SEQ ID NO:70, SEQ ID NO:72, SEQ ID NO:74, SEQ ID NO:76, SEQ ID NO:78, SEQ ID NO:80, SEQ ID NO:82, SEQ ID NO:84, SEQ ID NO:86, SEQ ID NO:88, SEQ ID NO:90, SEQ ID NO:92, SEQ ID NO:94, SEQ ID NO:96, SEQ ID NO:98, SEQ ID NO:100, SEQ ID NO:102, SEQ ID NO:104, SEQ ID NO:106, SEQ ID NO:108,

SEQ ID NO:110, SEQ ID NO:112, SEQ ID NO:114, SEQ ID NO:116, SEQ ID NO:118,
 SEQ ID NO:120, SEQ ID NO:122, SEQ ID NO:124, SEQ ID NO:126, SEQ ID NO:128,
 SEQ ID NO:130, SEQ ID NO:132, SEQ ID NO:134, SEQ ID NO:136, SEQ ID NO:138,
 SEQ ID NO:140, SEQ ID NO:142, SEQ ID NO:144, SEQ ID NO:146, SEQ ID NO:148,
 5 SEQ ID NO:150, SEQ ID NO:152, SEQ ID NO:154, SEQ ID NO:156 or SEQ ID
 NO:158.

13. A polypeptide which is a fragment as recited in claims 1-9 and claim 11 having an
 antigenic determinant in common with the polypeptide of part (i) of any one of claim 1
 to claim 9 which consists of 7 or more amino acid residues from the amino acid
 10 sequence recited in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ
 ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID
 NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID
 NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID
 NO:40, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48, SEQ ID
 15 NO:50, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, SEQ ID
 NO:60, SEQ ID NO:62, SEQ ID NO:64, SEQ ID NO:66, SEQ ID NO:68, SEQ ID
 NO:70, SEQ ID NO:72, SEQ ID NO:74, SEQ ID NO:76, SEQ ID NO:78, SEQ ID
 NO:80, SEQ ID NO:82, SEQ ID NO:84, SEQ ID NO:86, SEQ ID NO:88, SEQ ID
 NO:90, SEQ ID NO:92, SEQ ID NO:94, SEQ ID NO:96, SEQ ID NO:98, SEQ ID
 20 NO:100, SEQ ID NO:102, SEQ ID NO:104, SEQ ID NO:106, SEQ ID NO:108, SEQ ID
 NO:110, SEQ ID NO:112, SEQ ID NO:114, SEQ ID NO:116, SEQ ID NO:118, SEQ ID
 NO:120, SEQ ID NO:122, SEQ ID NO:124, SEQ ID NO:126, SEQ ID NO:128, SEQ ID
 NO:130, SEQ ID NO:132, SEQ ID NO:134, SEQ ID NO:136, SEQ ID NO:138, SEQ ID
 NO:140, SEQ ID NO:142, SEQ ID NO:144, SEQ ID NO:146, SEQ ID NO:148, SEQ ID
 25 NO:150, SEQ ID NO:152, SEQ ID NO:154, SEQ ID NO:156 or SEQ ID NO:158.

14. A purified nucleic acid molecule which encodes a polypeptide according to any one of
 the preceding claims.

15. A purified nucleic acid molecule according to claim 14, which comprises the nucleic
 acid sequence as recited in SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7,
 30 SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ
 ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID
 NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, SEQ ID

NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47 SEQ ID
 NO:49, SEQ ID NO:51, SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:57, SEQ ID
 NO:59, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:65, SEQ ID NO:67, SEQ ID
 NO:69, SEQ ID NO:71, SEQ ID NO:73, SEQ ID NO:75, SEQ ID NO:77, SEQ ID

5 NO:79, SEQ ID NO:81, SEQ ID NO:83, SEQ ID NO:85, SEQ ID NO:87, SEQ ID
 NO:89, SEQ ID NO:91, SEQ ID NO:93, SEQ ID NO:95, SEQ ID NO:97, SEQ ID
 NO:99, SEQ ID NO:101, SEQ ID NO:103, SEQ ID NO:105, SEQ ID NO:107, SEQ ID
 NO:109, SEQ ID NO:111, SEQ ID NO:113, SEQ ID NO:115, SEQ ID NO:117, SEQ ID
 NO:119, SEQ ID NO:121, SEQ ID NO:123, SEQ ID NO:125, SEQ ID NO:127, SEQ ID
 10 NO:129, SEQ ID NO:131, SEQ ID NO:133, SEQ ID NO:135, SEQ ID NO:137, SEQ ID
 NO:139, SEQ ID NO:141, SEQ ID NO:143, SEQ ID NO:145, SEQ ID NO:147, SEQ ID
 NO:149, SEQ ID NO:151, SEQ ID NO:153, SEQ ID NO:155 and/or SEQ ID NO:157, or
 is a redundant equivalent or fragment thereof.

16. A purified nucleic acid molecule according to claim 14 which consists of the nucleic
 15 acid sequence as recited in SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7,
 SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ
 ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID
 NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, SEQ ID
 NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47 SEQ ID
 20 NO:49, SEQ ID NO:51, SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:57, SEQ ID
 NO:59, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:65, SEQ ID NO:67, SEQ ID
 NO:69, SEQ ID NO:71, SEQ ID NO:73, SEQ ID NO:75, SEQ ID NO:77, SEQ ID
 NO:79, SEQ ID NO:81, SEQ ID NO:83, SEQ ID NO:85, SEQ ID NO:87, SEQ ID
 NO:89, SEQ ID NO:91, SEQ ID NO:93, SEQ ID NO:95, SEQ ID NO:97, SEQ ID
 25 NO:99, SEQ ID NO:101, SEQ ID NO:103, SEQ ID NO:105, SEQ ID NO:107, SEQ ID
 NO:109, SEQ ID NO:111, SEQ ID NO:113, SEQ ID NO:115, SEQ ID NO:117, SEQ ID
 NO:119, SEQ ID NO:121, SEQ ID NO:123, SEQ ID NO:125, SEQ ID NO:127, SEQ ID
 NO:129, SEQ ID NO:131, SEQ ID NO:133, SEQ ID NO:135, SEQ ID NO:137, SEQ ID
 NO:139, SEQ ID NO:141, SEQ ID NO:143, SEQ ID NO:145, SEQ ID NO:147, SEQ ID
 30 NO:149, SEQ ID NO:151, SEQ ID NO:153, SEQ ID NO:155 and/or SEQ ID NO:157 or
 is a redundant equivalent or fragment thereof.

17. A purified nucleic acid molecule which hybridizes under high stringency conditions
 with a nucleic acid molecule according to any one of claims 14 to 16.

18. A vector comprising a nucleic acid molecule as recited in any one of claims 14 to 17.
19. A host cell transformed with a vector according to claim 18.
20. A ligand which binds specifically to the Germinal Center Kinase (GCK) subfamily of the STE20 family of protein kinases, preferably to a NIK-like kinase and more preferably to a NIK-like embryo specific kinase (NESK) polypeptide according to any one of claims 1 to 13.
21. A ligand according to claim 20, which is an antibody.
22. A compound that either increases or decreases the level of expression or activity of a polypeptide according to any one of claims 1 to 13.
23. A compound according to claim 22 that binds to a polypeptide according to any one of claims 1 to 13 without inducing any of the biological effects of the polypeptide.
24. A compound according to claim 23, which is a natural or modified substrate, ligand, enzyme, receptor or structural or functional mimetic.
25. A polypeptide according to any one of claims 1 to 13, a nucleic acid molecule according to any one of claims 14 to 17, a vector according to claim 18, a host cell according to claim 19, a ligand according to claim 20 or claim 21, or a compound according to any one of claims 22 to 24, for use in therapy or diagnosis of disease.
26. A method of diagnosing a disease in a patient, comprising assessing the level of expression of a natural gene encoding a polypeptide according to any one of claims 1 to 13, or assessing the activity of a polypeptide according to any one of claims 1 to 13, in tissue from said patient and comparing said level of expression or activity to a control level, wherein a level that is different to said control level is indicative of disease.
27. A method according to claim 26 that is carried out *in vitro*.
28. A method according to claim 26 or claim 27, which comprises the steps of:
 - a) contacting a ligand according to claim 20 or claim 21 with a biological sample under conditions suitable for the formation of a ligand-polypeptide complex; and
 - b) detecting said complex.

29. A method according to claim 26 or claim 27, comprising the steps of:

a) contacting a sample of tissue from the patient with a nucleic acid probe under stringent conditions that allow the formation of a hybrid complex between a nucleic acid molecule according to any one of claims 14 to 17 and the probe;

5 b) contacting a control sample with said probe under the same conditions used in step a); and

c) detecting the presence of hybrid complexes in said samples; wherein detection of levels of the hybrid complex in the patient sample that differ from levels of the hybrid complex in the control sample is indicative of disease.

10 30. A method according to claim 26 or claim 27, comprising:

a) contacting a sample of nucleic acid from tissue of the patient with a nucleic acid primer under stringent conditions that allow the formation of a hybrid complex between a nucleic acid molecule according to any one of claims 14 to 17 and the primer;

15 b) contacting a control sample with said primer under the same conditions used in step a); and

c) amplifying the sampled nucleic acid; and

d) detecting the level of amplified nucleic acid from both patient and control samples; wherein detection of levels of the amplified nucleic acid in the patient sample that differ significantly from levels of the amplified nucleic acid in the control sample is indicative of disease.

20 31. A method according to claim 26 or claim 27 comprising:

a) obtaining a tissue sample from a patient being tested for disease;

b) isolating a nucleic acid molecule according to any one of claims 14 to 17 from said tissue sample; and

c) diagnosing the patient for disease by detecting the presence of a mutation which is associated with disease in the nucleic acid molecule as an indication of the disease.

32. The method of claim 31, further comprising amplifying the nucleic acid molecule to form an amplified product and detecting the presence or absence of a mutation in the

amplified product.

33. The method of claim 31 or claim 32, wherein the presence or absence of the mutation in the patient is detected by contacting said nucleic acid molecule with a nucleic acid probe that hybridises to said nucleic acid molecule under stringent conditions to form a hybrid double-stranded molecule, the hybrid double-stranded molecule having an unhybridised portion of the nucleic acid probe strand at any portion corresponding to a mutation associated with disease; and detecting the presence or absence of an unhybridised portion of the probe strand as an indication of the presence or absence of a disease-associated mutation.
34. A method according to any one of claims 26 to 33, wherein said disease includes, but is not limited to cell proliferative disorders, including neoplasm, melanoma, lung, colorectal, breast, pancreas, head and neck and other solid tumours; myeloproliferative disorders, such as leukemia, non-Hodgkin lymphoma, leukopenia, thrombocytopenia; angiogenesis disorder, Kaposi's sarcoma; autoimmune/inflammatory disorders, including allergy, inflammatory bowel disease, arthritis, psoriasis and respiratory tract inflammation, asthma, and organ transplant rejection; cardiovascular disorders, including hypertension, oedema, angina, atherosclerosis, thrombosis, sepsis, shock, reperfusion injury, and ischemia; neurological disorders including central nervous system disease, Alzheimer's disease, brain injury, amyotrophic lateral sclerosis, and pain; developmental disorders; metabolic disorders including diabetes mellitus, osteoporosis, and obesity, AIDS and renal disease; infections including viral infection, bacterial infection, fungal infection and parasitic infection and other pathological conditions and in particular developmental disorders of late embryogenesis and neural tube defects such as spina bifida.
35. A method according to any one of claims 26 to 33, wherein said disease is a disease in which members of the Germinal Center Kinase (GCK) subfamily of the STE20 family of protein kinases, preferably NIK-like kinases and more preferably NIK-like embryo specific kinases (NESK) proteins are implicated.
36. Use of a polypeptide according to any one of claims 1 to 13 as a group 1 GCK kinase.
37. Use of a polypeptide according to any one of claims 1 to 13 as a NIK-like kinase.

38. Use of a polypeptide according to any one of claims 1 to 13 as a NIK-like embryo specific kinase (NESK).

39. A pharmaceutical composition comprising a polypeptide according to any one of claims 1 to 13, a nucleic acid molecule according to any one of claims 14 to 17, a
5 vector according to claim 18, a host cell according to claim 19, a ligand according to claim 20 or claim 21, or a compound according to any one of claims 22 to 24.

40. A vaccine composition comprising a polypeptide according to any one of claims 1 to 13 or a nucleic acid molecule according to any one of claims 14 to 17.

41. A polypeptide according to any one of claims 1 to 13, a nucleic acid molecule
10 according to any one of claims 14 to 17, a vector according to claim 18, a host cell according to claim 19, a ligand according to claim 20 or claim 21, a compound according to any one of claims 22 to 24, or a pharmaceutical composition according to claim 39, for use in the manufacture of a medicament for the treatment of cell
15 proliferative disorders, including neoplasm, melanoma, lung, colorectal, breast, pancreas, head and neck and other solid tumours; myeloproliferative disorders, such as leukemia, non-Hodgkin lymphoma, leukopenia, thrombocytopenia, angiogenesis disorder, Kaposi's sarcoma; autoimmune/inflammatory disorders, including allergy, inflammatory bowel disease, arthritis, psoriasis and respiratory tract inflammation, asthma, and organ transplant rejection; cardiovascular disorders, including
20 hypertension, oedema, angina, atherosclerosis, thrombosis, sepsis, shock, reperfusion injury, and ischemia; neurological disorders including central nervous system disease, Alzheimer's disease, brain injury, amyotrophic lateral sclerosis, and pain; developmental disorders; metabolic disorders including diabetes mellitus, osteoporosis, and obesity, AIDS and renal disease; infections including viral infection, bacterial
25 infection, fungal infection and parasitic infection and other pathological conditions and in particular developmental disorders of late embryogenesis and neural tube defects such as spina bifida.

42. A polypeptide according to any one of claims 1 to 13, a nucleic acid molecule
30 according to any one of claims 14 to 17, a vector according to claim 18, a host cell according to claim 19, a ligand according to claim 20 or claim 21, a compound according to any one of claims 22 to 24, or a pharmaceutical composition according to claim 39, for use in the manufacture of a medicament for the treatment of a disease in

which members of the Germinal Center Kinase (GCK) subfamily of the STE20 family of protein kinases, preferably NIK-like kinases and more preferably NIK-like embryo specific kinases (NESK), are implicated.

43. A polypeptide according to any one of claims 1 to 13, a nucleic acid molecule
5 according to any one of claims 14 to 17, a vector according to claim 18, a host cell
according to claim 19, a ligand according to claim 20 or claim 21, a compound
according to any one of claims 22 to 24, or a pharmaceutical composition according to
claim 39, for use in the manufacture of a medicament for the treatment of a disease in
10 which NIK-like kinases and preferably NIK-like embryo specific kinases (NESK)
proteins are implicated.
44. A method of treating a disease in a patient, comprising administering to the patient a
polypeptide according to any one of claims 1 to 13, a nucleic acid molecule according
to any one of claims 14 to 17, a vector according to claim 18, a host cell according to
claim 19, a ligand according to claim 20 or claim 21, a compound according to any one
15 of claims 22 to 24, or a pharmaceutical composition according to claim 39.
45. A method according to claim 44, wherein, for diseases in which the expression of the
natural gene or the activity of the polypeptide is lower in a diseased patient when
compared to the level of expression or activity in a healthy patient, the polypeptide,
nucleic acid molecule, vector, ligand, compound or composition administered to the
20 patient is an agonist.
46. A method according to claim 44, wherein, for diseases in which the expression of the
natural gene or activity of the polypeptide is higher in a diseased patient when
compared to the level of expression or activity in a healthy patient, the polypeptide,
nucleic acid molecule, vector, ligand, compound or composition administered to the
25 patient is an antagonist.
47. A method of monitoring the therapeutic treatment of disease in a patient, comprising
monitoring over a period of time the level of expression or activity of a polypeptide
according to any one of claims 1 to 13, or the level of expression of a nucleic acid
molecule according to any one of claims 14 to 17 in tissue from said patient, wherein
30 altering said level of expression or activity over the period of time towards a control
level is indicative of regression of said disease.

48. A method for the identification of a compound that is effective in the treatment and/or diagnosis of disease, comprising contacting a polypeptide according to any one of claims 1 to 13 or a nucleic acid molecule according to any one of claims 14 to 17 with one or more compounds suspected of possessing binding affinity for said polypeptide or nucleic acid molecule, and selecting a compound that binds specifically to said nucleic acid molecule or polypeptide.
49. A kit useful for diagnosing disease comprising a first container containing a nucleic acid probe that hybridises under stringent conditions with a nucleic acid molecule according to any one of claims 14 to 17; a second container containing primers useful for amplifying said nucleic acid molecule; and instructions for using the probe and primers for facilitating the diagnosis of disease.
50. The kit of claim 49, further comprising a third container holding an agent for digesting unhybridised RNA.
51. A kit comprising an array of nucleic acid molecules, at least one of which is a nucleic acid molecule according to any one of claims 14 to 17.
52. A kit comprising one or more antibodies that bind to a polypeptide as recited in any one of claims 1 to 13; and a reagent useful for the detection of a binding reaction between said antibody and said polypeptide.
53. A transgenic or knockout non-human animal that has been transformed to express higher, lower or absent levels of a polypeptide according to any one of claims 1 to 13.
54. A method for screening for a compound effective to treat disease, by contacting a non-human transgenic animal according to claim 53 with a candidate compound and determining the effect of the compound on the disease of the animal.

Figure 1: Top ten NCBI non redundant protein database hits for INSP081.

BLASTP 2.2.2 [Jan-08-2002]

Reference: Altschul, Stephen F., Thomas L. Madden, Alejandro A. Schaffer, Jinghui Zhang, Zheng Zhang, Webb Miller, and David J. Lipman (1997), "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs", Nucleic Acids Res. 25:3389-3402.

Query= INSP081.pep
(1132 letters)

Database: ncbi-nr
1,039,718 sequences; 328,277,582 total letters

Searching.....done

Sequences producing significant alignments:	Score (bits)	E Value
dbj BAA87066.1 (AB035267) Nck-interacting kinase-like embryo sp...	1223	0.0
ref NP_038752.1 (NM_013724) Nik related kinase [Mus musculus] >...	1220	0.0
ref XP_125446.1 (XM_125446) similar to Nck-interacting kinase-1...	1160	0.0
ref XP_109557.1 (XM_109557) similar to Nik related kinase [Mus ...	747	0.0
ref NP_004825.1 (NM_004834) mitogen-activated protein kinase ki...	393	e-108
gb AAF03788.1 AF172270_1 (AF172270) Traf2 and NCK interacting ki...	392	e-107
gb AAF03786.1 AF172268_1 (AF172268) Traf2 and NCK interacting ki...	392	e-107
gb AAF03789.1 AF172271_1 (AF172271) Traf2 and NCK interacting ki...	392	e-107
gb AAF03785.1 AF172267_1 (AF172267) Traf2 and NCK interacting ki...	392	e-107
dbj BAA25477.2 (AB011123) KIAA0551 protein [Homo sapiens]	392	e-107
gb AAF03783.1 AF172265_1 (AF172265) Traf2 and NCK interacting ki...	392	e-107
gb AAF03782.1 AF172264_1 (AF172264) Traf2 and NCK interacting ki...	392	e-107
gb AAF03787.1 AF172269_1 (AF172269) Traf2 and NCK interacting ki...	392	e-107

Figure 2: INSP081 top blastp alignment result from NCBI non-redundant protein database sequences.

>dbj|BAA87066.1| (AB035267) Nck-interacting kinase-like embryo specific kinase [Mus musculus]
Length = 1455

Score = 1223 bits (3165), Expect = 0.0

Identities = 669/1154 (57%), Positives = 760/1154 (64%), Gaps = 47/1154 (4%)

Query: 1MAGPGGWRDREVTDLGHLDPDTGIFSLDKTIGLTGYGRIYGLHEKTGAFTAVKVMNARK 60
MAGPG WRD+EVTDLG LPDPTGIFSLDK IGLGTYGRI+LG+HEKTG+ AVKVM+ARK
Sbjct: 1MAGPGSWRDKEVTDLGQLPDPTGIFSLDKAIGLTGYGRIFLGIHEKTGSLVAVKVMNARK 60

Query: 61 TPLPEIGRRVRVKNKYQKSVGWRYSDDEEDLRTELNLLRKYSFHKNIVSFYGAFFKLSPPG 120
TPLPEIGRRVRVKNKYQKSVGWRYSDDEEDLRTELNLLRKYSFHKNI+FYGAFFKL+PPG
Sbjct: 61 TPLPEIGRRVRVKNKYQKSVGWRYSDDEEDLRTELNLLRKYSFHKNI+FYGAFFKL+PPG 120

Query: 121 QRHQLWMMELCAAGSVTDVVRMTSNQSLKEDWIAIYICREILQGLAHLHAHRVIHRDIK 180
+HQLWMMELCAAGSVTDVVRMT NQSLKEDWIAIYICREILQGLAHLHAH+VIHRDIK
Sbjct: 121 HQHQLWMMELCAAGSVTDVVRMTNRNQLKEDWIAIYICREILQGLAHLHAH+VIHRDIK 180

Query: 181 QNVLLTHNAEVKLVDGVSQAQVSRTNGRRNSFIGTPYWMapeVIDCEDPRRSYDYSRV 240
QNVLLTH+AEVK+VDGVSQAQVSRTNGRRNSFIGTPYWMapeVI CEDPR SYDYSRV
Sbjct: 181 QNVLLTHDAEVKIVDGVSAQVSRTNGRRNSFIGTPYWMapeVIHCEDEPRCSYDYSRV 240

Query: 241 WSVGITAEMAEGAPPLCNLQPLEALFVILRESAPTVMKSSGWSRKFNFMKCTIKNFLF 300
WSVGITAEMAEGAPPLC LQPLEAL VILRE+AP VKSSGWSRKFNFM C IKNFLF
Sbjct: 241 WSVGITAEMAEGAPPLCKLQPLEALCVILREAAFKVSSGWSRKFNFMENCMIKNFLF 300

Query: 301 RPTSANMLQHPFVRDIKNERHVESLTHRLTGIIKKRQKGIPLIFEREEAIKEQYTVRR 360
RPTS NML HPFV DIKNER VVESLT+HLTGII+KR+KKGIP+ FE EEA KEQY RR
Sbjct: 301 RPTSGNMLLHPFVHDIKNERRVVESLTKHLTGIIKREKKGIPVAPEGEAAKEQYITRR 360

Query: 361 FRGPSCTHELLRLPTSSRCRPLRVLHGEPSPRWLPDREEPXXXXXXXXXXXXRVFMPLQ 420
FRGPSCT ELLR+PTSSRCRPLRVLHGEP QPRWLPD+E+P VFMP
Sbjct: 361 FRGPSCTPELLRVPTSSRCRPLRVLHGEPQPRWLPDQEDPDQELQQLQKAAQVFMPLH 420

Query: 421 ALDSAPKPLKGQAQAPQRLQGAARVFMPLQAQVAKASKPLQMQUIKXXXXXXXXXXXXX 480
+ D+ KQ +L+GAA+V MP+ QV+AP Q+
Sbjct: 421 SQDNTSKLFPKQVEVAPYLRGAAQVMPVLVQVEA----PPQVSKAAQMLRSLPTQDNKA 476

Query: 481 XQAQVRAPRLXXXXXXXXXXXXXXXXXSEPDLDQVPEEFQGGQDVXXXXXXXXXXXXX 540
+V+AP+P+DLQVPEEFQGGQ+
Sbjct: 477 TSPEVQAP-----VAEGQQAQHEALETEQPKDLQVPEEFQGGQDRAPEQPRQGAAEQQQ 531

Query: 541 XHNQVPEQELXXXXXXXXXXXXXXXXXXXXXXXXXSLRVNAQVFLPLLSQDHHVLL 600
HN VPEQ++V+AQV LPLLSQ+ HVLL
Sbjct: 532 IHNVPVEQPPEEDREPEQAEVQEEAVEPPQAEIEDKEPEVVQVHAQVLLPLLSQNRHVLL 591

Query: 601 PLHLDQVLPVVEGQTEGSPQAQAWTLEPPQAIGSVQALIEGLSRDLLRAPNSNNSKPLG 660
PLHLD Q+LIPV Q E P+AQAW LE +A+G+VQALIEGLSRDLLRAPN+ +KPLG
Sbjct: 592 PLHLDRQLLIPVGEQNEEVFRAQAWDLASRAVGAVQALIEGLSRDLLRAPNAFVTKPLG 651

Query: 661 PLQTLMENLSSNRFYSQPEQAREKKSKVSTLRQALAKRLSPKRFRAKSSWRPEKLELSDL 720
PLQ +ENLS++ FY++PE ++KSKV++LR+A+AKRL PKRFRAK+ WR E E SD+

Sbjct: 652 PLQIFLENLSTDGFYTEPEPTQKKKSKVASLRKAIKRLRPKRFRKALWRLEDFEFSDV 711

Query: 721 EAXXXXXXXXXWEDIFNQHEEELRQVXXXXXXXXXXXXXVFHSIQAEVQIEPLKPYISNPK 780
E WEDIFNQHEE+LR+V VFHSIQAEVQIE P+ +NP

Sbjct: 712 ETSRRRRHRRWEDIFNQHEEQLRRVENDREDDSSDNDEVFHSIQAEVQIE---PHAANPA 768

Query: 781 KIEVQERSPSVPNNQDHAHVKFSSRTWHMLFCLFISVPQRSLLLEQAQKPIDIRQRSSQN 840
EV ERS +P N++ H VKFS L + PQ+Q Q+P++IR R+ N

Sbjct: 769 GNEVHERSAPMPCNRRNRTHRVKFSVSGEEEPSLEEAPQ---QQQQQPMNIRPRNCLN 824

Query: 841 RQNWLAAXXXXXXXXXPVGTGRSQSSPPYSTIDQKLLVDIHVPDGFVKVKISPPVYLTNE 900
QN+ A PVT R+SQSSPPYSTIDQKLL+DIHVPDGFVKVKISPPVYLTNE

Sbjct: 825 PQNFQAQSDSSSEEDSPVTRRKSQSSPPYSTIDQKLLIDIHVPDGFVKVKISPPVYLTNE 884

Query: 901 WVGYNALSEIFRNDWLTPAPVIQPPPEEDGDYVELYXXXXXXXXXXXXXXXXXXTYDHA 960
WVGYNALSEIF +DW+ P+PPEEDGDYVELY D A

Sbjct: 885 WVGYNALSEIFWDDWIMPTRPARPPEEDGDYVELY-DADANANGDEEVANGAYEDPRDGA 943

Query: 961 NGNDDLNDNQVDQANDVCXXXXXXXXXXXXXXXXXXYEAPSCPRASYGRDGCKQDGYDGS 1020
NG+DD++NQ+DQAN+ A + PRA+Y R G KDG

Sbjct: 944 NGHDDMNQLDQANG--YEGHGAAGYNGGDVGGNHGAAFNGPRANYPRAGILKNHNDGR 1001

Query: 1021 RGKEEAYRGYGSHTANRSHGGSAASEDNAAIGDQEEHAANIXXXXXXXXXXXXXXNEASN 1080
A+ +G + A HG AA E AA G+ H AN NE +

Sbjct: 1002 ALNRGAFGVFGDNAARAFHG--AAGEAGAAFGN---HGANRGNRGNRNRREANGRNEENG 1056

Query: 1081 AI--DSGAAPSAPDHESD-----NKDISESSTQSDFSANHSSPSK 1118
A DP ESDN SST FSSP +

Sbjct: 1057 AFGRDQHVFPPEFEHEESDRGTETSDSIALETISFDGEQNSGRPVSSSTMGFPIGRSSP-R 1115

Query: 1119 GSGMSADANFASAI 1132

GS +D ++ S I

Sbjct: 1116 GSDFGSDISYNSPI 1129

Figure 3: Top ten NCBI non redundant protein database hits for INSP082.

BLASTP 2.2.2 [Jan-08-2002]

Reference: Altschul, Stephen F., Thomas L. Madden, Alejandro A. Schaffer, Jinghui Zhang, Zheng Zhang, Webb Miller, and David J. Lipman (1997), "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs", Nucleic Acids Res. 25:3389-3402.

Query= chrX_101702493-101913965_hg11.pep
(1500 letters)

Database: ncbi-nr
1,039,718 sequences; 328,277,582 total letters

Searching.....done

Sequences producing significant alignments:	Score (bits)	E Value
dbj BAA87066.1 (AB035267) Nck-interacting kinase-like embryo sp...	1727	0.0
ref NP_038752.1 (NM_013724) Nik related kinase [Mus musculus] >...	1724	0.0
ref XP_125446.1 (XM_125446) similar to Nck-interacting kinase-l...	1664	0.0
ref XP_109557.1 (XM_109557) similar to Nik related kinase [Mus ...	1251	0.0
emb CAB06091.1 (Z83850) mouse NIK serine threonine protein kina...	599	e-170
ref NP_004825.1 (NM_004834) mitogen-activated protein kinase ki...	393	e-108
gb AAF03788.1 AF172270_1 (AF172270) Traf2 and NCK interacting ki...	392	e-107
gb AAF03786.1 AF172268_1 (AF172268) Traf2 and NCK interacting ki...	392	e-107
gb AAF03789.1 AF172271_1 (AF172271) Traf2 and NCK interacting ki...	392	e-107
gb AAF03785.1 AF172267_1 (AF172267) Traf2 and NCK interacting ki...	392	e-107
dbj BAA25477.2 (AB011123) KIAA0551 protein [Homo sapiens]	392	e-107
gb AAF03783.1 AF172265_1 (AF172265) Traf2 and NCK interacting ki...	392	e-107

Figure 4: INSP082 top blastp alignment result from NCBI non-redundant protein database sequences.

```
>dbj|BAA87066.1| (AB035267) Nck-interacting kinase-like embryo specific kinase [Mus
musculus]
Length = 1455

Score = 1727 bits (4473), Expect = 0.0
Identities = 923/1505 (61%), Positives = 1058/1505 (69%), Gaps = 55/1505 (3%)

Query: 1MAGPGGWRDREVTDLGHLDPDTGIFSLDKTIGLTGTYGRIYGLGHEKTGAFTAVKVMNARK 60
MAGPG WRD+EVTDLG LPDPTGIFSLDK IGLGTYGRI+LG+HEKTG+ AVKVM+ARK
Sbjct: 1MAGPGSWRDKEVTDLGQLPDPTGIFSLDKAIGLTGTYGRIFLGIHEKTGSLVAVKVMARK 60

Query: 61 TPLPEIGRRVRVNKYQKSVGWRYSDDEEDLRTELNLLRKYSFHKNIVSFYGAFFKLSPPG 120
TPLPEIGRRVRVNKYQKSVGWRYSDDEEDLRTELNLLRKYSFHKNI+FYGAFFKL+PPG
Sbjct: 61 TPLPEIGRRVRVNKYQKSVGWRYSDDEEDLRTELNLLRKYSFHKNI+FYGAFFKL+PPG 120

Query: 121 QRHQLWMVMELCAAGSVTDVVRMTSNQSLKEDWIAIYICREILQGLAHLHAHRVHIRDIK 180
+HQLWMVMELCAAGSVTDVVRMT NQSLKEDWIAIYICREILQGLAHLHAH+VHIRDIK
Sbjct: 121 HQHQLWMVMELCAAGSVTDVVRMTNRNQLKEDWIAIYICREILQGLAHLHAHQVHIRDIK 180

Query: 181 QNVLLTHNAEVKLVDGVSQAQVSRNTNGRRNSFIGTPYWMAPEVIDCEDPRRSYDYSRV 240
QNVLLTH+AEVK+VDGVSQAQVSRNTNGRRNSFIGTPYWMAPEVI CEDPR SYDYSRV
Sbjct: 181 QNVLLTHDAEVKIVDGVSAQVSRNTNGRRNSFIGTPYWMAPEVIHCEDEPRCSYDYSRV 240

Query: 241 WSVGITAEMAEGAPPLCNLQPLEALFVILRESAPTVMKSSGWSRKFNHFMKCTIKNPLF 300
WSVGITAEMAEGAPPLC LQPLEAL VILRE+AP VKSSGWSRKFNME C IKNPLF
Sbjct: 241 WSVGITAEMAEGAPPLCKLQPLEALCVILREAPKVKSSGWSRKFNFMENCMIKNPLF 300

Query: 301 RPTSANMLQHPFVRDIKNERHVVESLTRLHLTGIIKKRQKKGIPLIFEREAEKEQYTVRR 360
RPTS NML HPFV DIKNER VVESLT+HLTGII+KR+KKGIP+ FE EEA KEQY RR
Sbjct: 301 RPTSGNMLLHPFVHDIKNERRVVESLTKHLTGIIQKREKKGIPVAFEGEEAAKEQYITRR 360

Query: 361 FRGPSCTHELLRLPTSSRCRPLRVLHGEPSPQRWLPDREEPXXXXXXXXXXXXRVFMP 420
FRGPSC ELLR+PTSSRCRPLRVLHGEP QPRWLPD+E+P VFMP
Sbjct: 361 FRGPSCPELLRVPTSSRCRPLRVLHGEPQPRWLPDQEDPDQELQQLQAAGVFMPLH 420

Query: 421 ALDSAPKPLKGQAQAPQRLQGAARVFMPLQAQVKAKASKPLQMIXXXXXXXXXXXXXX 480
+ D+ KQ +L+GAA+V MP+ QV+AP Q+
Sbjct: 421 SQDNTSKLFPKQVEVAPYLRGAAQVMPVVLVQVEA----PPQVSKAAQMLRSLPTQDNKA 476

Query: 481 XQAQVRAPRLLXXXXXXXXXXXXXXXXXXXXSEPQDLQVPEEFQGGDQVXXXXXXXXXXXXX 540
+V+AP+P+DLQVPEEFQGGD+
Sbjct: 477 TSFEVQAP-----VAEGQQAQHEALETEQPKDLQVPEEFQGGDRAPEQPRQGQAAEQQQ 531

Query: 541 XHNQVPEQELXXXXXXXXXXXXXXXXXXXXXXXXXXXXSLRVNAQVFLPLLSQDHHVLL 600
HN VPEQ++V+AQV LPLLSQ+ HVLL
Sbjct: 532 IHNVPVPEQPPEEDREPEQAQEVQEEAVEPPQAEIEDKEPEVVQVHAQVLLPLLSQNRHVLL 591

Query: 601 PLHLDQVLIPVEGQTEGSPQAQAWTLEPPQAIGSVQALIEGLSRDLLRAPNSNNKPLG 660
PLHLD Q+LIPV Q E P+AQAW LE +A+G+VQALIEGLSRDLLRAPN+ +KPLG
Sbjct: 592 PLHLDROLLIPVGEQNEEVPRQAQWDLASRAVGAVQALIEGLSRDLLRAPNAFVTKPLG 651

Query: 661 PLQTLMLNLSNRFYSQPEQAREKSKVSTLRQALAKRLSPKRFRAKSSWRPEKLELSL 720
PLQ +ENLS++ FY++PE ++KSKV++LR+A+AKRL PKRFRAK+ WR E E SD+
Sbjct: 652 PLQIFLENLSTDFYTEPEPTQKKSKVASLRKAIAKRLRPKRFRAKALWRLEDFEFSV 711

Query: 721 EAXXXXXXXXXXWEDIFNQHEEELRQVXXXXXXXXXXXXXVFHSIQAEVQIEPLKPYISNPK 780
E WEDIFNQHEE+LR+V VFHSIQAEVQIE P+ +NP
Sbjct: 712 ETSRRRRHRRWEDIFNQHEELRRVENDREDDSSDNDEVFHSIQAEVQIE---PHANPA 768

Query: 781 KIEVQERSPSVPNNQDHAHVKFSSRTWHMLFCLFISVPQRSILEQAQKPIDIRQRSSQN 840
EV ERS +P N++ H VKFS L + PQ+Q Q+P++IR R+ N
Sbjct: 769 GNEVHERSAPMPCNRNRTHRVKFSVSGEESPLEEAQPPQ----QQQQPMNIRPRNCLN 824

Query: 841 RQNWLAAXXXXXXXXXXPVTGRSSQSSPPYSTIDQKLLVDIHVPDGFVKVGKISPPVYLTNE 900
QN+ A PVT R+SQSSPPYSTIDQKLL+DIHVPDGFVKVGKISPPVYLTNE
Sbjct: 825 PQNFQAQSDSSSEDSFVTRRSQSSPPYSTIDQKLLVDIHVPDGFVKVGKISPPVYLTNE 884

Query: 901 WVGYNALSEIFRNDWLTAPVVIQPPPEEDGDYVELYXXXXXXXXXXXXXXXXXXXXTYDHA 960
WVGYNALSEIF +DW+ P+PPEEDGDYVELY D A
Sbjct: 885 WVGYNALSEIFWDDWIMPTRPARPPEEDGDYVELY-DADANANGDEEVANGAYEDPRDGA 943

Query: 961 NGNDDLNDQVDQANDVCXXXXXXXXXXXXXXXXXXXXYEAPSCPRASYGRDGSCKQDGYDGS 1020
NG+DD++NQ+DQAN+ A + PRA+Y R G KDG
Sbjct: 944 NGHDDMNQLDQANG--YEGHGAAGYNGGDVGGNHGAAFNGPRANYPRAGILKNHNDGR 1001

Query: 1021 RGKEEAYRGYSHTANRSHGSSAASEDNAAIGDQEEHAANIXXXXXXXXXXXXXXNEASN 1080
A+ +G+ A HG AA E AA G+ H AN NE +
Sbjct: 1002 ALNRGAFGVFGDNARAFAHG--AAGEAGAAFGN---HGANGNGRGNRNRNEANGRNEENG 1056

Query: 1081 AI--DSGAAPSAPDHESDNKDISSESTQSDFSANHSSPSKSGSGMSADANFASAILYAGFV 1138
```


A DP ESD+ S + ++ + G +S+ GF
Sbjct: 1057 AFGRDQHVFPEFEHEESDRGTETSDSIALEITSFDGEQNSGRPVSTT-----MGF- 1107

Query: 1139 EVPEESPKQP---SEVNVNPLYVSPACKKPLIHMYEKEFTSEICCGSLWGVNLLLGTRSN 1195
+ SP+ S+++ N P++H+YEK+F+SE+ CGSLWGVNLLLGTS+
Sbjct: 1108 PIGRSSPRGSDFGSDISYN-----SPILHVYEKDFSSEVYCGSLWGVNLLLGTSQSH 1158

Query: 1196 LYLMDRSGKADITKLIRRRPFRQIQVLEPLNLLITISGHKNRLRVYHLTWLRNKILNNDP 1255
LYLMDRSGKA+I KLI+RRPFRQIQV+E LNLITISG KNRLRVYHL+WLRNKILNNDP
Sbjct: 1159 LYLMDRSGKAEIVKLIKRRPFRQIQVVEQLNLLITISGKNRLRVYHLSWLRNKILNNDP 1218

Query: 1256 ESKRRQEEMLKTEEACKAIDKLTGCEHFSVLQHEETTYIAIALKSSIHLYAWAPKSFDES 1315
+SK+RQ+ M K EEACKAIDKL GCEHFSVLQHEETTYIA+A+KSSIH+AWAPKSFDE+
Sbjct: 1219 KSKKRQKAMRKKEEACKAIDKLIGCEHFSVLQHEETTYIAVAVKSSIHLEAWAPKSFDE 1278

Query: 1316 TAIKVFPTLDHKPVTVDLAIGSEKRLKIFFSSADGYHLIDAESVMSDVTLPKXXXXXXX 1375
TAIKVFPT D KP+TVDLA+GSEK LKIFFSSA+GYH+IDAESVMS+VTLP
Sbjct: 1279 TAIKVFPTDLKPLTVDLAVGSEKTLKIFFSSANGYHIIDAESVMSVETLPN----- 1331

Query: 1376 XXXXXXXXDCGLGIGMMLTFNAEALSVEANEQLFKKILEMWKDIPSSIAFECTQRTTGWQ 1435
DCLG+G+ML+ NAEA S EANEQL KKIL++WKDIPSS+AFECT+R TGW Q
Sbjct: 1332 -NNVVILPDCLGLGVMLSLNAEAAEEANEQLLKKILDVWKDIPSSVAFECTKRITGWDQ 1390

Query: 1436 KAIEVRSLQSRVLESELKRRSIKKLRFLCTRGDKLFFSTLENHHSRVYFMTLGKLEELQ 1495
KAIEVRSLQS +LE+ELKRRSIKKLRFLC RGDK+FF STL N HSRVY M+LGKLEEL
Sbjct: 1391 KAIEVRSLQSTILENELKRRSIKKLRFLCARGDKMFFASTLSNDHHSRVYLSLGLKLEELH 1450

Query: 1496 SNYDV 1500
+Y V
Sbjct: 1451 RSYAV 1455

Figure 5: Top ten NCBI non redundant protein database hits for INSP082.

BLASTP 2.2.2 [Jan-08-2002]

Reference: Altschul, Stephen F., Thomas L. Madden, Alejandro A. Schaffer, Jinghui Zhang, Zheng Zhang, Webb Miller, and David J. Lipman (1997), "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs", Nucleic Acids Res. 25:3389-3402.

Query= genomic.pep
(1589 letters)

Database: ncbi-nr
1,039,718 sequences; 328,277,582 total letters

Sequences producing significant alignments:		Score (bits)	E Value
dbj	BAA87066.1 (AB035267) Nck-interacting kinase-like embryo sp...	1708	0.0
ref	NP_038752.1 (NM_013724) Nik related kinase [Mus musculus] >...	1704	0.0
ref	XP_109557.1 (XM_109557) similar to Nik related kinase [Mus ...	1232	0.0
ref	XP_125446.1 (XM_125446) similar to Nck-interacting kinase-l...	1048	0.0
emb	CAB06091.1 (Z83850) mouse NIK serine threonine protein kina...	599	e-170
ref	NP_004825.1 (NM_004834) mitogen-activated protein kinase ki...	393	e-108
gb	AAF03788.1 AF172270_1 (AF172270) Traf2 and NCK interacting ki...	392	e-107
gb	AAF03786.1 AF172268_1 (AF172268) Traf2 and NCK interacting ki...	392	e-107
gb	AAF03789.1 AF172271_1 (AF172271) Traf2 and NCK interacting ki...	392	e-107
gb	AAF03785.1 AF172267_1 (AF172267) Traf2 and NCK interacting ki...	392	e-107
dbj	BAA25477.2 (AB011123) KIAA0551 protein [Homo sapiens]	392	e-107

Figure 6: INSP091 top blastp alignment result from NCBI non-redundant protein database sequences.

>dbj|BAA87066.1| (AB035267) Nck-interacting kinase-like embryo specific kinase [Mus musculus]
Length = 1455

Score = 1708 bits (4423), Expect = 0.0
Identities = 935/1590 (58%), Positives = 1070/1590 (66%), Gaps = 136/1590 (8%)

```

Query: 1  MAGPGGWRDREVTDLGHLDPDTGIFSLDKTIGLTGTYGRIYGLHEKTGAFTAVKVMNARK 60
          MAGPG WRD+EVTDLG LPDPTGIFSLDK IGLGTYGRI+LG+HEKTG+ AVKVM+ARK
Sbjct: 1  MAGPGSWRDKEVTDLGQLDPDTGIFSLDKAIGLTGTYGRIFLGIHEKTGSLVAVKVMARK 60

Query: 61  TPLPEIGRRVRVVKYQKSVGWRYSDDEEDLRTLNLLRKYSFHKNTIVSFYGAFFKLSPPG 120
          TPLPEIGRRVRVVKYQKSVGWRYSDDEEDLRTLNLLRKYSFHKNTIV+FYGAFFKL+PPG
Sbjct: 61  TPLPEIGRRVRVVKYQKSVGWRYSDDEEDLRTLNLLRKYSFHKNTIVTFYGAFFKLNP 120

Query: 121  QRHQLWMVMELCAAGSVTDVVRMTSNQSLKEDWIAIYICREILQGLAHLHAHRVHRDIKG 180
          +HQLWMVMELCAAGSVTDVVRMT NQSLKEDWIAIYICREILQGLAHLHAH+VIHRDIKG
Sbjct: 121  HQHQLWMVMELCAAGSVTDVVRMTNQNQSLKEDWIAIYICREILQGLAHLHAHQVIHRDIKG 180

Query: 181  QNVLLTHNAEVKLVDFGVSAQVSRITNGRRNSFIGTPYWMAPVIEDCDEDPRRSYDYRSVD 240
          QNVLLTH+AEVK+VDFGVSAQVSRITNGRRNSFIGTPYWMAPVIEI CDEDP R SYDYRSVD
Sbjct: 181  QNVLLTHDAEVKLVDFGVSAQVSRITNGRRNSFIGTPYWMAPVIEIHCDEDP R SYDYRSVD 240

Query: 241  WSVGITAEMAEGAPPLCNLQPLEALFVILRESAPTVMKSSGWSRKFNHFMKCTIKNPLF 300
          WSVGITAEMAEGAPPLC LQPLEAL VILRE+AP VKSSGWSRKFNHFMKCTIKNPLF
Sbjct: 241  WSVGITAEMAEGAPPLCKLQPLEALCVILREAAAPVKSSGWSRKFNHFMENCMIKNPLF 300

Query: 301  RPTSANMLQHPFVRDIKNERHVESLTRLHTGIIKKRQKKGIPLIFEREAAIKEQYTVRR 360
          RPTS NML HPFV DIKNER VVESLT+HLTGII+KR+KKGIP+ FE EEA KEQY RR
Sbjct: 301  RPTSGNMLLHPFVHDIKNERRVVESLTKHLTGIIQKREKKGIPVAFEGEEAAKEQYITRR 360

Query: 361  FRGPSCTHELLRLPTSSRCRPLRVLHGEPSPQRWLPDREEPXXXXXXXXXXXXRVFMPLQ 420
          FRGPSC TELLR+PTSSRCRPLRVLHGEP QPRWLPD+E+P VFMP L
Sbjct: 361  FRGPSCPELLRVPTSSRCRPLRVLHGEPQPRWLPDQEDPDQDELQQLQKAGVFMPLH 420

Query: 421  ALDSAPKPLKGQAQAPQRLQGAARVFMPLQAVKAKASKPLQMQIKXXXXXXXXXXXXXXX 480
          + D+ K Q + L+GAA+V MP+ QV+A P Q+
Sbjct: 421  SQDNTSLKFPKQEVAFYLRGAQVMPVLVQVEA----PPQVSKAAQMLRSLPTQDNKA 476

Query: 481  XQAQVRAPRLXXXXXXXXXXXXXXXXXSEPDLDQVPEEFQGDQVXXXXXXXXXXXXXXX 540
          +V+AP +P+DLDQVPEEFQGD+
Sbjct: 477  TSFEVQAP-----VAEQQAQHEALETEQPKDLQVPEEFQGDRAPEQPRQQAEEQQ 531

Query: 541  XHNQVPEQELXXXXXXXXXXXXXXXXXXXXXXXXXXXXSLRVNAQVFLPPLSQDHHVLL 600
          HN VPEQ ++V+AQV LPLLSQ+ HVLL
Sbjct: 532  IHNVPVPEQPEEDREPEQAEVQEEAVEPPQAEIEDKEPEVQVHAQVLLPPLSQNRHVLL 591

Query: 601  PLHLDQVLIPLVGEQTEGSPQAQAWTLEPPQAIGSVQALIEGLSRDLLRAPNSNNSKPLG 660
          PLHLD Q+LIPV Q E P+AQAW LE +A+G+VQALIEGLSRDLLRAPN+ +KPLG
Sbjct: 592  PLHLDRLQVLIPLVGEQNEEVFRAQAWDLEASRAVGAQVQALIEGLSRDLLRAPNAFVTKPLG 651

Query: 661  PLQTLMLNLSNRFYSPQEQAREKSKVSTLRQALAKRLSPKFRFRKSSWRPEKLELSDL 720
          PLQ +ENLS++ FY++PE ++KSKV++LR+A+AKRL PKRFRAK+ WR E E SD+
Sbjct: 652  PLQIFLENLSTDGFYTEPEPTQKKSKVASLRKAIAKRLRKRFRKALWRLEDPEFSDV 711

Query: 721  EAXXXXXXXXXXWEDIFNQHEELRQVXXXXXXXXXXXXXVFHSIQAEVQIEPLKPYISNPK 780
          E WEDIFNQHEE+LR+V VFHSIQAEVQIEP + +NP
Sbjct: 712  ETSRRRRHRRWEDIFNQHEELRRVENDREDDSSDNDEVFHSIQAEVQIEP---HAANFA 768

Query: 781  KIEVOERSPSVPMNQDHAHHVKFSSVPQRS-LLEQAQKPIDIRQRSSQNRQNLAAAGSD 839
          EV ERS +P N++ H VKFS SV + LE+AQ
Sbjct: 769  GNEVHERSAPMPCNRNRTHRVKFSVSGVEEELSLEEAQ----- 807

Query: 840  SKHKILAGKTQSYCLTIYISEVKKEEFQEGMNQKCGAQVGLGPEGHCIWQLGESSEEE 899
          +++ Q+ MN + + L P+ +SSSEE+
Sbjct: 808  -----QQQQQPMNIRPRNC---LNPQN--FQAQSDSSSEED 839

Query: 900  SPVTGRRSQSSPPYSTIDQKLLVDIHVPDGFVKVGKISPPVYLTNEWVGYNALSEIFRNDW 959
          SPVT R+SQSSPPYSTIDQKLL+DIHVPDGFVKVGKISPPVYLTNEWVGYNALSEIF +DW
Sbjct: 840  SPVTRRSQSSPPYSTIDQKLLDIHVPDGFVKVGKISPPVYLTNEWVGYNALSEIFWDDW 899

Query: 960  LTPAPVIQPPEDGDYVELYXXXXXXXXXXXXXXXXXXXXXTYDHANGNDDLNDQVDQAND 1019
          + P +PPEEDGDYVELY D ANG+DD++NQ+DQAN
Sbjct: 900  IMPTRPARPPEEDGDYVELYDADANANGDEEVANGAYEDPR-DGANGHDDMNQLDQANG 958

Query: 1020 VCXXXXXXXXXXXXXXXXXXYEAPSCPRASYGRDGSCQDQGYDGSRGKEEAYRGYGSHTA 1079
          + A + PRA+Y R G K DG A+ +G+ A
Sbjct: 959 Y--EGHGAAGYNGDVGCGNHGAAFNGPRANYPRAGILKNHNDGRALNRGAFGVFGDNAA 1016

```

Query: 1080 NRSHGGSAA SEDNAAIGDQEEHAANIXXXXXXXXXXXXXXVVRTSEESGALGLNGEENCs 1139
 HG AA E AA G+ H AN +G N E N
 Sbjct: 1017 RAFHG--AAGEAGAAFGN---HGAN-----RGNGRGNNRNRANGR 1051

Query: 1140 ETDGPGLKRPASQDFEYLQEEPGGNEASNAIDSGAAPSAPDHESDNKDISESSTQSDFS 1199
 + R E+ EE G E S++I A N SST F
 Sbjct: 1052 NEENGAFGRDQHVFPPEFEHEESDRGTETSDSI---ALEITSFDGEQNSGRPVSSTTMGFP 1108

Query: 1200 ANHSSPSKSGSGMSADANFASAILYAGFVEVPEESPKQPSSEVNPNLYVSPACKKPLIHMY 1259
 SSP +GS +D ++ S P++H+Y
 Sbjct: 1109 IGRSSP-RGSDFGSDISYNS-----PILHVV 1133

Query: 1260 EKEFTSEICCGSLWGVNLLGTRSNLYLMDRSGKADITKLIRRRPFRQIQVLEPLNLLIT 1319
 EK+F+SE+ CGSLWGVNLLGT+S+LYLMDRSGKA+I KLI+RRPFRQIQV+E LNLLIT
 Sbjct: 1134 EKDFSSEVYCGSLWGVNLLGTQSHLYLMDRSGKAEIVKLIKRRPFRQIQVVEQLNLLIT 1193

Query: 1320 ISGHKNRLRVYHLTWLRNKILNNDPESKRRQEEMLKTEEACKAIDKLTGCEHFSVLQHEE 1379
 ISG KNRLRVYHL+WLRNKILNNDP+SK+RQ+ M K EEACKAIDKL GCEHFSVLQHEE
 Sbjct: 1194 ISGKNRLRVYHLSWLRNKILNNDPKSKKRQKAMRKKEEACKAIDKLIGCEHFSVLQHEE 1253

Query: 1380 TTYIAIALKSSIHLYAWAPKSFDESTAIKVFPTLDHKPVTVDLAIGSEKRLKIFFSSADG 1439
 TTYIA+A+KSSIH+AWAPKSFDE+TAIKVFPT D KP+TVDLA+GSEK LKIFFSSA+G
 Sbjct: 1254 TTYIAVAVKSSIHLEAWAPKSFDETAIKVFPTDLKPLTVDLAVGSEKTLKIFFSSANG 1313

Query: 1440 YHLIDAEESEVMSDVTLPKXXXXXXXXXXXXXDCLGIGMMLTFNAEALSVEANEQLFKK 1499
 YH+IDAEESEVMS+VTLP DCLG+G+ML+ NAEA S EANEQL KK
 Sbjct: 1314 YHIIDAEESEVMSEVTLPN-----NNVVILPDCLGLGVMLSLNAEASEANEQLLKK 1365

Query: 1500 ILEMWKDIPSSIAFECTQRTTGWGQKAIEVRSLQSRVLESELKRRSIKKLRFLCTRGDKL 1559
 IL++WKDIPSS+AFECT+R TGW QKAIEVRSLQS +LE+ELKRRSIKKLRFLC RGDK+
 Sbjct: 1366 ILDVWKDIPSSVAFECTKRITGWDQKAIEVRSLQSTILENELKRRSIKKLRFLCARGDKM 1425

Query: 1560 FFTSTLRNHHSRVYFMTLGKLEELQSNYDV 1589
 FF STL N HSRVY M+LGKLEEL +Y V
 Sbjct: 1426 FFASTLSNDHSRVYLMSLGKLEELHRSYAV 1455

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.